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Abstract 
 In horses, a painful and often debilitating disease known as laminitis can result in 
impaired function and, in severe cases, euthanasia.  Equine Metabolic Syndrome (EMS) is a 
syndrome in horses that results in development of laminitis and is characterized by the 
presence of general and/or regional adiposity (“cresty neck”), aberrations in blood lipid 
concentrations, insulin resistance (IR) and/ or hyperinsulinemia. 
  Therapies have focused on improving the state of obesity and insulin resistance with 
the goal of diminishing the likelihood of laminitis development.  A definitive cause for 
laminitis has not been established, but hyperinsulinemia and IR are likely candidates as 
experimental states of hyperinsulinemia have been shown to induce laminitis and 
improvements in insulin sensitivity and obesity have been associated with a decreased risk 
of laminitis development. 
  This dissertation discusses associations between obesity and IR, as well as potential 
therapies for alleviating insulin resistance with the ultimate goal of decreasing the risk of 
developing laminitis.  Therapies evaluated included chromium and magnesium, 
levothyroxine sodium, and metformin hydrochloride.  Horses were treated with each 
supplement for 10 to 36 weeks, depending on the supplement tested, and physical 
measurements such as body weight, neck circumference, and body condition score were 
obtained.  Throughout each study, blood concentrations of glucose, insulin, and plasma 
lipids were analyzed.  Chromium and magnesium currently do not appear to have any effect 
on insulin sensitivity, whereas results of levothyroxine administration indicate therapeutic 
responses, as does metformin, though results indicate further work are required. 
  Research contained in this dissertation focuses on the potential of identifying animals 
at risk of developing IR and laminitis through measurement of blood biomarkers such as 
adiponectin and glucagon-like peptide 1.  Assays to measure markers included enzyme-
linked immunosorbent assays, western blots, and radioimmunoassays.  Glucagon-like 
peptide 1 currently does not appear to differ between healthy and IR animals, but protein 
band density of high-molecular weight adiponectin does appear to be lower in horses with 
IR when compared to healthy animals.   
vi 
 
  There is still much to learn about IR in horses, and therapy appears to be dependent 
on a case by case basis. 
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Chapter 1 
Literature Review 
Laminitis is a common medical condition of equids that does not have a clear 
pathogenesis.  This disease affects domesticated horses and ponies (Equus caballus) 
throughout the world and has financial and welfare implications.1-3  It is a potentially 
crippling disease of adult horses that can result in early retirement due to permanent lameness 
or euthanasia.1  Laminitis is generally associated with, or diagnosed in conjunction with, 
other medical conditions, including insulin resistance (IR), obesity, and pituitary pars 
intermedia dysfunction (PPID), which is also known as equine Cushing’s disease.4  This 
literature review will focus upon obesity and IR as risk factors for laminitis, and examine 
potential treatments for these conditions.   
 
1. Obesity and insulin resistance in horses and ponies 
1.1 Body condition and fat mass assessment 
 A scoring system was devised by Henneke, et al.5 to assign a body condition score 
(BCS) to horses.  This scoring system has a scale ranging from 1 to 9, with 1 representing an 
emaciated animal and 9 representing a morbidly obese animal.  This scale allows a score to 
be assigned after visual appraisal and palpation of fat at 6 strategic locations:  over the ribs, 
the area caudal to the shoulder, along the withers, in the tail head region, along the back, and 
along the neck.5,6  This scoring system has been adapted and utilized by veterinarians, 
nutritionists, and horse owners as a means to evaluate the horse’s condition compared to an 
ideal score of 5.  According to this system, a score ≥ 7 represents obesity.2,6  This is a 
subjective method of assessment, however, and is prone to variability among scorers.  
Alternative methods of assessing obesity are cadaver dissection,6,7 rump-fat thicknes,6,8,9 and 
body mass index (BMI).6,10  Of these procedures, BCS and rump-fat thickness are the easiest 
to perform.6  Rump fat thickness is measured using B-mode ultrasonography at a site 5 cm 
lateral to midline at the center of the pelvic bone.6,8  Percentage body fat is calculated from 
ultrasound measurements using the formula:8 
% fat = 2.47 + 5.47 (rump fat in cm) 
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1.2 Adipose distribution 
 In obese horses that concurrently suffer from IR, there is often enlargement of adipose 
tissues within the neck region, which is referred to as a “cresty neck”, or regional 
adiposity.6,11  In humans, regional adiposity refers to an increased waist circumference and 
this is a risk factor for metabolic syndrome (MetS).12  One can evaluate the deposition of 
adipose tissue in the neck region of horses by obtaining mean neck circumference 
measurements using the following procedure:6 with the horse carrying its head in a normal, 
upright position, measure the distance (×) along the neck from the poll to the cranial aspect of 
the withers (Figure 1).  Perpendicular to the line of the neck, measure circumference at 
0.25×, 0.50×, and 0.75×.  As obesity increases or decreases, neck measurements change 
accordingly.  Mean neck circumference measurements were  positively correlated with  IR in 
one study of obese insulin-resistant horses.6  A cresty neck scoring system, along with BCS 
has also been found to have a strong association with blood variables such as insulin and 
glucose concentrations.13  Both crest height and neck circumference are associated with 
higher insulin, glucose, leptin, and triglyceride concentrations.13 
                     
Figure 1.1: Neck circumference measurements in the horse.  From Frank N et al. Physical 
characteristics, blood hormone concentrations, and plasma lipid concentrations in obese 
horses with insulin resistance J Am Vet Med Assoc 2006;228:1,383-1,390. 
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2. Insulin resistance 
2.1 Insulin secretion and function 
 Insulin is a hormone synthesized and secreted by the β cells of the pancreatic Islets of 
Langerhans in response to hyperglycemia, and has the main function of regulating glucose 
utilization and production.1,14  This hormone also affects lipid metabolism by enhancing 
cellular glucose uptake and lipogenesis15,16, and blood circulation because of its vasodilatory 
properties.17  Hypertension and vascular disease can result from hyperinsulinemia (high blood 
insulin concentrations).18  Insulin is extracted by the liver after its secretion, with 
approximately 50% lost on first pass.19-21 
 Insulin synthesis starts with a pro-insulin form consisting of an A-chain, B-chain, and 
C-peptide (connecting peptide).22  During the synthesis of insulin, C-peptide serves an 
integral role by linking the A and B chains and thereby ensuring correct folding and 
interchain disulfide bond formation.22  Before functional insulin (A and B chains joined 
together) is secreted, C-peptide is cleaved from the pro-insulin molecule, and remains stored 
in secretory granules.  After C-peptide is removed, the carboxyl end of the B-chain of insulin 
has the appropriate conformation for binding to the insulin receptor.22  Insulin and C-peptide 
are secreted in equimolar amounts so any difference in their ratio implies impaired insulin 
clearance by the liver.22-23  The half lives of insulin and C-peptide are 4 minutes and >30 
minutes, respectively.20,21,23,24 
Insulin secretion is highly dependent on insulin sensitivity (SI).  In a study of British 
children, SI was dependent upon body mass index (BMI).25-27 This study revealed that insulin 
sensitive people released less endogenous insulin in response to glucagon stimulation when 
compared to individuals with type 2 diabetes mellitus and IR.25   
 
2.2 Insulin receptor and signaling 
Insulin is released by the pancreas in response to feeding and acts through an insulin 
receptor mechanism to stimulate glucose uptake and regulation by adipose tissue, skeletal 
muscle, and the liver.1,14,28  The insulin receptor is located within the cell membrane and is 
composed of two α and two β sub-units which are linked by disulfide bonds.29,30  The α 
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subunits are located extracellularly and are the site of insulin binding, while the β sub-units 
consist of transmembrane and intracellular domains.30  The transmembrane domain conveys a 
signal to the intracellular domain that insulin has bound to the receptor, and this signal 
involves tyrosine kinase.29,30  When insulin binds to its receptor, tyrosine kinase is activated 
and this leads to autophosphorylation of the β sub-unit at tyrosyl residues, which begins an 
intracellular signaling pathway that causes phosphorylation of cytosolic protein substrates 
such as insulin receptor substrate-1 (IRS-1).30  Upon activation of the receptor and its 
intracellular signaling cascade, the insulin-responsive glucose transporter GLUT 4 
translocates from intracellular vesicles within the cytosol to the cell membrane and this 
allows passage of glucose into cells.29   
The ability of insulin to enhance the total net disappearance of glucose from 
extracellular fluid (plasma), by either inhibiting endogenous glucose production and/or 
enhancing the use of glucose by the body represents SI.31  Insulin normally maintains plasma 
glucose concentrations within a range and therefore protects the tissues from glucotoxicity.1  
In horses, fasting blood glucose concentrations range from 60 to 90 mg/dL16, compared with 
70 to 105 mg/dL in humans, but ranges do differ according to the assays utilized by 
respective laboratories.32  Insulin is also responsible for stimulating lipogenesis and inhibiting 
hepatic gluconeogenesis.28  Insulin resistance is defined and recognized by a subnormal 
physiologic response to normal circulating concentrations of insulin.13,14  Fasting 
hyperinsulinemia serves as an indicator of IR in horses and humans.33-35  Normal, healthy 
state levels of insulin in humans is recognized at values of <25 µIU/mL32, while normal, 
healthy state fasted insulin concentrations in horses are <20 µIU/mL.16  In humans, chronic 
hyperinsulinemia is associated with consequences such as disorders of carbohydrate 
metabolism, lipid metabolism, and vascular disease such as atherosclerosis.36,37  The 
occurrence of laminitis in obese horses may be a result of IR and vascular disorders such as 
atherogenesis, however, it has yet to be confirmed.36 
 
2.3 Mechanisms of insulin resistance 
Insulin resistance can be found in both physiologic (e.g. starvation, pregnancy) and 
pathologic (e.g. obesity, hyperadrenocorticism) conditions.14,38  Proposed mechanisms of IR 
include breakdown of insulin-signaling mediators, down-regulation of insulin receptors, or a 
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decrease in number of insulin receptors.15,36,39,40  The most common mechanisms however, 
involve alterations in post-receptor binding signaling pathways, associated with a decrease in 
autophosphorylation of β sub-units, and therefore decreased tyrosine kinase activity.15,41,42  
This causes a domino effect in which phosphorylation of IRS-1 decreases, leading to reduced 
activation of phosphatidylinositol 3-kinase (PI3K).15,41,42  Impaired regulation of enzymes 
such as hexokinase and glycogen synthase can also result in disruption of intracellular 
glucose metabolism, which leads to reduction in insulin-mediated uptake of glucose and 
subsequent storage by the liver as glycogen or by adipose tissue as fat.15,41-43 
In horses, a syndrome that includes abnormal distribution of adipose tissue, 
hyperinsulinemia, glucose intolerance, elevated plasma lipid concentrations, and a 
predisposition to laminitis, is referred to as Equine Metabolic Syndrome (EMS).36  Horses 
affected by this syndrome are usually between 8 and 18 years of age, are usually obese, 
possess a “cresty neck”, and have excess adipose accumulation in the rump area and 
prepuce/mammary region, as well as histories of laminitis and being an “easy keeper”.6,36   
Plasma lipid concentrations increase with obesity and a lack of exercise in humans, 
and this is explained by the fact that adipose tissues have a finite capacity to store fat, so 
excess fat is found in the circulation and other tissues (i.e. skeletal muscle).6,44 Insulin, which 
is often circulating at higher concentrations in obese humans than in non-obese humans, also 
elicits lipogenic effects and inhibits lipase activity leading to improper accumulation of fatty 
acids as diacylglycerols within tissues.6,44  This phenomenon can be referred to as lipotoxicity 
and this process is capable of disrupting insulin receptor signaling in muscle cells or β cell 
function within the pancreas.6,44  In one study looking at the physical characteristics and 
plasma lipid profiles of a group of horses, it was found that plasma non-esterified fatty acid 
(NEFA) concentrations were elevated in obese horses compared with non-obese 
counterparts.6  A link has also been established between free fatty acids and the development 
of obesity and IR (and Type 2 diabetes) in humans.36,45  Elevated NEFA concentrations 
induce IR in both skeletal muscle and the liver.36,46  The fact that IR is associated with weight 
gain, and loss, strongly suggests a cause and effect relationship.36 
Horses with obesity-associated laminitis usually suffer from glucose intolerance.36 
Glucose intolerance is diagnosed when hyperglycemia is prolonged due to delayed resolution 
after a glucose load either intravenously, orally, or post-prandially (reflecting following a 
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meal).36  In healthy individuals, the ingestion of a meal or glucose challenge, leads to an 
increase in blood glucose concentrations at which time insulin is released by the β cells of the 
pancreas.  The increase in serum insulin concentrations signals a halt to liver glucose 
production via glycogenolysis and gluconeogenesis, and stimulates the uptake of glucose by 
skeletal muscle and adipose tissue.36,40  The state of glucose intolerance implies insensitivity 
of peripheral tissues (skeletal muscle and adipose tissue) or the liver to the actions of insulin, 
that amounts of insulin produced by the β cells of the pancreas are decreased, or both.36,39  
With respect to equids, it has been shown in earlier studies that pony breeds appear to be 
glucose intolerant (relatively) when compared to horses.34,36,47 
 
3. Lipid metabolism 
3.1 Lipotoxicity 
 The development of an overweight or obese state is, by definition, due to a positive 
energy balance.48  It has been shown, that when there is an imbalance between energy intake 
and expenditure, fat is deposited due to a positive fat balance.48-50  Of the macro-nutrients 
utilized by the body for energy (protein, carbohydrates, fat), dietary fat is the most energy 
dense, providing approximately 37 kJ/g versus approximately 17 kJ/g by proteins and 
carbohydrates.48  When dietary fat intake is increased, fat oxidation increases slowly leading 
to an overall accumulation of fat in adipose stores due to a positive energy balance.48,51,52   
 In humans suffering from type 2 diabetes (T2D) and horses with IR, plasma NEFA 
and cholesterol concentrations are increased, and an overall state of dyslipidemia exists.6,53,54  
Blood NEFA concentrations increase with obesity and lack of physical activity in humans 
because hormone sensitive lipase (HSL) increases, leading to enhanced mobilization of 
NEFAs from adipocytes.6,44  This state of dyslipidemia causes fatty acids to be stored in non-
adipose tissues such as muscle, liver, and pancreas, in patients suffering from T2D.48  One of 
the main contributing factors to the development of IR is the overabundance of NEFAs 
within the blood.55  Hydrolysis of stored triglyceride (TG) into fatty acids and glycerol is 
regulated by insulin, as well as catecholamines and natriuretic peptides.55,56  Insulin normally 
inhibits the hydrolysis of TG and increases fat storage by stimulating re-esterification of fatty 
acids.55,57 
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3.2 Ectopic lipid accumulation 
 High circulating NEFA concentrations can lead to ectopic accumulation of lipids in 
skeletal muscle and liver, and a negative correlation exists between the degree of IR and the 
TG content of skeletal muscle.53,58-61  Elevated plasma NEFA concentrations accompany 
obesity, IR, and T2D in humans, and have also been noted in obese insulin-resistant horses 
and ponies.6,58,62  These elevations drive the accumulation of intramyocellular lipids (IMCL) 
and increase the severity IR by disrupting insulin receptor signaling and creating cell damage, 
which is referred to as lipotoxicity.6,44,53,58,63,64   
Intramyocellular lipids are small lipid droplets located in the sarcoplasm of muscle 
cells and are predominantly found in the vicinity of the mitochondria.48  Lipotoxicity is 
thought to occur by one or more of the following cellular/molecular mechanisms: 1) 
inflammation, 2) diacylglycerol (DAG)/protein kinase C (PKC) pathway, or 3) 
hyperinsulinemia.65  It is still unclear whether IMCL accumulation is the cause or 
consequence of IR.53,65  Higher IMCL concentrations have been detected under physiological 
conditions, such as muscles of endurance athletes and individuals undergoing short-term (4 
week) exercise training.58,66,67  This discrepancy implies that higher IMCL concentrations are 
a marker for other lipid metabolites that may be inducing IR, rather than a direct effect. 58 
The mechanism by which IMCL plays a role in IR involves the insulin signaling 
pathway.62  Diacylglycerols accumulate within muscle tissue and stimulate PKC, which 
inhibits tyrosine kinase activity of the insulin receptor and tyrosine phosphorylation of IRS-1, 
which decreases myocyte glucose uptake.62,68-70   In vivo studies and ex vivo biochemical 
analyses of muscle tissue biopsies from humans indicate  that obesity and IR are associated 
with decreased mitochondrial fatty acid (FA) oxidative capacity.58,71-76  This may be the 
result of decreased myocyte mitochondrial numbers, abnormal mitochondrial morphology, or 
decreased levels of the mitochondria-associated enzymes required for FA oxidation.58,71-76  It 
is therefore possible that the increased IMCL concentrations associated with IR in humans 
result from a decreased capability to oxidize FA.58  Kelley et al.72 demonstrated that 
mitochondria in patients with T2D are smaller and have morphological aberrations compared 
with controls. It was also shown that the mitochondrial area was positively correlated with 
insulin sensitivity.  Mitochondrial function might also be influenced by diet, with high 
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saturated fatty acid diets having a stronger negative effect on hepatic and peripheral insulin 
sensitivity than mono-unsaturated fatty acids and polyunsaturated fatty acids.68,77-79 
 
3.3 The role of β-oxidation 
 The mechanism behind lipid-induced IR was proposed more than 30 years ago when 
Randle and colleagues introduced the concept of a glucose-fatty acid cycle.68  In this cycle, 
fatty acids and glucose are thought to compete for their respective substrate oxidation .80  
Perdomo et al.58 found in work performed with L6 muscle cells that there was a distinct 
influence of β-oxidation rate on the severity of IR in skeletal muscle.  The equilibrium, or 
lack thereof, between FA oxidation and re-esterification into TG is important in the 
determination of lipid storage in muscle.62  Healthy skeletal muscle is characterized by 
having the capacity to utilize either lipid or carbohydrate fuels for energy and to effectively 
interchange between these two sources, depending on the stimulus and energy demands of the 
tissue.62  For example, in a state of early starvation when glucose availability is minimal, the 
body shifts from utilizing glucose as its energy source to using FAs produced by TG 
oxidation.81   
The inability of skeletal muscle to adequately oxidize TGs is an important aspect of 
skeletal muscle insulin insensitivity in the obese or T2D state.62  Beta oxidation requires that 
FAs leave the circulation, move into the sarcoplasm, and then enter the mitochondria by first 
passing through the outer mitochondrial membrane and then the inner mitochondrial 
membrane.  In states of obesity and T2D, fatty acid synthesis is promoted, rather than 
oxidation, which leads to lipid accumulation within skeletal muscle.62 
 
 3.4 Mechanisms of β-oxidation 
3.4.1 Carnitine Palmitoyl Transferase 
 Entry of FAs into mitochondria is regulated by carnitine palmitoyltransferase-1 
(CPT-1).  Fatty acids that enter the cytosol of a muscle cell must first be converted to a fatty 
acyl-CoA via acyl-CoA synthetase within the outer mitochondrial membrane.82  In order to 
cross the inner-mitochondrial membrane, fatty acyl-CoA must join with carnitine and form 
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acyl-carnitine, which is catalyzed by CPT-1 on the outer face of the inner mitochondrial 
membrane.82  The acyl group is then transferred back to a CoA-SH to re-form fatty acyl-CoA 
and a free carnitine.82  There is an even exchange between the matrix and the inter-membrane 
space of carnitine for acyl-carnitine via carnitine acylcarnitine translocase.83,84 
 Carnitine palmitoyltransferase-1 is inhibited by malonyl-CoA, which is the first 
intermediate in the synthesis of long chain fatty acids.  When carbohydrate substrates are 
ample, the concentration of malonyl-CoA increases, creating a negative feedback on CPT-1 
activity and therefore inhibition of β-oxidation.  Malonyl-CoA is formed from the conversion 
of pyruvate, produced by glycolysis, into acetyl-CoA.   
 
3.4.2 Adenosine monophosphate kinase 
Adenosine monophosphate kinase (AMPK) is a fuel sensing enzyme that monitors 
cellular energy status, increases glucose uptake, and activates catabolic pathways (β-
oxidation and glycolysis) leading to ATP production.85-88  This enzyme also inhibits anabolic 
pathways (gluconeogenesis) that utilize ATP and has a regulatory role in two critical liver 
functions, gluconeogenesis and lipogenesis.  A decrease in intracellular energy levels 
activates AMPK and this is also the route of action for anti-diabetic drugs such as metformin 
and the hormone adiponectin.64   
The AMPK enzyme is a multi-substrate heterotrimer that contains a catalytic α-
subunit and two regulatory, β and γ, subunits.86,89  Increases in the intracellular AMP:ATP or 
creatine:phosphocreatine ratios lead to its activation.64,86  Phosphorylation on the threonine-
172 (Thr-172) residue can also lead to its activation.86  In its active form, AMPK 
phosphorylates and consequently inactivates acetyl CoA carboxylase (ACC), which is its 
direct substrate.85  When ACC is inactivated, malonyl-CoA concentrations decrease and this 
leads to activation of CPT-1 and increased oxidation of long chain fatty acids.85,90   
Interactions between AMPK and glycogen stores in muscle have been reported in 
some studies, with this enzyme phosphorylating, and therefore inactivating, glycogen 
synthase.86,91  It has also been shown that the β-subunit of AMPK contains a motif capable of 
binding glycogen, which implies that it plays a role in depleting glycogen stores.86,92-94  One 
study85 found that increased AMPK activation by the insulin sensitizing drug troglitazone 
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caused an increase in long chain fatty acid oxidation, which reduced IMCL accumulation.  
However, the resulting increase in glucose uptake stimulated lactate production, rather than 
glycogen synthesis, as expected.85  A similar finding occurred in a study looking at the 
influence of adiponectin on glucose uptake, in that glycogen synthesis decreased, whereas 
lactate production increased.86  Increased β-oxidation lowers IMCL concentrations and 
thereby protects cells from the harmful effects of FA accumulation on insulin signaling. 
Work performed by Perdomo et al.58 suggests that β-oxidation also increases insulin 
sensitivity independently of its impact on lipid accumulation. With its role in regulating and 
influencing β-oxidation, AMPK is viewed as a “metabolic switch”. 
 
4. Hepatic insulin resistance 
4.1 Non-alcoholic fatty liver disease  
The hepatic manifestation of IR in humans is referred to as non-alcoholic fatty liver 
disease (NAFLD).95  This condition is one of the most common causes of liver dysfunction in 
humans and arises from abnormal lipid droplet accumulation in hepatocytes, caused by 
increased calorie intake and enhanced lipogenesis, particularly in states of IR.96  Messenger 
RNA expression of key lipogenic enzymes is increased with obesity, IR, and dyslipidemia in 
humans and this stimulates lipid synthesis.95,97  Fatty acids are taken out of the circulation by 
the liver and undergo β-oxidation, storage as TG, or export within very low-density 
lipoprotein (VLDL).98  In the fasted state, FAs are mobilized and energy is produced within 
the liver through β-oxidation, whereas in the fed state insulin stimulates lipogenesis.98,99 
 The liver is one of the most important organs in the body and is involved in digestion, 
detoxification, production, and storage.98  The liver has a central role in glucose and lipid 
metabolism and it, along with skeletal muscle and adipose tissue, is a key site of insulin 
action.99  It plays a major role in determining circulating insulin concentrations because 50 to 
70% of insulin secreted by the pancreas is removed from the portal circulation by the liver on 
first pass.100-103  Intrahepatic fat content can range from 0 to 100%, with the amount 
increasing in parallel with obesity.101,104  In obese humans, patients with elevated intrahepatic 
fat are affected by IR and hyperinsulinemia.101  Hepatic IR is defined by the ability of insulin 
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to suppress hepatic glucose production, while not affecting lipid synthesis and VLDL 
production.99,101,105,106  Hyperinsulinemia reflects both insulin clearance and insulin action.101 
 In one study examining the effect of liver fat on insulin clearance, Kotronen et al. 101  
demonstrated that subjects with a high liver fat content (15%) were more obese, had higher 
fasting glucose, insulin, and TG concentrations, higher liver enzyme activities, and lower 
serum high density lipoprotein (HDL) concentrations than low liver fat (2%) patients.  Those 
individuals with higher liver fat content had more hepatic glucose production, indicating 
hepatic IR.101  Hepatic IR and insulin clearance are independent determinants of fasting 
serum insulin concentrations.101  Decreases in hepatic fat via drug therapy and weight loss 
improves hepatic insulin sensitivity and increases insulin clearance.101  This reinforces the 
theory that hepatic insulin sensitivity is a function of liver fat content.    
 
4.2 Regulation of hepatic lipid content 
Sterol regulatory element binding protein 1-c (SREBP1-c) is a key regulator of 
hepatic FA metabolism that influences gene expression for enzymes such as fatty acid 
synthase (FAS) that are involved in FA synthesis within the liver.99,107,108  Increased 
expression of SREBP-1 has been shown to induce hepatic steatosis and hyperlipidemia.109-111   
Peroxisome proliferator activated receptor alpha (PPARα), gamma (PPARγ), and 
delta (PPARδ) also regulate hepatic FA metabolism.99  Insulin-sensitive liver, skeletal 
muscle, and adipose tissues express PPARα and this leads to an up-regulation of genes 
involved in FA uptake and β-oxidation.99  There are two isoforms of PPARγ; isoform-1 is 
expressed in the liver and skeletal muscle and isoform-2 is only found in adipose tissue where 
it is involved in the regulation of adipocyte differentiation and FA storage.99  Activation of 
PPARγ increases FA uptake by adipose tissue and thereby decreases amounts delivered to the 
liver via a mechanism referred to as “the fatty acid steal hypothesis”.99,112,113  In animal 
models, PPARδ improves lipid profiles and increases energy expenditure, while also 
increasing carbohydrate catabolism in the liver and suppressing hepatic glucose 
production.63,99,114,115 
 The state of peripheral IR is thought to be a factor in the development of hepatic fat 
accumulation since IR is characterized by hyperinsulinemia and insulin elicits lipogenic 
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effects.  Hyperinsulinemia also increases FA influx into the liver and stimulates hepatic TG 
production.116  High serum insulin and glucose concentrations promote de novo lipogenesis 
and NAFLD may ultimately lead to the development of hepatic IR.116   
 
4.3 Visceral adiposity and the liver 
The location of fat might also affect the development of obesity-associated metabolic 
disorders. The visceral fat constituting truncal obesity is most closely associated with 
metabolic syndrome (MetS) and adverse outcomes in humans.117-121  Human metabolic 
syndrome is a syndrome comprised of a collection of risk factors for the development of type 
2 diabetes and cardiovascular disease.122  Risk factors include dyslipidemia reflected in 
elevated triglycerides and low high-density lipoproteins (HDL), elevations in blood pressure 
and glucose, and abdominal obesity which has been associated with a pro-thrombotic and 
pro-inflammatory state.122  The association between truncal obesity and MetS has been 
explained by the “portal/fatty acid flux” theory.  According to this theory, visceral fat has 
enhanced lipolytic activity that increases the amounts of FAs that enter the portal circulation 
and go directly to the liver, which leads to intrahepatic lipid accumulation and hepatic 
IR.57,118,123  Subcutaneous fat on the other hand appears to be metabolically protective 
because it is correlated with lower serum TG concentrations and higher HDL concentrations 
as well as strong positive correlations with adipokines such as adiponectin and leptin 
(discussed below).118  These adipokines improve insulin sensitivity in peripheral and hepatic 
tissues.  
 
5. Obesity and Inflammation 
 It has historically been the belief that fat tissue is nothing more than an energy 
reserve; however, within recent years it has been established that adipose tissue is an 
endocrine organ that secretes numerous hormones known as adipokines.1,124,125  These 
adipokines are potential contributors to IR in humans and horses and are secreted by both 
adipocytes and macrophages.124,126,127  Key underlying pathologic processes of obesity 
therefore include chronic inflammation and dysregulation of adipokines.128  Macrophages are 
the primary mediators of the immune response, and in adipose tissues they make up 
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approximately 40% of the infiltrating cells of adipocytes in obese humans.124,129  Adipokines 
are soluble compounds that are secreted by white adipose tissue (WAT) from adipocytes and 
cells associated with WAT known as stroma vascular fraction cells.36,128,130,131  Multiple 
adipose tissue-derived signaling molecules are currently being studied as correlates of IR.124 
 Endocrinologically active adipocytes are found in omental and retroperitoneal fat 
tissues, which are associated with intra-abdominal adiposity in humans.4,125  Accumulation of 
adipocytes in these locations is thought to be more significant that adipocytes in other 
locations such as subcutaneous tissues and the lower extremities.36,62  In obese horses with 
EMS, there can be accumulations of retroperitoneal fat subjacent to the body wall, sometimes 
as thick as 3 to 5 cm.36 
In horses, relationships exist among obesity, inflammatory cytokines, and insulin 
sensitivity; inflammation increases with obesity and this is associated with a decrease in 
insulin sensitivity.132  Adipocytes participate in the innate inflammatory response in horses.126  
In IR humans, administration of anti-inflammatories such salicylates (aspirin) have been 
shown to reverse IR, further supporting the role of inflammation.126,133  Since laminitis is 
associated with both obesity and IR, it is postulated that adipose-derived inflammatory 
cytokines are also associated with laminitis.126,132  Pro-inflammatory cytokines such as tumor 
necrosis factor alpha (TNF-α) increase with obesity whereas anti-inflammatory cytokines 
such as interleukin-10 (IL-10) decrease.132,134,135  However, the adipokines that are coming to 
the forefront of investigations of IR and MetS in both horses and humans are leptin, 
adiponectin, and resistin.   
 
6. Adipokines and incretins 
6.1 Leptin 
 The concept of a “thrifty gene” was first proposed for humans in 1962 by Neel,136 and 
was proposed as an explanation for why some humans become obese and others do not.  This 
theory is based upon the belief that Paleolithic humans had to be thrifty in order to survive on 
limited nutritional availability.  The concept of the thrifty gene has also been proposed as a 
mechanism for why some horses appear more metabolically efficient and are termed “easy 
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keepers”.137 These animals gain weight on diets that would be considered nutritionally 
sufficient for maintenance in most other horses.   
 Leptin is the product of the obese (ob) gene and is a 16 kDa hormone comprised of 
167 amino acids.64,137-139  It is secreted by adipocytes and plays an important role in appetite 
regulation and energy homeostasis.64,137-139  It was one of the first molecules to be classified 
as an adipokine and is considered to be an anti-obesity hormone owing to its capacity to 
regulate food intake.64  In horses and ponies, leptin concentrations are positively correlated 
with BCS.137,140,141  Higher plasma leptin concentrations have also been positively correlated 
with area under the curve (AUC) measures of insulin and glucose dynamics.6  Although the 
measure of BCS reflects adiposity, it only measures subcutaneous depots of fat and therefore 
there may be varying concentrations of leptin among horses of similar BCS.137,142   
When considering leptin as a screening tool in horses for IR, one must also take 
season into account.  Fitzgerald and McManus143 found that serum leptin concentrations were 
elevated in mature mares during late summer into early fall, and reached their lowest 
concentrations during the winter.  However, the same group subsequently determined that 
leptin concentrations were higher in the winter than in the summer in young and mature 
mares.144,145  Steelman et al.144 performed a study to examine the effects of grain meal size 
and frequency on leptin concentrations.  Horses receiving smaller, more frequent meals had 
leptin secretion patterns similar to those seen on pasture, perhaps due to the similarity in feed 
amounts.  There was no diurnal variation in leptin secretion observed even though leptin 
concentrations are higher in the evening versus the morning in mature horses.144,146,147 
 
6.1.1Leptin secretion 
Leptin and insulin share a similar pattern of secretion in that concentrations tend to 
increase in fed states and decrease in fasted or feed restricted states, with leptin being 
produced by adipose tissue in response to glucose uptake, and insulin by the pancreas in 
response to elevations in circulating glucose concentrations.81,144  In studies evaluating effects 
of feeding on leptin concentrations in mature mares and geldings, hyperleptinemia and 
hyperinsulinemia were identified in 30% of a population of horses with high BCS.141,148,149  
Leptin concentrations have been correlated with fasted insulin concentrations in other species 
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such as the rat and rhesus monkey.146,148,150,151  Leptin stimulates glucose uptake and FA 
oxidation within skeletal muscle and inhibits insulin secretion by acting through leptin 
receptors on pancreatic β cells.138,152,153   
Insulin and leptin have opposing actions.  Insulin is lipogenic whereas leptin is 
lipolytic;  leptin also reduces adipose depot size through its ability to suppress insulin 
secretion.154  There was a decrease in leptin concentration in healthy horses in response to 
feed restriction;137  however, when food intake was no longer restricted, there was a slower 
than expected increase in leptin concentrations when compared to other species.  This delay  
may represent an evolutionary adaptation to ensure increased feed consumption after the 
body perceives a scarcity of forage.   
 
6.1.2 Leptin function 
 It has been suggested that leptin functions as an “adipometer” that signals the brain 
whether calorie reserves are sufficient or not.81  Leptin regulates fuel partitioning by 
promoting β-oxidation and protein synthesis and inhibiting lipogenesis, which lowers TG 
content in WAT without any resultant increase in circulating NEFA concentrations.154-156  
When looking at the influence different fat reserves have on leptin concentrations, the 
visceral/subcutaneous fat ratio has a moderately negative correlation with leptin.118  When 
there is sufficient energy, the central nervous system directs the expenditure of excess 
calories towards non-feeding activities such as reproduction and immunity.81   
Leptin elicits an anorexic effect and in states of starvation this effect is lessened, 
which stimulates feed intake.81  The hormone exerts its action by binding to the leptin 
receptor (Ob-R) which is broadly expressed.99  There have been several variants of the 
receptor described but the soluble leptin receptor is a major determinant of circulating leptin 
concentrations.  This receptor contributes to the pharmacokinetics and action of leptin by 
stabilizing the molecule in the blood and preventing the bound form from interacting with 
other leptin receptors without affecting the activity of the free hormone.99,157,158  Within the 
hypothalamus, leptin exerts its effect by binding to its receptors at the arcuate nucleus and 
thereby communicating the overall degree of adiposity, which in circumstances of obesity 
leads to inhibition of food intake and a decrease in body fat mass due to increased calorie 
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expenditure.81  In overfeeding, proopiomelanocortin (POMC) neurons are activated and 
contribute to the decrease in food intake in response to a positive energy balance.159  The 
decrease in body fat mass leads to a decrease in leptin concentrations, with this cycle 
representing a classic negative feedback loop.81 
 
6.1.3 Leptin resistance 
 Obesity is associated with leptin resistance instead of deficiency, with higher leptin 
concentrations detected, implying impairment of negative feedback.81,137,159  The state of 
leptin resistance is defined by high leptin concentrations with hyperphagia and obesity.159  
Humoral mediator elevations in a negative feedback loop are the hallmark of a resistance 
syndrome.81,160  Generally in a classic feedback loop, the cause of the resistance is either 
receptor or post-receptor insensitivity, however with leptin there are two additional methods 
in which resistance can be caused – impaired transport of leptin across the blood-brain barrier 
or impairment of downstream neuronal signaling.81  In both human and animal models, the 
majority of cases of leptin resistance occurs due to impairment at the blood-brain barrier or 
receptor/post-receptor level.81  A state of peripheral leptin resistance is diagnosed when 
exogenous doses of leptin are unable to elicit anorectic drive, indicating the inability of 
circulating leptin to signal the brain.81  Central leptin resistance is defined by a lack of 
response to leptin being  administered directly to the brain and it appears from one rodent 
model, that peripheral resistance is more severe or precedes central resistance.81,161   
A transcription factor called STAT3 plays an important role in leptin resistance by 
affecting the leptin-induced regulation of food intake and hepatic glucose production.154,159  
The target gene for STAT3 is suppressor of cytokine signaling 3 (Socs3) which is produced 
in response to cytokine signaling and provides negative feedback.159,162,163  It was shown in 
animal experiments that Socs3 plays a role in leptin resistance, because mice with genetic 
modifications that eliminated or inhibited its ability to bind the leptin receptor had decreased 
food intake and body weight.159,164  Another mechanism in leptin resistance is phosphatase 
PTP1B which is responsible for the dephosphorylation of Janus Kinase 2 (Jak2), the initial 
tyrosine kinase involved in leptin receptor signaling.159,165,166  When the gene for this enzyme 
is deleted, mice are lean and hypersensitive to leptin.159,165,166 
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 As leptin concentrations increase in the obese state, it appears to exert less influence 
on centrally-mediated appetite and weight control81  Triglycerides have been shown to 
decrease transport of leptin across the blood-brain barrier, and hypertriglyceridemia is 
detected in obese humans and animals.81,167   
 
6.2 Adiponectin 
6.2.1 Structure and discovery 
 Adiponectin is a 30 kDa adipose-derived factor composed of 247 amino acids that 
directly affects glucose homeostasis and regulates insulin sensitivity.86,168  The gene for 
adiponectin was first isolated from adipose tissue in 1996 and has lower expression in obese 
animals and humans.99,169  The protein itself, however, was discovered by multiple 
laboratories throughout the 1990s and was given multiple names, including complement-
related protein 30, adipoQ, adipose most abundant gene transcript, gelatin-binding protein, 
and adiponectin.169-172  
Adiponectin has been studied in conjunction with MetS because its absence is noted 
in states of IR and glucose intolerance, and it has been shown to induce weight loss, inhibit 
hepatic glucose production, and increase FA oxidation.99,173,174  It is comprised of 4 regions; 
an N-terminal region with no homology to any known proteins, a 27 variable amino acid 
region, a collagen-like region, and a C-terminal globular domain that is homologous to 
complement factor C1q and type VIII and X collagens.64,170,172  It is the most abundant 
secretory protein of adipose tissue in humans and acts as an anti-inflammatory, insulin 
sensitizing anti-diabetic hormone, and anti-atherogenic agent.124,171,175,176  Adiponectin 
concentrations are inversely correlated with central adiposity, IR, and the homeostasis model 
of IR (HOMA-IR), which is discussed below.124,171,175,176  It is the predominant adipokine 
influencing SI and plays a role in FA oxidation, leading to lower plasma TG concentrations 
and improved glucose homeostasis.175,177 
 Circulating adiponectin occurs as trimers, hexamers, and multimers with low 
molecular weight (LMW; single trimer), mid-molecular weight (MMW; two trimers), and 
high molecular weight (HMW; multiple hexamers) forms.64,86,177  Globular forms are also 
isolated, which are comprised of the globular head (C-terminal end) portion of this adipokine.  
18 
 
Plasma concentrations are approximately 5µg/mL in humans, with lower levels detected in 
individuals suffering from T2D, IR, and hyperinsulinemia.108,168,177,178   Adiponectin 
concentrations are higher in women compared to men and are generally reduced in obese 
animals and in patients with T2D.168,175,177  In a study evaluating metabolic markers of IR in a 
population of British children, there was no significant difference noted between boys and 
girls;26 however, as children aged and BMI increased, there was a decrease in adiponectin 
concentrations for both genders attributed to fat acquisition in the years before puberty.  The 
HMW form of adiponectin is proposed to have a stronger correlation with IR compared with 
total circulating concentrations because this form is more biologically active.124,179   
In horses, plasma total adiponectin concentrations reflect obesity and therefore fitness.  
Gordon et al.180 showed that plasma adiponectin concentrations were higher in a research 
population of physically fit Standardbred mares when compared to unfit counterparts.  There 
was no diurnal variation in adiponectin secretion detected in the same study.   This lack of a 
diurnal rhythm was also documented in humans, although one group detected a significant 
decline in this adipokine at night.180-182   
 
6.2.2 Adiponectin receptors 
There are two known receptors for adiponectin, referred to as AdipoR1 and AdipoR2.  
The first is predominantly expressed in skeletal muscle and WAT and shows a higher affinity 
for the globular form of adiponectin, which increases FA oxidation and prevents diet-induced 
obesity, when experimentally injected.86,128,183,184  In contrast, AdipoR2 is predominantly 
expressed in the liver and only responds to the full length protein.86,184  Humans with IR and 
T2D have lower expression of both receptors in skeletal muscle, and the expression of both 
receptors is positively correlated with SI.177,185,186  Ceddia et al.86 demonstrated that, by 
administering globular adiponectin to rat L6 myocytes, glucose uptake increased as a result of 
increased GLUT4 translocation to the myocyte membrane.  Adiponectin receptor knock-out 
mice develop severe glucose intolerance and IR when both receptors are disrupted, proving 
that these receptors play an important role in the regulation of insulin sensitivity.64,187  In the 
same study it was shown that the two adiponectin receptors had functional differences, with 
AdipoR1 being more tightly linked with AMPK activation and AdipoR2 being associated with 
PPAR-α activation and the inhibition of inflammation and oxidative stress.64,187 
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6.2.3 Role of adiponectin in insulin resistance 
 In humans, the prevalence of IR decreases with increasing plasma adiponectin 
concentrations.124,168  Adiponectin is positively associated with SI, and states of 
hypoadiponectinemia are associated with IR.124,176  The mechanisms by which adiponectin 
exerts it effect on insulin action are not completely known, but are thought to involve PPAR-
α, and AMPK activation, which increase FA oxidation in muscle and liver, and therefore 
decrease tissue TG concentrations.64  Lowering TG concentrations within skeletal muscle 
improves insulin signaling.   
Several factors regulate the production of adiponectin by WAT, including 
inflammatory cytokines such as TNFα and interleukin 6 (IL-6), as well as PPAR-γ.128,188,189  
Activation of PPAR-γ increases levels of adiponectin and creates a shift in fat from visceral 
to subcutaneous depots.118,190  van der Poorten et al.118 demonstrated that there is an inverse 
correlation between adiponectin levels and visceral fat depots.  The inflammatory effect of 
TNFα is opposed by the anti-inflammatory effect of adiponectin.64,128,191  Adiponectin 
inhibits TNFα release and attenuates the inflammation associated with obesity by inducing 
production of other anti-inflammatory mediators such as interleukins 1 and 10 (IL-1, IL-
10).64,128,191  However, the expression of adiponectin is down regulated with obesity and 
hypoadiponectinemia is observed in patients with visceral obesity and IR.98,108,174  This 
observation is especially important in circumstances of excess visceral adipose tissue because 
inflammation reduces adiponectin secretion.64,192  Increased inflammatory cytokine 
production and the release of FA into the portal circulation leads to hepatic TG accumulation 
and IR.64,192 
The concept of a genetic influence on adiponectin concentrations has also been 
proposed because offspring of hypertensive patients have lower plasma adiponectin 
concentrations when compared to offspring of normotensive patients.175  Matsubara et al.193 
showed that plasma adiponectin concentrations are negatively correlated with serum TG 
concentrations and the atherogenic index, and are positively correlated with HDL-cholesterol 
levels.168,193  It has also been shown that single nucleotide polymorphisms of genes encoding 
adiponectin protein and receptors have associations with T2D phenotypes.177  Adiponectin is 
not likely to be the main determinant of insulin sensitivity as many other factors have been 
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associated with insulin sensitivity as well, but may be a marker of metabolic state which is 
influenced by interactions among different organs (adipose, skeletal muscle, and liver).177 
 
6.3 Resistin 
6.3.1. Discovery and distribution 
 One of the newest adipokines to be discovered and studied for its role in IR and MetS 
is resistin.  Resistin was discovered by three research groups and has been associated with 
IR.168,194-196  A link between resistin and IR has been found in animal models, but there have 
been inconsistent results in humans.124,195,197  Resistin is a 12.5 kDa polypeptide hormone that 
belongs to the family of small cysteine-rich secretory proteins.64,195  This adipokine is 
expressed predominantly by adipose tissue, but is mainly produced by the infiltrating 
macrophages of the adipose tissue, which are the primary mediators of the immune response 
and represent up to 40% of adipose tissue.99,124,129,168,198,199   
High plasma resistin concentrations are detected in humans with morbid obesity.168,200  
This elevation in resistin may indicate a role in the pro-inflammatory state associated with 
obesity.64,124  However, other investigators have failed to demonstrate a relationship between 
obesity or IR and resistin expression.175  Resistin serves as a signaling molecule between the 
energy storage organ of adipose tissue with the insulin-sensitive liver and skeletal muscle 
tissues.46,201 
 
6.3.2 Influence of resistin on insulin sensitivity 
 In rats, a sexual dimorphism has been found in the expression of the resistin gene, 
with male rats having a greater expression compared to females.168,202  In animals and 
humans, the administration of thyroid hormones increases basal and insulin-induced glucose 
uptake by skeletal muscle, most likely due to an increase in GLUT4 function.168,203  In states 
of drug-induced hypothyroidism, resistin mRNA expression increases in adipose tissue, 
which suggests that decreased resistin concentrations are involved in the improvement in 
insulin sensitivity seen with thyroid hormone supplementation.168,202  The treatment of 
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patients with insulin-sensitizing drugs decreases resistin levels, further supporting the 
suggestion that this adipokine is an important mediator of IR.36,195 
 Hivert et al.124 found that individuals with MetS had higher resistin concentrations 
and lower levels of adiponectin.  In this group, the prevalence of IR increased positively with 
increasing concentrations of resistin.124  The expression of resistin is increased in response to 
pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1, and resistin blood concentrations 
are positively correlated with blood concentrations of these inflammatory markers.64,204  
Resistin may also stimulate the same pro-inflammatory cytokines, implying a positive 
feedback loop.128,132   
 
6.3.3 Role of resistin in hepatic insulin resistance 
Resistin is thought to be involved in the development of hepatic IR because infusion 
of recombinant resistin impairs hepatic insulin sensitivity and increases hepatic glucose 
production.99,198  Hepatic resistance mediated by resistin in states of diet-induced obesity has 
been related to the inactivation and inhibition of AMPK and the opposing activation of ACC 
and Socs3.109,205-207  It has been shown in rats that acute administration of resistin increases 
blood glucose concentrations by both inhibiting insulin-stimulated glucose uptake and 
enhancing hepatic glucose production.198,208,209 
 Singhal et al. 109 demonstrated that deleting the resistin gene (retn) in wild type and 
ob/ob mice decreased hepatic TG content when compared to controls and lowered serum TG, 
cholesterol, glucose and insulin concentrations.  In the mice deficient for the resistin gene, 
there was also a decrease in mRNA expression of SREBP-1, ACC, and FAS, as well as 
protein levels of ACC.  The receptor for resistin is currently unknown, but the induction of IR 
via resistin has been attributed to reduced phosphorylation of AMPK and activation of 
Socs3.109,206,207  In states of resistin deficiency, insulin sensitivity is improved, which leads to 
decreased hepatic glucose production, improvement in hepatic IR, and increased glucose 
uptake by peripheral tissues.109,205,206  In resistin deficient mice, key lipogenic genes, 
including SREBP-1 and FAS, are suppressed in the liver whereas genes involved in lipolysis 
remain unaffected.109 
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 Treating rat hepatocytes with resistin and insulin has been shown to significantly 
decrease glycogen content, supporting the concept that resistin antagonizes the effects of 
insulin on glucose uptake and storage201 via decreased glycogen synthesis or increased 
glycogenolysis.  Additionally, such treatment reduces the number of insulin receptors, and as 
a consequence, there is a decrease in glycogen synthase activation and decrease in glycogen 
phosphorylase, with an increase in hepatic glucose production.201  However, in the absence of 
insulin, there was no effect of resistin on glycogen phosphorylase activity, which led to the 
conclusion that resistin enhances glycogen phosphorylase activity by down-regulation of the 
insulin receptor.201  This sequence of events may explain the association between resistin and 
hepatic IR.   
  
6.4 Glucagon-Like Peptide 1 
6.4.1 Structure and discovery 
Glucagon-like peptide 1 (GLP-1) was first discovered in 1968 when it was 
established that a glucagon-like immunoreactive material secreted by L-cells of the intestine 
in response to an oral glucose load was different from glucagon itself.210  It differed from 
glucagon both physiochemically and biologically and was found to be a component of the 
major proglucagon fragment that forms in parallel with glucagon during post-translational 
processing.210,211  It is a 29-amino acid protein that is secreted in an active form, designated as 
GLP-1 7-36 amide, and is inactivated to GLP-1 9-36 amide as a result of rapid removal of the 
NH2 terminus by an enzyme known as dipeptidylpeptidase-4 (DPP-4).210,212  Glucagon-like 
peptide 1 is an incretin hormone, which is defined as a hormone capable of amplifying the 
glucose-induced secretion of insulin following oral glucose administration when compared to 
intravenous glucose administration.213   
 
6.4.2 Measurement of GLP-1 
 Since the active form of GLP-1 is degraded rapidly by DPP-4, it is necessary to 
prevent its inactivation by treating blood samples with a DPP-4 inhibitor if active GLP-1 is 
the hormone of interest.214  It has been determined that the majority of active GLP-1 secreted 
is already inactivated by the time it reaches the portal vein, resulting in a short half-life of 
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several minutes.214  Assays that measure total GLP-1 use antibodies directed towards the 
carboxyl (COOH-) end of the protein, which is not cleaved by DPP-4.210  However, assays 
designed to measure active GLP-1 utilize antibodies directed towards the intact NH2 terminus 
as described above.   
 
6.4.3 Association with insulin resistance and obesity 
The main effect of GLP-1 is to enhance insulin secretion following an oral glucose 
dose; however, it has recently been discovered that GLP-1 also affects gastric emptying rate 
and satiety.215  By slowing the rate of gastric emptying, the glycemic response to a meal is 
also diminished, aiding in glucose homestasis.215  Glucagon-like peptide 1 has also been 
associated with inhibition of pancreatic glucagon secretion and hepatic glucose production.211   
Studies have shown that there is abnormal secretion in conditions associated with 
insulin resistance and/or obesity such as type 2 diabetes, polycystic ovary syndrome (PCOS), 
and myotonic dystrophy.216-218  It has been determined that attenuated GLP-1 secretion is a 
result of obesity, with lean subjects showing more pronounced responses to an oral sugar 
challenge when compared to obese individuals.211,218  In a study of patients with MetS, it was 
determined that fasting levels of serum GLP-1 were 28% higher in people with MetS, 
compared to individuals with Pre-MetS.122  Elevations in fasting GLP-1 concentrations were 
significantly related to the presence of dyslipidemia.122  This supports earlier findings that 
higher fasting plasma concentrations of GLP-1 are associated with higher resting energy rates 
and fat oxidation.219  Obesity is often associated with IR and diabetes as higher fat mass 
inhibits insulin action.220,221 
Polycystic ovary syndrome is one of the most common endocrine disorders in women 
that negatively impacts fertility and increases the incidence of T2D.217  When compared to 
normal women undergoing an oral glucose tolerance test, basal concentrations were found to 
be similar during the early part of the test, but differed in the later part of the test, with lower 
concentrations in PCOS patients.217  This is relevant to the finding that post-prandial GLP-1 
concentrations and area under the curve values are significantly lower in type 2 diabetics 
compared to people with normal glucose tolerance.218  However, in a study of 18 men with 
myotonic dystrophy, which is characterized with pronounced IR and hyperinsulinemia, a 
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significantly greater increase in GLP-1 concentrations was detected following an oral glucose 
load compared to controls.216  Baseline GLP-1 concentrations were also lower in the 
myotonic dystrophy patients compared to controls.  
 
6.4.4 Potential role in therapy 
 Glucagon-like peptide 1 is associated with enhanced insulin secretion by the β-cells of 
the pancreas and has been investigated as a therapy for impaired glucose control and 
IR.212,222-225  In dogs that have undergone total pancreatectomy, administration of GLP-1 was 
shown to potentiate insulin action during a hyperinsulinemic clamp, and this was attributed to 
the effects of GLP-1 on insulin-stimulated glucose utilization.222  This study also showed 
suppression of FA and glycerol concentrations because GLP-1 potentiates the anti-lipolytic 
effects of insulin.  In humans, administration of a GLP-1 analogue significantly reduced 
glycosylated haemoglobin concentrations and improved fasting and post-prandial glucose 
control when administered in conjunction with metformin.224  Hyperglycemia is a frequent 
occurrence in critically ill patients on mechanical ventilation and total parenteral nutrition, 
and this problem can adversely affect medical outcomes.  The overall glycemic response to 
enteral nutrient infusion was reduced in patients treated with GLP-1 over 270 minutes on 2 
consecutive days compared with placebo and this was accompanied by increased insulin to 
glucose ratio.223 
 Administration of DPP-4 inhibitors has also been evaluated as a potential therapy for 
impaired glucose tolerance and IR.  Inhibitors have been evaluated on their own or in 
conjunction with other anti-diabetic compounds.212  They enhance GLP-1 activity by 
preventing its rapid inactivation following secretion by the small intestine.212  In dogs, the 
DPP-4 inhibitor vildagliptin was found to increase hepatic glucose uptake during GLP-1 
infusion.225  It was also determined that the oral administration of vildagliptin via stomach 
gavage 20 minutes prior to glucose and GLP-1 infusions was capable of suppressing DPP-4 
activity throughout the 4-hour test period.225   
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6.4.5 Conclusions 
 Results of studies suggest that obesity, rather than IR, may play a more important role 
in GLP-1 secretion as obese humans tend to show higher fasting concentrations but 
diminished responses during oral glucose tests.  This may allow GLP-1 to function as an 
adequate marker for identifying humans and animals that are at greater risk for the 
complications associated with obesity.  Administration of GLP-1 or DPP-4 inhibitors appears 
to improve insulin sensitivity and glucose tolerance.  At the time of writing, there are 
currently three selective DPP-4 inhibitors, sitagliptin (Januvia), vildagliptin (Galvus), and 
saxagliptin (Onglyza) available for use in the United States and Europe.212  Both GLP-1 
analogues and DPP-4 inhibitors can therefore be used to treat impaired glucose tolerance and 
insulin resistance.      
 
7. Methods of assessing insulin sensitivity and resistance in the horse 
7.1. Frequently-sampled intravenous glucose tolerance test 
 The frequently-sampled intravenous glucose tolerance test (FSIGTT) is used to 
quantify insulin sensitivity via application of the minimal model.226-229  Minimal model 
analysis is a mathematical construct that partitions glucose disposal into insulin-dependent 
(insulin sensitivity – the capacity of insulin to promote glucose disposal) and insulin-
independent (glucose effectiveness – the capacity of glucose to mediate is own disposal) 
glucose utilization, while also estimating the sensitivity of pancreatic β-cells to glucose.226-229  
The minimal model of glucose and insulin dynamics is a nonlinear regulatory model fitted to 
data collected during the FSIGTT.31 
 
7.1.1 Procedure in horses 
An insulin-modified FSIGTT is performed in horses.228-231  The overall procedure of 
this test is to administer a body weight (bwt) dependent bolus of dextrose intravenously, 
collect samples at specific time points, and at 20 minutes post-dextrose, administer insulin 
intravenously at a weight dependent dose, and then continue with collection of blood samples 
for a test duration of 180 minutes.228,231  Hoffman et al.228was the first research group to 
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utilize the FSIGTT for assessment of insulin sensitivity and glucose metabolism in the horse.  
The procedure assessed by this group included baseline samples followed by administration 
of a 50% dextrose solution bolus at 0.3 g/kg bwt via jugular catheter.  Blood samples were 
collected via catheter at time points 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, and19 minutes.  At 20 
minutes, an insulin bolus was administered through the catheter at a dose of 30 mU/kg bwt, 
and sample collection resumed at 22 minutes and continued at times 23, 24, 25, 27, 30, 35, 
40, 50, 60, 70, 80, 90, 100, 120, and 180 minutes.  Glucose and insulin concentrations were 
measured in each sample.228 
 
7.1.2 Calculations 
Minimal model analysis utilizes a computerized algorithm which supplies the 
investigator with 3 variables: (1) the index of insulin sensitivity (SI), (2) glucose 
effectiveness (Sg), and (3) the acute insulin response to glucose, (AIRg).31,227,228  The 
disposition index (DI) is often calculated.  The measure Sg represents the capacity of glucose 
to mediate its own disposal, independent of changes in the circulating levels of insulin as well 
as its ability to inhibit hepatic glucose production.  The following formula is used: 
                   G' (t) = -(X+ Sg) x G(t) + (Sg x Gb) 
where G'(t) represents the rate of glucose clearance from plasma (min -1); X represents insulin 
action; G(t) represents the plasma glucose concentration (mg/dL) at time t, G(0) is the 
theoretical concentration of glucose at time 0; and Gb represents the basal glucose 
concentration (mg/dL) which is maintained by hepatic glucose production.228,232 
 The SI value represents the capacity of insulin to promote glucose disposal (L mU-1 
min-1) and can be defined as the fractional glucose disappearance per insulin concentration 
unit and calculated using the following formulas: 
        X' (t) = -p2 x X(t) + (p3 x [I(t) – Ib]) 
     SI = p3/p2 
where X' (t) (min-2) represents the change in insulin action over time; p2 represents the rate 
(min-1) of decline of insulin action; X(t) represents insulin action (min-1), p3 is the rate (min-1) 
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of introduction of insulin into the interstitial space; I(t) is the insulin concentration (mU/L) at 
time t; and Ib is the basal insulin concentration (mU/L).228,232 
 Pancreatic function is represented by AIRg (mU min L-1) which quantifies the 
endogenous insulin secretion occurring in response to the glucose dose and is calculated 
using the formula; 
    AIRg = ∫ [I(t) – Ib] x dt 
where I(t) is the insulin concentration at time t and Ib is the basal insulin concentration.228 
 Finally, DI is an index that describes pancreatic β-cell responsiveness and accounts 
for the influence of AIRg and Si and is calculated using the following formula; 
            DI = AIRg x SI.228 
 
7.1.3 Use of the FSIGTT in horses 
Hoffman et al.228  introduced the FSIGTT as a tool for examining glucose and insulin 
dynamics in horses and responses to glucose were similar to other species.228,233,234  However, 
Pratt et al.227 subsequently demonstrated that the standard FSIGTT without an insulin bolus 
has a higher mean coefficient of variation when compared with the euglycemic 
hyperinsulinemic clamp (EHC) technique, which is discussed below.  It was noted that 
insulin sensitivity can be more precisely estimated when there is a defined demarcation 
between 1st and 2nd phase insulin responses, so the  FSIGTT was modified to include an 
insulin bolus.227  The insulin-modified FSIGTT has been used to detect IR in a group of 
mature obese mares and provides important information regarding pancreatic insulin 
output.29,228,235  Disadvantages of the EHC are that it is time consuming, requires trained 
personnel, relies upon steady-state conditions, and demands constant adjustment, whereas the 
FSIGTT is more straightforward, less invasive, and technically simpler to perform.31,227,228,232 
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7.2 Euglycemic hyperinsulinemic clamp  
7.2.1 Introduction   
The EHC technique involves inducing and maintaining a state of hyperinsulinemia via 
continuous infusion of insulin, while at the same time maintaining euglycemia by 
administering variable amounts of dextrose.227  Insulin infusion suppresses endogenous 
glucose production by the liver and euglycemia provides physiologic inhibition of 
endogenous insulin secretion.14  The clamp technique, like the FSIGTT, has been used 
successfully in the horse.227,228,236,237 
The EHC procedure was established by DeFronzo et al.237 in 1979 as a method of 
quantifying insulin secretion and resistance in humans, using the principle that a patient with 
normal insulin sensitivity would require more glucose to maintain euglycemia than an 
individual with IR.  This same situation was first demonstrated in a horse when a 29-year-old 
mare suffering from persistent hyperglycemia and hypertriglyceridemia was evaluated.235  
When simplified, the amount of glucose required to maintain basal concentrations is equal to 
the amount of glucose taken up by the tissues, and therefore represents a measure of 
peripheral tissue sensitivity to insulin.  During the insulin infusion period, the amount of 
glucose required to maintain euglycemia increases, so measurements taken during the plateau 
period are utilized for calculations.14 
 
7.2.2 Procedure in horses 
 Baseline blood samples are collected and then the horse is connected to a peristaltic 
infusion pump which administers human recombinant regular insulin at a constant rate of 3 
mU/min/kg bwt, or 5 to 20 mU.m-2.min-1 in humans, when the dose is based upon body 
surface area.232  In an early study performed in horses, a priming dose of insulin was 
administered at a dosage of 323 µmol/kg bwt dissolved in 50 mL saline over 10 minutes.14  
Once the priming dose was administered, the constant infusion of insulin was started and 
continued throughout the study at a rate of 43 µmol/kg.min-1.14  Dextrose was administered at 
the same time as insulin to prevent hypoglycemia.   
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The EHC procedure usually takes 180 minutes to perform and blood samples are 
taken at 5 minute intervals so that glucose concentrations can be measured using a portable 
glucometer.  Depending upon the measured glucose concentration, an infusion of 50% 
dextrose solution is administered at variable rates by calibrated syringe pump so that blood 
glucose concentrations are maintained within euglycemic range.  In the procedure performed 
by Pratt et al.,227 blood samples were also collected at 15 minute intervals for measurement of 
insulin concentrations.  The first 90 minutes of the clamp procedure can be considered an 
equilibrium period, and the data collected from the samples obtained in the last 60 minutes 
are utilized for the calculation of whole body glucose uptake and an index of insulin 
sensitivity.227 
 
7.2.3 Calculations 
 Whole-body glucose uptake (M) represents the amount of glucose taken up by 
glucose utilizing tissues in response to insulin and it is assumed that  hyperinsulinemia has 
suppressed endogenous glucose production completely.227,237  Since euglycemia is not 
maintained perfectly throughout the procedure, a correction factor referred to as the space 
correction (SC) must be calculated to determine M.  This correction is calculated to account 
for the glucose that has been added to, or removed from, the glucose space outside of normal 
metabolism.  The following formula is used: 
         SC = (G2 – G1)(0.19 bwt)/(T x bwt) 
where G1 and G2 represent the beginning and ending glucose concentrations of each time 
interval, T is the time interval (5 minutes), bwt is calculated in kg, and (0.19 bwt) is equal to 
the glucose space in liters.  The result of this equation is required to calculate M: 
               M = GIR – SC 
where GIR is the glucose infusion rate measured in mmol/kg/min.227,237 
 The index of insulin sensitivity measured from this technique is calculated from the 
steady-state insulin concentration (I) which is the average of the serum insulin concentration 
measured during the final 60 minutes of the EHC and is used to calculate the M/I ratio.  This 
ratio reflects the rate of glucose disposal per unit of insulin and serves as a reasonable index 
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of insulin sensitivity.14,227,237  Another calculation for this index that can also be utilized and 
is: 
          SIClamp = M/(G x ∆I) 
where G is the blood glucose concentration during the steady-state, and ∆I is the difference 
between the fasting and steady-state insulin concentrations.232 
 A study looking at the glucose disposal rate of both lean and obese mares found that 
mares with a BCS of approximately 4.5 had glucose disposal rates ranging from 3.9 to 10.5 
µmol/kg/min, while obese mares with a BCS of approximately 8.5 had glucose disposal rates 
ranging from 0 to 14.5 µmol/kg/min.31,236 
 
7.2.4 Conclusions  
 When tests were compared in horses, mean coefficient of variation was 14% for the 
EHC compared to 24% for the FSIGT.227  Rijnen et al.14 also assessed the repeatability of 
EHC results by performing the procedure in the same horses on 3 different occasions over a 
3-week period.  This study showed close agreement among the repeated tests in terms of M 
values (0.013, 0.016, and 0.016 mmol/kg/min), but the M/I ratio had wider variability 
(0.00037, 0.00057, and 0.00067 mmol/kg/min).14,227  A main advantage of the EHC is that it 
provides a direct measure of whole body glucose disposal at a given level of insulinemia 
under steady-state conditions.232  A limitation of this technique is that supraphysiological 
levels of insulin are maintained during the procedure.232 
 
7.3 Combined glucose-insulin test 
7.3.1 Introduction 
 Many tests can aid in the diagnosis of diabetes mellitus, including fasting blood 
glucose concentrations, intravenous glucose tolerance tests, and clamp techniques.238  A 
glucose tolerance test measures the rate of clearance of glucose from the blood after oral or 
IV administration, with the time for blood concentrations to return to baseline measured.235,239  
Tests of insulin sensitivity measure the blood glucose response to an injection of exogenous 
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insulin.235  Eiler et al.238 combined these two types of test and developed the combined 
glucose-insulin test (CGIT) for use in horses.  This test was designed for use in the clinical 
setting and provides a more accurate measure of insulin sensitivity by combining information 
from glucose tolerance and insulin challenge tests.  
 
7.3.2 Procedure 
 When performing a CGIT, a single intravenous catheter is placed in the jugular vein 
to serve as the route of dextrose and insulin infusion, as well as sample collection.  Blood 
glucose concentrations are measured using a hand-held glucometer.  Once baseline values are 
obtained, 50% dextrose solution is rapidly administered (<1 minute) at a dose of 150 mg/kg, 
immediately followed by a bolus of human recombinant regular insulin at a dose of 0.1 U/kg 
diluted in 3 mL of isotonic saline.  Samples are collected by withdrawing 3 mL blood, which 
is discarded, and then the blood sample is collected.  Blood samples are collected at 0, 1, 15, 
25, 35, 45, 60, 75, 90, 105, 120, 135, and 150 minutes.238 
Healthy horses show a two phase blood glucose curve with a positive phase 
(hyperglycemia) that goes above baseline and a negative phase (hypoglycemia) which falls 
below baseline.  Each phase of the curve has an ascending and descending area, with 
ascending occurring first followed by descending in the positive phase, and the reverse is 
seen in the negative phase.  In healthy animals, the positive phase should descend to baseline 
concentration around 30 minutes post glucose and insulin administration, at which time the 
negative phase begins and glucose concentrations fall below baseline.  The nadir of glucose 
concentration in the negative phase has occurred by 75 minutes after the start of the 
procedure, at which time the ascending linear area begins around 105 minutes and is 
completed by approximately 140 minutes. In horses with IR, the positive phase is prolonged, 
causing a slower (≥ 45 minutes) return to baseline (Figure 1.2).6  
 
7.3.3 Conclusions 
 The CGIT test is easily interpreted by examining graphed results or using the 45-
minute result as a cut-off value.  The procedure is relatively simple to perform and well 
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tolerated.238  Due to the simplicity and ease of this procedure, the CGIT is a recommended 
test for diagnosing IR in horses. 
 
7.4 Proxy measures of insulin sensitivity 
7.4.1 Introduction 
Proxies and surrogates are single sample predictors of insulin sensitivity that utilize 
plasma glucose and insulin concentrations.33  They serve as inexpensive and easily applied 
quantitative tools.232  Single samples often provide good representation of glucose and insulin 
dynamics because they describe the chronic, non-agitated state of the individual.33  Treiber et 
al.33 evaluated proxies for insulin sensitivity by comparing single plasma glucose and insulin 
values to minimal model analysis results in horses. 
 
7.4.2 Types of proxy measurement 
 There are currently five proxies used to screen insulin sensitivity and β-cell 
responsiveness in humans, and two new proxies have been proposed for screening horses.33  
The proxies currently utilized in human medicine are the homeostasis model assessment 
(HOMA), the quantitative insulin sensitivity check index (QUICKI), the glucose-to-insulin 
ratio, the percent HOMA-beta cell function (HOMA-BC%), and the insulin-to-glucose ratio.   
The two new proxies established for use in horses are the reciprocal of the square root of 
insulin (RISQI) and the modified insulin-to-glucose ratio (MIRG). 
 
7.4.3 Equations for proxy measurements 
 For the following equations, all glucose and insulin values are basal measures and r is 
the correlation coefficient used to compare predicted insulin sensitivity with SI from the 
minimal model.   
HOMA = (glucose-insulin)/22.5 
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Figure 1.2: Glucose concentrations of non-obese (squares) and obese (diamonds) horses 
during a CGIT.  Glucose concentrations in obese horses remained above baseline for the 
duration of the test, whereas concentrations in non-obese animals return to baseline by 15 
minutes following a glucose infusion.  From Frank N et al. Physical characteristics, blood 
hormone concentrations, and plasma lipid concentrations in obese horses with insulin 
resistance J Am Vet Med Assoc 2006;228:1,383-1,390. 
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with 22.5 being a normalizing factor which is the product of fasting glucose (4.5 mmol/L) 
and insulin (5 µU/mL) concentrations in healthy humans.232  An individual with normal 
insulin sensitivity should, in theory, have a HOMA=1.  This proxy has r values of 0.60 and 
0.89 with SI.33,240,241 
QUICKI = (log[glucose × insulin])-1 
HOMA-BC% = (20 × insulin)/(glucose-63) 
Correlations with SI are 0.89 for the QUICKI and 0.60 and 0.58 for the HOMA-
BC.33,241,242  The insulin-to-glucose ratio is easily calculated and has correlation coefficients 
of 0.79 and 0.86; this measure correlates with insulin secretion by the pancreas.31,33  In 
contrast, the glucose-to-insulin ratio correlates with insulin sensitivity and has reported r 
values of 0.73, 0.91, and 0.92 with SI.31,33,241 
 The RISQI proxy measure of insulin sensitivity was devised specifically for use in 
horses by Treiber et al.33 and is calculated by the equation: 
RISQI = 1/√insulin=insulin-0.5 
 The same group developed MIRG, which is a measure of pancreatic insulin output 
and is calculated using the formula: 
MIRG = (800-0.30 × [insulin-50]2)/(glucose-30) 
Both RISQI (r = 0.77) and MIRG (r = 0.75) correlated well with SI and AIRg, 
respectively in the population of horses studied.33 This group provided calculations for SI and 
AIRg using proxy measurements:  
SI = ((7.93)(RISQI)-1.03) 
AIRg = ((70.1[MIRG])-13.8) 
 
7.4.4 Use of proxy measures 
 The HOMA measurement was devised to take advantage of the reciprocal relationship 
between basal insulin and basal glucose concentrations.33  In humans, the HOMA has good 
correlation with EHC results, as well as the SI values obtained from the minimal model.33,240  
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The QUICKI, similarly, was established for use in humans as a simple method of assessing 
insulin sensitivity as it relies upon the same reciprocal relationship between insulin and 
glucose.33,243  When compared, the QUICKI correlates better with insulin sensitivity.33,243   
The glucose-to-insulin ratio is based upon the concept that the insulin-secreting 
response of the β-cells is exaggerated with IR, despite normal glucose concentrations; a low 
glucose-to-insulin ratio therefore indicates lower insulin sensitivity.33  In the case of diabetes 
mellitus when hyperglycemia develops, the ratio increases, resulting in a conceptual flaw of 
this particular proxy.232  This ratio has stronger correlation with insulin sensitivity than the 
HOMA or QUICKI.33,35,244  The insulin-to-glucose ratio estimates the amount of insulin 
secreted by β-cells in response to glucose; a high ratio indicates reduced insulin sensitivity 
because there is compensatory secretion of insulin by the pancreas.33 
 The HOMA-BC% was first proposed in 1985 by Matthews et al.245 and correlates 
well with clamp and IV glucose tolerance test results.  This measure is a proxy for  AIRg and 
provides similar information to the insulin-to-glucose ratio.242  Studies in humans have shown 
that estimates of β-cell function are adequate in groups of individuals with similar health, but 
do not correlate well across different groups.244,246   
In horses, RISQI correlates well with insulin sensitivity and MIRG with pancreatic 
function , so these measures can be used to identify animals that are compensating for 
decreased insulin sensitivity with increased pancreatic insulin secretion.33  Proxies for SI and 
AIRg have specificity, sensitivity, and total predictive power of 85% and 88%, 45% and 
50%, and 78% and 80%, respectively in horses.33,235   When combined, these measures can 
aid in distinguishing healthy horses (normal SI and AIRg), from normoglycemic insulin-
resistant horses with compensatory insulin secretion (normal or low SI and high AIRg) and 
hyperglycemic horses with β-cell failure (low SI and AIRg).33,235  Proxies also allow 
investigators to make multiple determinations in a population or monitor clinical cases when 
more accurate measures such as the FSIGTT or EHC are impractical.33   
 
8. Treatment of insulin resistance 
 Drugs and supplements are used to treat IR in humans and horses, either directly or 
indirectly via weight reduction, and these therapies will be reviewed in the following section.  
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8.1 Levothyroxine 
8.1.1 Introduction 
 Levothyroxine sodium (LT4) is a synthetic thyroid hormone used to treat 
hypothyroidism, which is rare in adult horses.247  Studies performed by our research group 
have established that LT4 can be administered to horses to promote weight loss.247-249  The 
hypothalamic-pituitary-thyroid axis consists of the secretion of thyrotropin releasing hormone 
(TRH) by the hypothalamus, which stimulates the release of thyrotropin stimulating hormone 
(TSH) by the pituitary gland, which then stimulates the thyroid gland to release 
triiodothyronine (T3) and thyroxine (T4).  Thyroid hormones are measured as free T3, free 
T4, total T3 or total T4.  Free forms are physiologically active because they are readily 
available for use by the cells, whereas total measures are the sum of free and bound forms.  A 
negative feedback loop occurs and LT4 significantly decreases TSH concentrations in 
healthy, euthyroid horses.248,250 
 
8.1.2 Levothyroxine use in horses 
 Sommardahl et al.248 administered LT4 to healthy adult horses over an 8-week period 
and detected significant decreases in body weight compared to untreated controls.  Total daily 
doses of LT4 were 24, 48, 72, and 96 mg/d, with horses receiving LT4 at each dosage for 2 
weeks at a time.  There were no significant changes in health parameters (heart rate, 
respiratory rate, and rectal temperature) and only agitation was reported when horses received 
96 mg LT4 per day.248  Loss of body weight may result from increased energy expenditure 
and enhanced lipolysis.249,251  Humans receiving LT4 supplementation as a treatment for 
hypothyroidism have lower BMI and lower serum concentrations of TG, total cholesterol 
(TC), and VLDL.252,253 Rats receiving T4 supplementation have also shown increases in SI 
resulting from increased rates of glucose disposal and glucose-stimulated insulin 
secretion.252,253 
 Effects of LT4 supplementation on serum lipids and glucose dynamics were also 
examined in the same study of healthy mares.249  After 8 weeks of supplementation, there 
were significant decreases in plasma TG, TC, and VLDL concentrations in treated horses, 
with weak correlations found between LT4 dose and TG and TC concentrations.  These weak 
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correlations may be explained by a cumulative effect of LT4 dosing since washout periods 
were not inserted between treatment periods.249  No significant changes were noted for NEFA 
concentrations, regardless of LT4 dose.  When effects of hypothyroidism on VLDL 
concentrations have been examined, the opposite response was detected.254,255  Humans 
suffering from hyperthyroidism show higher catabolic rates of VLDL-TG fractions, implying 
that thyroid hormones stimulate the clearance of VLDL from the circulation.249,256   
Associations also exist between hyperthyroidism and serum concentrations of other 
lipoproteins and apolipoproteins.249,253  Thyroid hormones stimulate FA consumption by 
increasing β-oxidation rate as well as uncoupled thermogenesis in hepatocytes.249,257,258  The 
increase in β-oxidation in the liver is thought to lead to a reduction in the amount of TG 
available for VLDL synthesis, and it has been found that the TG carried by VLDL in the 
circulation is catabolized at a faster rate in humans suffering from hyperthyroidism.249,256 
 Use of LT4 in obese horses is important because obesity and IR are both risk factors 
for laminitis and insulin sensitivity increases in response to LT4 treatment in horses.6,11,228   
Horses receiving LT4 have shown a >2-fold increase in SI11 and significant increase in 
insulin disposal rate.249  When LT4 was administered to healthy mares, insulin sensitivity 
increased 1.8-, 2.4-, and 1.9-fold at 16, 32, and 48 weeks, respectively.11  A negative 
correlation (r = -0.42) existed between SI and body weight, and glucose effectiveness 
increased with treatment, while AIRg decreased.  A maximum of 10% weight loss occurred 
at 16 weeks and then body weight increased again.  However, there was an overall decrease 
in body weight of 5% compared with pre-treatment values.11  Weight loss may have been 
even greater if feed intake had been restricted because horses were allowed out on pasture to 
graze ad libitum.  This is an important point because it has been shown that rats receiving 
thyroid supplementation undergo weight loss associated with increased calorie expenditure, 
decreased adipocyte size, and decreased fat pad weight, and also exhibit hyperphagia, which 
can offset weight loss.11,251 
In humans, cardiac abnormalities including tachycardia, arrhythmia, and hypertension 
are associated with hyperthyroidism or overzealous use of LT4.249,259,260  Prolonged use of 
LT4 in humans can result in left ventricular hypertrophy, but does not appear to affect heart 
rate, blood pressure, or overall cardiac function.259,260  Since LT4 is commonly prescribed to 
promote weight loss in obese horses, Frank et al.259 performed cardiac evaluations on the 
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same mares described above that received 48 mg LT4/day for 48 weeks.  No adverse effects 
were noted when echocardiograms were performed and there were no changes in cardiac 
troponin I concentrations or creatine kinase MB activities.  Serum tT4 concentrations 
increased to levels 1.5- to 2-fold higher than reference range, but decreased again during the 
withdrawal period.259   
It should be noted that the duration of treatment in the aforementioned study was only 
48 weeks, which is short in relation to the lifespan of horses.  The duration of treatment may 
therefore explain the lack of cardiac alterations seen in these horses.259-261   
 
8.1.3 Levothyroxine and insulin sensitivity  
One explanation for the increase in insulin sensitivity associated with thyroid 
supplementation is that glucose transporter expression increases.  When mouse 3T3-L1 
adipocytes are exposed toT3, GLUT1 and GLUT4 increase by 87% and 90% respectively, 
causing a 3.6-fold increase in glucose uptake.249,262,263  Frank et al.11 detected higher mRNA 
expression of GLUT4 in adipose tissue collected from LT4-treated horses, suggesting that 
this transporter increases in abundance with treatment.  However, the opposite effect was 
observed in adipocytes harvested from rats that were treated with T4 for 7 days.263  There was 
a decrease in the density of insulin receptors, a reduction in the amount of insulin-stimulated 
glucose uptake, and a decrease in GLUT4 translocation to the plasma membranes upon 
stimulation by insulin.  It is possible that increased GLUT4 mRNA expression represents a 
compensatory response to these alterations.  
Weinstein et al.203 found that rats treated with T3 for 3 days showed increased (115% 
and 136%) basal glucose uptake in both soleus and extensor digitorum longus muscles 
respectively, as well as increased insulin-stimulated glucose uptake (55% and 42%, 
respectively).  These results indicate that thyroid hormone supplementation increases both 
basal and insulin-stimulated glucose transport in mammalian skeletal muscle.  This group 
also demonstrated that GLUT4 protein expression increased in both muscle types.  Results 
also implied that T3 has a role in increasing the fractional partitioning of GLUT4 from its 
intracellular stores to its location in the plasma membrane.203 
39 
 
An increase in metabolic clearance rate of insulin has been detected in humans with 
hyperthyroidism and rats that were treated with T4 for 5 days.264-266  Increases in insulin 
binding and insulin receptor density have also been detected in adipocytes harvested from 
rats receiving T4 therapy.266   The influence of LT4 on the glucose dynamics in horses has 
been attributed to reductions in body weight, but direct effects must also be considered.249   
Thyroid hormones also modulate proliferation and differentiation of adipocytes.267,268  
In humans, hyperthyroidism enhances lipolysis while hypothyroidism has the opposite effect, 
which can be attributed to increases cAMP and HSL activity.267  Viguerie et al.267 showed 
that treatment of human adipose tissue cultures with T3 induced gene expression in 
adipocytes, indicating that supplementation with thyroid hormone increases lipolysis.  
Elevations in cAMP seen with thyroid supplementation result from down-regulation of 
phosphodiesterase, the enzyme responsible for the hydrolysis of cAMP.267  When energy 
supplies are low, via hypoglycemia, glucagon, or catecholamines, cAMP levels increase and 
activate HSL which catalyzes breakdown of stored TG in adipose tissue into FA that can be 
used for energy.82   
Rats with hypothyroidism have an overall decrease in glucose turnover and glucose 
utilization by skeletal muscle and adipose tissues.269,270  With thyroid supplementation, there 
is an increase in AMPK activity, resulting in a subsequent decrease in ACC activity and 
lower malonyl-CoA levels.269  This reduction in malonyl-CoA availability increases FA 
oxidation and lowers the fat content of peripheral tissues such as skeletal muscle and adipose.  
As previously noted, the decrease in fat accumulation in insulin-sensitive tissue often leads to 
increased insulin sensitivity.269,271 
Another mechanism by which LT4 might increase insulin sensitivity is through 
modification of lipid metabolism.  Hypothyroidism reduces activity of enzymes involved in 
lipoprotein remodeling and lowers the number of LDL receptors, which are responsible for 
internalization of cholesterol into cells.272  A recent study looking at the correlation between 
thyroid function and MetS in humans found a negative relationship between FT4 and the 
HOMA index, with low-normal FT4 concentrations associated with greater IR.273  This study 
also found a significant negative correlation between levels of free T3 and free T4 and both 
TC and LDL-cholesterol concentrations.  Hypercholesterolemia is associated with 
hypothyroidism because LDL catabolism is inhibited by a lower number of LDL receptors.273  
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Higher serum TG concentrations in hypothyroid patients are attributed to decreased activity 
of hepatic TG lipase and slowed removal of circulating TG.273,274 
 
8.1.4 Conclusions 
Levothyroxine administration has been associated with weight loss and increased 
insulin sensitivity in horses, but studies are now required to evaluate this treatment in obese 
insulin-resistant horses with EMS.11,248,249,259   
 
8.2 Metformin 
8.2.1 Introduction 
 Metformin hydrochloride is an oral dimethylbiguanide anti-diabetic drug that is used 
in human medicine to improve insulin sensitivity.64  This drug has been used in for the 
treatment of T2D in humans since 1957 and is currently the most widely prescribed insulin-
sensitizing drug.275-278  A study in obese women with polycystic ovary syndrome (PCOS) 
that received one of 2 doses of metformin for 8 months, showed hepatic fat content decreased 
in response to treatment.275  Metformin is an attractive drug because it is cost-effective and 
has beneficial modes of action.276   
 
8.2.2 Metformin use in horses 
Durham et al.276 examined the efficacy of metformin in insulin-resistant  horses at a 
15 mg/kg bwt twice daily dosage and showed that treatment significantly lowered serum 
insulin and glucose concentrations, as well as proxy measures of insulin sensitivity and 
pancreatic output.  In human studies, there are consistent initial reductions in fasting insulin 
and glucose concentrations along with improved insulin sensitivity.276,279,280  However, 
efficacy waned over time in the study performed by Durham et al.276 and the same finding 
was reported by Vick et al.281  These results suggest insulin sensitivity deteriorates over time 
or the pharmacodynamics differ from other drugs.  The optimum metformin dose in man is 
approximately 2,000 mg/d, with a range of 500 to 3,000 mg/d.278  In horses, dosages have 
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ranged from 5.6 to 16.8 mg/kg bwt.276,281  Furthermore, the oral bioavailability of metformin 
is < 10% in the horse, compared with 40-60% in humans, with peak levels 1 to 3 hours post-
dosing, and a half-life of 4 to 9 hours.276,282,283 
 
8.2.3Mechanisms of metformin action 
 Metformin has diverse modes of action that include both insulin-dependent and 
insulin-independent actions to promote insulin-stimulated glucose uptake as well as glycogen 
and TG synthesis, lipolysis, and inhibition of hepatic glucose production.276,279,284  Plasma 
lipid concentrations also decrease with metformin treatment.276,285   
Treatment of rats with metformin elicits dose- and time-dependent activation of 
AMPK.277  Phosphorylation of AMPK is promoted by AMP in response to a decrease in the 
ATP:AMP ratio, with the threonine 172 residue (Thr 172) becoming phosphorylated.277  It 
has also been proposed that metformin may elicit its influence on AMPK activation by either 
directly activating the AMPK-kinase, or by making AMPK a better substrate for this enzyme 
by binding to it directly.277  By enhancing the activation of AMPK, the activity of ACC 
decreases, which lowers malonyl-CoA levels.277  Beta oxidation and lipolysis are stimulated 
as malonyl CoA concentrations decrease.   
Lipogenesis is also decreased with metformin treatment, as the activation of AMPK 
leads to a down-regulation of genes involved in FA synthesis, such as FAS.277  Insulin 
stimulates lipogenesis via the lipogenic transcription factor SREBP-1c, which affects genes 
such as FA synthase.277  Zhou et al.277 showed that incubation of rat hepatocytes with 
metformin strongly suppressed SREBP-1c.  These effects  may explain the ability of 
metformin to lower serum TG and VLDL concentrations  in vivo.277   Metformin also inhibits 
tyrosine phosphatase hPTP-1B and it should be noted that mice that do not express this 
protein are very resistant to obesity.286-288  This may explain why individuals using metformin 
often maintain or lose weight.  Inhibition of hPTP-1B also lowers blood lipid 
concentrations.287 
Gluconeogenesis by the liver is also inhibited by treatment with metformin and this is 
attributed to activation of AMPK and the insulin receptor.277  Results of several studies 
indicate that active AMPK is required for metformin to exert its inhibitory effects on hepatic 
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glucose production.277,287  Studies have also implicated AMPK activation in stimulating 
glucose uptake by skeletal muscle.277,289,290  Zhou et al.277 showed that there was an increase 
in the activity of the catalytic sub-units of AMPK when rat skeletal muscle was incubated 
with metformin, and also a significant increase in glucose uptake that was additive after the 
addition of insulin. 
Metformin might also regulate hepatic glucose production via activation of the insulin 
receptor.  This signals that energy supplies are sufficient, and by its activation, it inhibits 
glucose production by the liver.  Metformin increases tyrosine kinase activity, as well as 
tyrosine phosphorylation of the insulin receptor, and therefore its activation.287  Both insulin 
binding and metformin increase the phosphorylation of tyrosine residues in the β-subunit of 
the insulin receptor in a comparable amount, however, it takes metformin longer to elicit its 
effect (90 minutes) compared to insulin (20-30 minutes).287   
 
8.2.4 Conclusions 
Metformin acts by decreasing hepatic glucose production and increasing skeletal 
muscle glucose uptake.87  It is believed that metformin accomplishes this by decreasing 
lipogenesis, increasing lipolysis, activating AMPK, and activating the insulin receptor.  This 
drug is considered safe in humans, although side effects seen in humans include 
gastrointestinal symptoms of diarrhea, abdominal comfort, nausea, and anorexia.279  Given 
the sensitivity of horses to developing colic, close attention must be paid to animals receiving 
metformin.  However, no adverse reactions have been noted to date when metformin has been 
administered to horses orally.276  Metformin might therefore serve as a safe and affordable 
treatment for IR in horses. 
 
8.3 Chromium 
8.3.1 Introduction 
 Chromium (Cr) is an essential trace mineral required by mammals, and plays a role in 
carbohydrate and lipid metabolism.291,292  In 2001, it was established by the US Food and 
Nutrition Board that the daily adequate intake for men was 35 µg and 25 µg for women.292  
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Chromium has two main oxidative forms, trivalent (Cr+3) and hexavalent (Cr+6); the trivalent 
form is the most stable whereas the hexavalent form has been shown to cause clinical 
cancer.291,293  The trivalent form is found in foods, such as egg yolks, whole grain products, 
nuts, meat, and dietary supplementation.294  Chromium supplements are available in many 
forms, including picolinate, chloride salt, and complex forms with nicotinic acid and amino 
acids.294  Of these forms, the picolinate form appears to be the most stable and biologically 
available.294  When compared to chromium chloride, which has a bioavailability of 0.4% at a 
dose of 1,000 µg/d, chromium picolinate has a bioavailability of 2.8%.294,295   
Studies in Eastern and Western world populations show positive metabolic effects of 
both chromium picolinate and chromium chloride (CrCl) by resulting in decreases in fasting 
plasma glucose concentrations, increased insulin sensitivity, and a reduction in the 
requirement of oral anti-diabetic drugs.294,296  Absorption of chromium is enhanced by 
administration of vitamin C and amino acids, but is diminished by the use of antacids, and 
intake of simple sugars.294  The highest levels in the body are found in the liver (an important 
site of glucose metabolism), spleen, and the kidneys, and the normal range in blood is 4.9 to 
9.5 ng/mL in humans.294,295,297,298  In diabetics, there is a decrease in circulating levels of 
chromium, and an increase in urinary excretion of this mineral.30,294,298,299  Chromium 
supplementation has also been shown to reverse diabetes induced by glucocorticoid 
administration, as patients treated with 600 µg Cr/d showed reductions in fasting plasma 
glucose concentrations from 250 to 150 mg/dL, and the use of hypoglycemic drugs was 
reduced in 50% of patients.294,300  This was attributed to chromium lowering cortisol 
concentrations.301,302  It has also been shown that increased ingestion of simple sugars and 
elevations in cortisol lead to an increase in chromium losses, and perhaps this plays a role in 
the IR that occurs in horses with pituitary pars intermedia dysfunction or those that develop 
pasture-associated laminitis.303,304  However, results have been inconsistent.  This may be 
explained by the lower doses that are tested (~200-250 µg/d), or the limited bioavailability of 
certain formulations, such as chromium chloride (CrCl3).294,305,306 
The importance of chromium in the diet was demonstrated by Schwarz and Mertz307 
in 1959 when it was found that rats fed a diet containing yeast as their sole protein source, 
had difficulty clearing glucose, but this function returned when chromium (Cr+3) was added 
to the diet.295,307  The idea of chromium deficiency having a role in the development of IR 
and diabetes in humans came about in 1977, when a patient on long term total parenteral 
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nutrition developed clinical signs of diabetes, including glucose intolerance and peripheral 
neuropathy that required insulin administration of 45 units/d for control.291,294,298  When 
chromium supplementation was added at 200µg/d to the patient’s parenteral nutrition 
formulation, diabetic signs resolved and insulin use was no longer required.291,294,298  
Chromium is now routinely added to parenteral nutrition preparations.303  Chromium 
deficiency has been observed in humans suffering from elevated blood concentrations of 
glucose, insulin, TG, and cholesterol, and lower HDL concentrations; however, the hallmark 
sign of chromium deficiency is still impaired glucose tolerance.294,301  Unfortunately there is 
no reliable method for assessing deficiency other than observing the expected beneficial 
changes to glucose, insulin, and lipid variables before and after supplementation.295,303  
Deficiency can occur for the obvious reason of inadequate dietary intake, but also develops 
with poor intestinal absorption.  Chromium absorption is improved by the addition of a 
chelator, and picolinic acid is most commonly used.308,309 
 
8.3.2 Chromium and insulin sensitivity 
Chromium increases insulin sensitivity in rats, with Kim et al.291 demonstrating that 
fasting insulin concentrations decreased by approximately 50% and area under the insulin 
curve decreased by almost 60% in response to treatment.291  Other studies have also shown 
improvement in insulin sensitivity and fasting glucose and insulin concentrations, 
independent of changes in body weight or body fat percentage.291,303,310  In contrast, Uusitupa 
et al.311 detected significant reductions in the BMI of elderly patients suffering from impaired 
glucose tolerance. In another study,  Martin  et al.312 concluded that chromium does not 
induce weight loss, but may help to regulate weight gain so that there are smaller increases in 
body weight, percentage body fat, and total abdominal fat compared to individuals receiving 
placebos.  Preventing an  increase in body weight of 0.5 to 1.0 kg/yr becomes significant in 
long-term clinical trials.301   
 
8.3.3 Chromium and lipid metabolism 
There have also been variable results related to changes in serum lipid profiles 
following chromium supplementation.294,313  Elevations in serum cholesterol and the 
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formation of aortic plaques have been attributed to feeding rats low-chromium diets because 
these abnormalities were not detected in rats receiving supplemental CrCl.308,314  In a double-
blind, crossover study, Press et al.308  evaluated effects of chromium picolinate on TC, LDL, 
HDL, TG, apolipoprotein A-I, and apolipoprotein B.  Apolipoprotein B is the principal 
protein of VLDL and LDL whereas apolipoprotein A-I is the principal protein of HDL.  
Patients were administered 200 µg/d chromium picolinate and after 6 weeks of therapy there 
was a significant decrease in TC (7%; 276 to 256 mg/dL), LDL (10.5%; 200 to 178 mg/dL), 
and apolipoprotein B (16%; 155 to 130 mg/dL), whereas apolipoprotein A-I levels 
significantly increased with supplementation.308  A significant decrease in TC after 4 months 
of treatment with 1,000 µg chromium picolinate /d has also been detected 303.  Chromium 
picolinate may therefore serve as a treatment for hyperlipidemia, which has been associated 
with obesity and IR in horses.  In the aforementioned studies, improvement in blood lipid 
profiles was most pronounced in individuals with the highest lipid concentrations before 
treatment.294,315   
 
8.3.4 Chromium mechanisms of action 
 Chromium potentiates insulin action by inducing auto-amplification of the insulin 
signal.294  The concentration of insulin receptors varies depending on the tissue type, with an 
approximate concentration of 40 receptors per cell in erythrocytes to >200,000 in adipocytes 
and hepatocytes.294  In the early 1980s, Wada et al.316 were the first to have a breakthrough in 
the mechanism of chromium function by the isolation and characterization of a chromium-
binding oligopeptide referred to as low-molecular weight chromium-binding substance 
(LMWCr) or more commonly known as chromodulin.295,316  It has a molecular weight of only 
1.5 kDa (approximately) and is comprised of only 4 amino acid residues, i.e., glycine, 
cysteine, glutamate, and aspartate.295,317  This oligopeptide binds four equivalents of chromic 
ions, and this binding plays a role in its potentiating effect of insulin action.295  The site of 
activation of chromodulin appears to be at or near the tyrosine kinase active site of the β-
subunit of the insulin receptor, and the binding of four chromium ions is required for optimal 
activity.295   
 As blood glucose concentrations increase, insulin secretion by the pancreas is 
stimulated leading to binding and activation of the insulin receptor.  As circulating levels of 
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insulin increase, there is an influx of chromium from the circulation to within insulin-
sensitive cells.295  The form of chromodulin that is not bound to chromium (apochromodulin) 
is stored within the cytosol and nuclei of insulin-sensitive cells.295  The transfer of chromium 
into the insulin-sensitive cells from the circulation is likely to be mediated by transferrin, and 
as chromium enters the cells, it binds to apochromodulin to form holochromodulin (Cr4-
chromodulin).295,318  The newly formed holochromodulin binds to the activated insulin 
receptor and as a result, maintains the receptor’s active conformation and amplifies its 
signal.295  The bound holochromodulin amplifies the insulin receptor signal by stimulating 
concentration dependent tyrosine kinase activity of the insulin receptor in the presence of 
insulin, but not in its absence.294  Not only is there increased activation of tyrosine kinase, 
which stimulates intracellular signaling, but there is also inhibition of tyrosine phosphatase 
activity, and this prolongs activation of the insulin receptor.294  All of these actions increase 
insulin sensitivity.  Chromium supplementation also increases insulin binding by increasing 
the number of insulin receptors.291 
 
8.3.5 Chromium toxicity 
 Chromium picolinate is the most popular form of chromium supplement, and it should 
be noted that this form of Cr is absorbed in a different fashion from that of dietary Cr.295  It is 
a remarkably stable complex that remains intact for several hours in synthetic gastric juice 
and is capable of passing through the jejunum intact.295,319  The reference dose of safety for 
Cr, as established by the U.S. Environmental Protection Agency (EPA) is 350 times the upper 
limit of the daily intake dose of 200 µg/d.303  When humans that have taken the supplement 
over prolonged periods have been examined, significant DNA cleavage has been detected and 
this is attributed to the production of hydroxyl radicals.295,320  This occurs as picolinate causes 
the redox potential to shift to the chromic center, making it susceptible to reduction and 
therefore reactive oxygen species production.292  There has also been increased lipid 
peroxidation in rats with DNA damage, but doses used in these studies have been 20 times 
higher than those used in humans.292,321  There have been no reports of chromium picolinate 
consistently affecting the health of humans at recommended doses, but isolated cases include 
weight loss, anemia, thrombocytopenia, dermatitis, hypoglycemia, and liver dysfunction and 
kidney failure.292,303  
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8.3.6 Conclusions 
Results of studies evaluating chromium supplementation have been mixed, so there 
are questions about whether individuals suffer from different degrees of chromium 
deficiency.  Chromium shows promise as a supplement for the improvement of insulin and 
glucose dynamics, but the questions about safety of the picolinate form warrant further 
investigation. It must still be determined whether chromium supplementation improves 
insulin sensitivity in insulin-resistant horses.  
 
8.4 Magnesium 
8.4.1 Introduction  
 Magnesium (Mg2+) is the second most abundant intracellular cation after 
potassium.322  It has been established as a cofactor for over 300 metabolic reactions, 
including protein synthesis, cellular energy production and storage, and glucose and insulin 
metabolism.322,323  There are at least three different pools within the body: Extracellular (1%), 
intracellular (34%), and skeletal (65%).323,324  In humans, low blood Mg2+ concentrations 
have been associated with increased risk of MetS and T2D.322,325,326  Several foods that are 
good sources of dietary Mg2+, include almonds, halibut, bananas, milk chocolate, and peanut 
butter.322  Magnesium is an intracellular cation, so circulating levels may not provide an 
accurate measure of overall body Mg2+ status.  Low plasma Mg2+ concentrations are a 
specific, but not sensitive indication of deficiency.322  Plasma Mg2+ concentrations remains 
fairly constant in healthy humans and range from 0.75 to 0.96 mmol/L, with a recommended 
daily intake of 310 to 420 mg/d for adult humans.322,327 
 
8.4.2 Magnesium deficiency 
The primary sites of intestinal Mg2+ absorption are the distal jejunum and ileum, and 
intestinal absorption is inversely proportional to the amount ingested from dietary or 
supplement sources.324  It was found that an intake of 36 mg/d resulted in 65% absorption, 
while intake of 973 mg/d only resulted in an absorption of 11%.324  Magnesium deficiency is 
likely to contribute to the development of diseases such as MetS and T2D, but it is also 
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possible that these diseases lower magnesium stores.128  The balance of Mg2+ within the body 
is controlled by the kidneys, and diets low in Mg2+ have reduced urinary excretion.  In 
humans with T2D, there is an increase in urinary magnesium due to glucosuria.324  The 
normal range of urinary Mg2+ output is 120 to 140 mg/d.324 
In both rodents and humans, Mg2+ deficiency has been associated with both IR and 
MetS.322  Guerrero-Romero and Rodríguez-Morán328 found that serum Mg2+ concentrations 
were significantly lower in people with MetS compared with those who were healthy (1.8 ± 
0.3 mg/dL vs. 2.2 ± 0.2 mg/dL).  A close association with dyslipidemia was also detected.  
Magnesium deficiency may also play a role in T2D.  Lima et al.329 found that 75% of people 
with poorly controlled T2D had low Mg2+ concentrations and approximately 31% had low 
intracellular Mg2+ concentrations.  Hyperinsulinemia is a hallmark of IR, and in a study of 
obese children without T2D, Mg2+ concentrations were inversely correlated with fasting 
insulin concentrations and positively associated with QUICKI values (178.8 ± 19.8 vs. 63.2 ± 
6.6 pmol/L and 0.31 ± 0.04 vs. 0.35 ± 0.01, respectively).322,330   
 States of Mg2+ deficiency can result from decreased nutritional intake and increased 
renal losses. It is uncertain if supplementation elicits the same effect as increasing dietary 
Mg2+ intake.128,327  Major manifestations of Mg2+ deficiency in man can include 
neuromuscular abnormalities as well as biochemical (hypokalemia and hypocalcemia) and 
cardiovascular abnormalities.324  Guerrero-Romero et al.331 worked to establish whether Mg2+ 
supplementation improves insulin sensitivity in a study of humans that did not suffer from 
T2D.  Affected patients suffered from IR and hypomagnesemia (serum concentration ≤ 0.74 
mmol/L).  When supplementation was administered at 2.5g/d, serum Mg2+ concentrations 
significantly increased (0.61 ± 0.08 to 0.81 ± 0.08) and HOMA-IR decreased (4.6±2.8 to 
2.6±1.1).322,331  This result indicates that Mg2+ supplementation may address risk factors for 
T2D and lower the probability of disease. 
 
8.4.3 Effects of magnesium on insulin sensitivity 
 Magnesium exerts its positive effects by affecting insulin action.  Deficiency of 
intracellular Mg2+ suppresses tyrosine kinase activity of the insulin receptor causing a 
decrease in insulin sensitivity.332  Another potential mechanism is the role of Mg2+ as a 
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calcium (Ca2+) channel blocker because in states of Mg2+ depletion there is a rise in 
intracellular Ca2+.322,333,334   
Insulin is a key hormone in the regulation of Mg2+ metabolism and is capable of 
stimulating its intracellular accumulation.323,327  However, activation of the insulin receptor is 
required for this action, which is diminished in states of hyperinsulinemia due to 
desensitization of the receptor.323,327  It has been suggested ATPase pumps are stimulated 
when insulin binds its receptor and this increases Mg2+ entry into the cell.323,335  Elevations in 
intracellular Ca2+ accompany Mg2+ deficiency because of increased uptake of extracellular 
Ca2+ as well as release from intracellular stores.324  Increased  intracellular Ca2+ may 
negatively impact insulin sensitivity in adipocytes and skeletal muscle, and the antagonistic 
role of Mg2+ may be the mechanism by which it improves  insulin sensitivity; Mg2+ can 
function as a weak Ca2+ channel blocker.322,323 
With a reduced function of the insulin receptor in states of hyperinsulinemia, there is 
a decrease in Mg2+ influx which reduces its capacity to regulate Ca2+ influx.323,324  A 
deficiency in Mg2+ lowers intracellular potassium concentrations and results in a partial 
depolarization that favors Ca2+ influx.323,324  Draznin et al.336 showed that gluteal adipocytes 
incubated with insulin showed a significant increase in cytosolic Ca2+ concentrations, and as 
a result, had no cellular uptake of glucose, even in the presence of insulin.  Elevations in 
blood glucose also result in higher intracellular Ca2+ concentrations and this may lower Mg2+ 
concentrations and inhibit insulin receptor activity and insulin-stimulated glucose uptake.337   
 
8.4.4 Effect of magnesium on tyrosine kinase activity 
Effect of Mg2+ on insulin sensitivity are multi-factorial and involve reduction in 
tyrosine kinase activity of the insulin receptor as well as modulation of intracellular Ca2+ 
concentrations.128  In order for the insulin receptor to elicit its effect, it must first bind insulin 
which causes a conformational change and begins the intracellular signaling cascade, starting 
with autophosphorylation of β-subunits on tyrosine residues.  Suárez et al.333 showed a 
reduction in glucose clearance rate of 40% during an IVGTT in rats fed a diet designed to 
lead to hypomagnesemia.  This same group of rats also showed a decreased insulin response, 
implying an impairment of the pancreatic β-cell response, as well as reduced insulin 
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sensitivity.  The concentration of Mg2+ is critical in the phosphorylation of tyrosine kinase of 
the insulin receptor, and a deficiency of this mineral impairs phosphorylation.322,327,338   
Hyperglycemia occurs with Mg deficiency and this is associated with a decrease in 
insulin-stimulated glucose uptake.333  Pancreatic insulin output is also decreased and 
diminished β-cell function is related to the Mg2+ to Ca2+ ratio.333  It has been established that 
Mg2+ deficiency impairs the body’s ability to handle blood glucose, at both the basal and 
post-prandial (or induced if during a tolerance test) levels.322,327,338  Whether this results from 
decreased insulin receptor signaling or impaired β-cell function has yet to be definitively 
determined.  
 
8.4.5 Magnesium excess 
 Magnesium toxicity is very rare and has not been extensively studied.  Since Mg2+ is 
lost in the urine and absorption is inversely proportional to intake, it would be very difficult to 
induce toxicity, except in cases of renal insufficiency.324  In 1998, a tolerable upper intake 
level for Mg2+ was established as 350 mg/d for humans that are 9 years and over.324,339   
In the rare situations in which toxicity occurs, the first symptoms are neuromuscular 
in nature and begin with the absence of tendon reflexes at serum concentrations of 5 to 7 
mg/dL, and progress to respiratory complications at 9 to 12 mg/dL, with muscle paralysis and 
cardiac or respiratory failure developing at 1mg/dL and above.324  Less severe toxicity 
symptoms include diarrhea, dehydration, nausea, flushing, double vision, slurred speech, and 
weakness.324,339,340         
 
8.4.6 Conclusions 
 No studies have been performed to date to examine the therapeutic effect of Mg2+ 
supplementation on insulin sensitivity in horses.  Given its positive outcomes in humans and 
rats and the wide margin of safety, Mg2+ supplementation should be considered as treatment 
for IR in horses. 
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8.5 Cinnamon 
8.5.1 Introduction 
 Cinnamon (Cinnamomon cassia), which is also known as sweet wood, has long been 
used in Eastern medicine.301,341,342  This nutraceutical contains methylhydroxychalcone 
polymer (MHCP) that increases insulin sensitivity by mimicking the action of insulin.341-343  
Aqueous extracts of cinnamon potentiate insulin activity as much as 20-fold.301  Not only has 
cinnamon been implicated in the improvement of insulin action, but it may also inhibit HMG-
CoA reductase activity, resulting in lower blood lipid concentrations in humans and 
animals.341,344 
 
8.5.2 Cinnamon and glycemic control 
 Qin et al.342 performed one of the first in vivo studies to examine the effects of 
cinnamon administration on insulin action in non-anesthetized rats.  Rats received either 
saline or 2 doses (30 m/kg bwt or300 mg/kg bwt) of cinnamon daily for 3 weeks and then 
underwent EHC and skeletal muscle biopsy procedures.  Rats receiving cinnamon extract had 
significantly higher glucose infusion rates compared to controls (30 mg/kg: 118%; 300 
mg/kg: 146%), suggesting increased whole body glucose utilization, compared with controls.  
When muscle tissue was evaluated, rats receiving cinnamon had significantly higher tyrosine 
phosphorylation of the insulin receptor β-subunit, when compared to control animals (118% 
greater than control).  Phosphorylation of IRS-1 (133% greater than control) was also 
significantly increased (41% above control).342  This study showed that orally administered 
cinnamon enhanced in vivo glucose utilization in a dose dependent manner.342 
Mang et al.341 examined effects of an aqueous cinnamon extract on fasting blood 
glucose, lipid, and glycated hemoglobin (HbA1c) concentrations in diabetic humans.  The 
supplement was administered across a 4-month period three times daily with meals, and was 
compared with a placebo.  After 4 months of supplementation, there was a significant 
reduction in plasma glucose from baseline, and the mean absolute percentage difference was 
significantly lower compared to the placebo group (10.3 ± 13.2% versus 3.37 ± 14.2%, 
respectively).341  There were no significant differences in HbA1c or lipid concentrations 
between groups.  Kahn et al.344 also found that cinnamon supplementation significantly 
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lowered blood glucose concentrations, with decreases ranging from 18 to 29%, which are 
higher than previously reported.341  It has been suggested that the beneficial effects of 
cinnamon are more pronounced in patients with poorer glycemic control before therapy.341  It 
has also been noted that cinnamon has greater effects in patients taking anti-diabetic drugs 
because these individuals have higher insulin sensitivity and cinnamon has the same action as 
insulin.301   
 
8.5.2 Cinnamon and insulin sensitivity 
In states of IR, decreased phosphorylation of the insulin receptor can most likely be 
attributed to the action of tyrosine phosphatases, which have been detected at elevated 
cytosolic levels in aged IR rats.343,345  In vitro studies have shown that cinnamon enhances the 
uptake of glucose by activating the insulin receptor.341,343  This occurs through stimulation of 
the kinase activity required for autophosphorylation of the insulin receptor and enhanced 
glycogen synthase activity.  Cinnamon is also capable of improving the anti-oxidant status of 
diabetic individuals, as metabolites of lipid peroxidation (malondialdehyde) decrease with 
cinnamon supplementation, implying protection of cells against oxidation.301 
One of the compounds that increases dephosphorylation of the insulin receptor is 
PTP-1B and cinnamon potentiates the effect of insulin by inhibiting PTPase activity.343  
When rat adipocytes were incubated with wortmannin, an agent that inhibits PI3K, the insulin 
response from cinnamon or insulin was diminished, suggesting that cinnamon, like insulin, 
acts through a signaling pathway upstream of PI3K.343  Cinnamon acts specifically on protein 
tyrosine phosphatases above the level of PI3K. 
 
8.5.4 Conclusions 
 Cinnamon elicits strong positive response on insulin activity, whether by directly 
enhancing phosphorylation of the insulin receptor and its downstream components, or 
inhibiting the dephosphorylation of those same sites.  Humans and rodents have not 
experienced any adverse health effects as a result of cinnamon supplementation, so this 
nutraceutical should be evaluated as a treatment for IR in horses. 
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9. Pituitary pars intermedia dysfunction  
9.1 Introduction 
 Pituitary pars intermedia dysfunction (PPID), which is also called equine Cushing’s 
Disease, is the most common endocrinopathy affecting horses.  This endocrine disorder is 
diagnosed in horses ranging from 7 to 42 years, with approximately 85% being >15 years at 
the time of diagnosis.346,347  The incidence of PPID has increased over time as a result of  
greater awareness, an increase in the geriatric horse population, and availability of diagnostic 
tests.347   
 Clinical signs of PPID develop when the pars intermedia enlarges and eventually 
forms one or more functional adenomas.  There is clonal expansion of POMC-secreting cells 
secondary to loss of hypothalamic dopaminergic innervations.4,346,348,349  The release of 
dopamine from the hypothalamus inhibits the synthesis of POMC peptides, and this lack of 
dopaminergic inhibition is responsible for the higher ACTH concentrations detected in horses 
with PPID.346   
 
9.2 Influence of PPID on insulin sensitivity 
 Horses with PPID have histories of obesity-induced laminitis in their younger years.36  
Excess glucocorticoids can also induce abnormal adipose tissue distribution, 
hyperinsulinemia, increased plasma lipid concentrations, and glucose intolerance.4,36  It has 
also been speculated that EMS predisposes horses to PPID by playing a role in the loss of the 
dopaminergic inhibition. 
Insulin and cortisol antagonize one another, so glucocorticoids might have a direct 
impact on insulin function.4,36  Proposed mechanisms of glucocorticoid-induced IR include 
reduction in the number of insulin receptors, decreased receptor affinity for insulin, and 
defects in the intracellular insulin signaling pathway.4  The pars intermedia of the pituitary 
gland also secretes corticotrophin-like intermediate peptide, and this is a secretagogue of 
insulin in genetically obese mice.348,350  Mouse 3T3-L1 adipocytes treated with ACTH also 
show a transient decrease in insulin-induced glucose uptake by 45%, implying that ACTH, 
rather than cortisol plays a role in the IR associated with PPID.351 
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 Excessive exposure to glucocorticoids in PPID could also result in IR through the 
over accumulation of intra-abdominal adipose tissue.  Accumulation of omental adipocytes 
has been associated with increased expression of 11β-hydroxysteroid dehydrogenase 1 (11β-
HSD1), which converts biologically inactive cortisone to active cortisol.36,352,353  This may 
play a role in the development of IR if cortisol impairs insulin-induced inhibition of hepatic 
glucose production and thereby induces hyperglycemia.   Glucocorticoids raise blood glucose 
concentrations and induce transient IR to preserve glucose delivery to essential tissues such 
as the central nervous system and heart.4,352  It is important to note, however, that measured 
cortisol concentrations are not always elevated in horses with PPID.36,354 
 Higher blood lipid concentrations are detected in horses with PPID and this reflects 
stimulation of catabolic pathways and increased lipolysis.352  This enhanced catabolic effect 
is also related to the characteristic rounded abdomen and loss of muscle mass observed with 
PPID as protein breakdown causes decreases in muscle mass and tone.346,348,352  In states of 
IR, dietary carbohydrates are diverted to the liver for the production of triglyceride and 
ultimately stored in peripheral tissues.34,36  This accumulation of lipids in tissues can also 
perpetuate IR, as previously discussed. 
 
9.3 Effects of season on glucose testing in horses with PPID 
 Work performed by McFarlane et al.355 revealed seasonal variability in pars 
intermedia activity.   Seasonal alterations in plasma α-MSH concentrations indicate that pars 
intermedia melanotrophs become hyperplastic in the fall compared to other times of the 
year.354,355  This finding has been reinforced by other studies in which higher plasma ACTH 
and α-MSH concentrations have been detected in September, and it is now accepted that false 
positive results will be obtained when PPID testing is performed in the fall.10,354-356   The 
dexamethasone suppression test for PPID is also affected by season.354  Since glucocorticoids 
antagonize insulin, seasonal variation would also be expected to alter blood glucose and 
insulin concentrations, but this question has not been addressed in horses. 347,348 
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10. Equine laminitis 
10.1 Introduction  
 Laminitis is a painful condition of equids that can result in permanent lameness.1,347  
In a survey performed by the USDA in 1998, it was found that 13% of farms had at least one 
horse develop laminitis within the previous year and 4.7% either died or were euthanized.357  
The cause of laminitis is not always identified, but contributing factors include 
gastrointestinal tract disease, endocrine disorders (e.g. PPID), and IR.4,347  The time course of 
laminitis can be described as 5 stages; (1) Predisposition stage – animals suffer from a 
predisposing factor such as genetics, nutritional/metabolic, inflammatory (sepsis), and/or 
mechanical/trauma, (2) Development stage (prodromal) – this stage generally takes hours to 
days after a triggering event such as the rapid fermentation of soluble carbohydrates, (3) 
Acute stage – clinical signs are evident and there are demonstrable structural and metabolic 
lesions, along with the loosening of the connective tissue between the hoof wall and pedal 
bone, (4) Sub-acute stage – this stage can go on for weeks to months and is usually 
characterized by less obvious clinical signs,  and (5) Chronic or persistent Stage – repair of 
damage can never be complete and there is generally some degree of persistent 
lameness.2,3,358   
 
10.2 Laminar damage 
The hoof-lamellar junction is formed by the attachment of the epidermal aspect of the 
hoof wall to the underlying dermal connective tissue, and ultimately the pedal bone.352  
Laminitis is a degradative inflammatory condition of the foot in which the lamellar interface 
becomes damaged, resulting in separation of the sensitive and insensitive lamellae 
(dermoepidermal separation) at the level of the basal keratinocytes and their attachment to the 
underlying lamellar basement membrane (LBM).1,352,359  The feet of equids suffering from 
laminitis have typical physical characteristics that include solar prolapse, divergent growth 
lines (or laminitic rings) that typically are close at the toe and diverge at the heel, a widening 
of the white line zone, and an elongated narrow foot.36,360   
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10.3 Pathophysiology of laminitis  
Laminitis has been associated with impaired endothelial function with increased 
enodthelin-1 (ET-1, a vasoconstrictor) and decreased nitric oxide (NO, a vasodilator).2,36,361  
These alterations in NO and ET-1 levels are compatible with findings in patients with 
diabetes.4,36,362  Insulin has been associated with vasodilation and capillary recruitment in 
skeletal muscle, and increased digital pulses observed with laminitis may be due to this 
effect.363,364  Increased digital pulses have been palpated when laminitis has been 
experimentally induced in ponies by infusing exogenous insulin intravenously at 
supraphysiological concentrations.363  In human diabetics, the common occurrence of 
neuropathy of the feet is attributed to an increase in venous pressure resulting in foot 
ulceration.363,365  Arteriovenous anastamoses develop as a consequence of hyperinsulinemia 
in these patients and may also play a role in the development of laminitis in insulin-resistant 
horses, with shunting of the blood depriving laminae of nutrients.363   
 
10.4 Risk factors for pasture-associated laminitis 
 Laminitis is a common condition in equids, but it is important to note that not all 
animals under the same managerial practices develop the condition.  This suggests that some 
horses and ponies are predisposed to pasture-associated laminitis.  It is therefore important to 
identify animals with greater predisposition so that disease can be prevented.    
 Treiber et al.366 were able to identify ponies from an inbred herd that showed greater 
risk of developing pasture-associated laminitis and referred to this as pre-laminitic metabolic 
syndrome (PLMS).  In a herd of 170 Dartmoor and Welsh ponies, 54 animals had histories of 
pasture-associated laminitis (pre-laminitic; PL) and the remaining 116 ponies did not (never 
laminitic; NL).   A dominant mode of inheritance was detected for PLMS  and affected 
ponies had higher body condition scores and elevated blood concentrations of insulin and TG 
concentrations.366  Proxies for insulin sensitivity and β-cell function were calculated 
(discussed earlier) and PL ponies had insulin sensitivity scores in the lowest reference 
quintiles and β-cell function scores in the highest reference quintile, indicating IR with 
pancreatic compensation.  When animals were assessed using PLMS, thirteen PL ponies 
developed pasture-associated laminitis in May whereas NL ponies remained unaffected.366   
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10.5 Insulin resistance and laminitis susceptibility 
 Horses and ponies with EMS and PPID are susceptible to pasture-associated laminitis.  
Insulin status is a strong predictor of laminitis in horses with PPID.363,367  Horses were more 
likely to develop laminitis and survive less than 2 years after diagnosis if basal insulin 
concentrations were >188 µU/mL.  Hyperinsulinemia is associated with IR and it has been 
shown that extended exposure to exogenous insulin lowers production of vasodilators such as 
NO and increases production of vasoconstrictors such as ET-1.2,361,368  This finding is 
inconsistent with the known vasodilatory properties of insulin, but can be explained by the 
presence of IR.15  Platelet activation has also been implicated in the pathophysiology of 
laminitis and increases thromboxane activity.2,369,370   
 Insulin resistance may also play a role in the pathogenesis of laminitis by reducing 
glucose availability to laminae, which results in separation of the sensitive and insensitive 
laminar tissues.363  In a study by Asplin et al.363, it was hypothesized that insulin toxicity has 
a role in the development of laminitis.  Prolonged hyperinsulinemia was induced in ponies by 
infusing exogenous insulin and the mean insulin concentration was 1,036 µU/mL during 
infusion.  All treated ponies developed laminitis in all four feet.  Lamellar explants were 
obtained and damage was consistent with laminitis.  Results of this study indicate a role for 
insulin toxicity in the development of laminitis and this may have important repercussions in 
animals that experience carbohydrate overload.363  Epidermal basal cells of lamellar tissues 
lack insulin receptors, but they are present on endothelial cells which supports the theory that 
vascular impairment resulting from hyperinsulinemia and IR contributes to laminitis.363,371 
 
10.6 Conclusions 
Laminitis has no definitive cause, but is associated with obesity, IR, and 
hyperinsulinemia, which are components of EMS.  Several studies to date have shown that 
impairment of the vasculature plays a role in laminitis and recent evidence suggests that IR 
and hyperinsulinemia affect blood flow.  Laminitis has distressing outcomes that are 
financial, physical, and emotional.  Further studies are required to diagnose and manage IR 
and hyperinsulinemia in horses, in order to prevent laminitis.    
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11. Synopsis 
 As has been discussed throughout this literature review, there are many factors that 
affect the development of laminitis, and also the predisposing conditions for this disease such 
as IR and hyperinsulinemia.   New treatments and management practices must be developed 
for EMS to control IR and hyperinsulinemia, and thereby lower the risk of laminitis.  
Additional diagnostic tests must be developed to identify at-risk horses by assessing insulin 
sensitivity and metabolic disturbances.  This dissertation will therefore focus upon the 
management and diagnosis of EMS in horses with the goal of evaluating therapies for IR and 
the identification of animals most likely to be at risk of developing IR and therefore laminitis.  
It is hypothesized that chromium and magnesium, L-T4, and metformin will be capable of 
improving SI and decreasing body measurements, while active GLP-1 and adiponectin may 
be associated with different levels of severity of IR and obesity and consequently serve as 
biomarkers of horses at increased risk of developing laminitis in the future.   
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Chapter 2 
 
Effects of a supplement containing chromium and magnesium on 
morphometric measurements, resting glucose and insulin 
concentrations, and insulin sensitivity in laminitic obese horses 
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This chapter is a revision of a paper that has been accepted for publication in Equine 
Veterinary Journal. 
My primary contribution to this paper included I) execution of the study discussed 
herein and II) primary author of this paper.  Co-authors include Dr. Nicholas Frank who I) 
served as mentor, II) co-designer, and III) editor of the study, Sarah B. Elliott who served as 
laboratory technical support, and Dr. Raymond Boston who served as data analyst (minimal 
model analysis). 
 
Abstract 
 Insulin resistance (IR) has been associated with an increased risk of pasture-
associated laminitis in ponies and is associated with obesity and reduced insulin sensitivity in 
horses and ponies.  Current therapies focus on alleviating insulin resistance and obesity due 
to their connection to laminitis.  Chromium and magnesium have been touted as capable of 
improving insulin sensitivity in humans, and as a result, supplements containing chromium 
and magnesium are commercially available for use in horses.  However, to date there is no 
scientific evidence of their efficacy in equids.  The purpose of this study was to determine if a 
supplement containing chromium, magnesium, and various herbs was capable of affecting 
physical measurements, blood variables, and insulin sensitivity in previously laminitic horses.  
Fourteen obese horses with histories of laminitis were randomly allocated to receive 2 oz. of 
supplement once daily (n = 8), or serve as controls (n = 6), for a total of 16 weeks.  Two 
horses with active laminitis were included in the treatment group. Hyperinsulinemia was 
detected in 12/14 horses prior to treatment.  Glucose and insulin data from one mare was 
excluded due to persistent laminitis.  Mean ± SD (n = 13) insulin sensitivity was 0.64 ± 0.62 
× 10-4 L·min-1·mU-1 prior to treatment for the remaining 13 horses.  Time and treatment × 
time effects were not significant for any of the variables examined, with the exception of 
resting insulin concentrations which significantly increased over time (P = 0.018).  Results of 
this study do not support the administration of chromium and magnesium to manage obesity, 
regional adiposity, hyperinsulinemia, or insulin resistance in horses. 
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2.1  Introduction 
Strategies for treating insulin resistance (IR) must be evaluated in horses because this 
condition has been associated with increased risk of pasture-associated laminitis in equids. 
372,373
  Chromium and magnesium supplements are readily available to horse owners and are 
often administered to horses with IR and laminitis.  Chromium supplements have been used 
in human medicine since the 1970s when it was discovered that patients developed diabetes 
mellitus while receiving total parenteral nutrition and affected individuals benefited from 
chromium supplementation.291,293,294 Chromium is thought to elicit its effects by enhancing 
intracellular post-insulin receptor signaling pathways.294 This may occur through enhanced 
tyrosine kinase activity or reduced tyrosine phosphatase activity, which prolongs the effects 
of insulin binding to its receptor and thereby increases insulin sensitivity.294,295  Chromium 
supplements are taken by people with IR or type 2 diabetes mellitus and both chromium 
picolinate and chromium chloride lower fasting plasma glucose concentrations, increase 
insulin sensitivity, and reduce requirements for oral anti-diabetic drugs in humans.331,374  
Dietary chromium tripicolinate also improves glucose tolerance in healthy non-obese cats 
when supplemented at 300 or 600 parts per billion in the diet.375  
Magnesium deficiency has been associated with IR and metabolic syndrome in 
rodents and humans.374 In one study, serum magnesium concentrations were significantly 
lower in 192 human subjects with metabolic syndrome when compared with 384 healthy 
individuals, and an association exists between magnesium deficiency and dyslipidemia.328,374 
In addition, magnesium supplementation has been associated with improved HOMA-IR 
scores in humans, indicating improved insulin sensitivity.331,374  This mineral is thought to 
elicit its positive effects on insulin sensitivity by enhancing intracellular signaling and 
increasing tyrosine kinase activity via calcium channel blockade.323,332   
Chromium supplementation has previously been evaluated in horses, but results have 
varied markedly among studies.376-378  In contrast, there is little information available 
regarding magnesium supplementation in horses and studies have not been performed to 
determine the effects of magnesium supplementation on insulin sensitivity.  This study was 
therefore undertaken to test the hypothesis that a dietary supplement containing chromium 
and magnesium would lower resting glucose and insulin concentrations and increase insulin 
sensitivity in horses.  We specifically selected laminitic obese horses for this study because 
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obesity, IR, and laminitis are associated.372,373 and can be collectively referred to as Equine 
Metabolic Syndrome (EMS).36,379  
 
2.2  Materials and Methods 
Horses – Fourteen adult horses donated to the University of Tennessee because of 
recurrent laminitis episodes were included in the study.  Inclusion criteria for the study 
included histories of laminitis, obesity, and impaired insulin sensitivity (SI).  Twelve horses 
had a history of laminitis according to the owner and referring veterinarian (n = 12) and 2 
horses suffered from clinical laminitis at the time of the study.   Clinical laminitis was 
defined by bilateral forelimb lameness and radiographic evidence of third phalanx rotation.  
All horses were obese, which was defined as a body condition score ≥ 7 using the 1 to 9 
scoring system developed by Henneke et al.9 The study was performed between January and 
May 2008.  Nine geldings and 5 mares were included in the study and horses ranged in age 
from 8 to 20 years (median, 14 years), with initial body weights ranging from 422 to 595 kg 
(median, 454 kg).   
Diet – All horses were fed to provide 1.25 × digestible energy for maintenance 
according to National Research Council guidelines,380 with 670 kcal/day supplied by 0.25 kg 
oats/d (fed in the morning) and the remainder with Orchard/Timothy grass hay.  Feed 
analysis was performed by a commercial forage testing laboratory.a  Hay fed to study horses 
contained 6.2 % water-soluble carbohydrate, 5.2 % ethanol-soluble carbohydrate, and 0.7 % 
starch on a dry matter basis. Water was available ad libitum.  Horses were fed between 0700 
and 0800 and again between 1500 and 1630.   
Experimental design – A randomized study design with repeated measures was 
applied across a 16-week study period.  Twelve previously laminitic obese horses were 
randomly allocated to treatment (n = 6) and control (n = 6) groups and two obese horses with 
clinical laminitis were included in the treatment group.  Horses in the treatment group 
received 56g (2 oz) of a powdered dietary supplement containing chromium (5 mg/d as 
yeast), magnesium (8.8 g/d as oxide/proteinate), as well as Gymnema sylvestri, Banaba leaf 
extract, American ginseng, ginger root, cinnamon, biotin, L-carnitine, Bittermellon extract, 
                                                 
a
  Dairy One Forage Testing Laboratory, Ithaca, NY  
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and Fenugreek seed.  Dosages of chromium and magnesium supplied by the supplement were 
determined by the manufacturer.  Supplement was top-dressed on oats in the morning for 16 
weeks and horses were monitored to ensure that all of the feed and supplement were 
consumed.  Horses in the control group received the same feed without added supplement.  
Custom farrier care was provided and housing assignments were determined by foot 
stability.  Previously laminitic horses were housed in pairs (one horse allocated to each 
group) within three dirt paddocks measuring 15-m × 55-m (n = 6) or kept in individual stalls 
(2.75-m × 3.5-m) and attached outdoor dry-lots (3.7-m × 10-m; n = 6).  Clinically laminitic 
horses (n = 2) were housed in individual stalls (3.7-m ×3.7-m) within the University of 
Tennessee Large Animal Hospital.  Frequently-sampled intravenous glucose tolerance test 
(FSIGTT) procedures were performed at 0, 8, and 16 weeks, and blood was collected for 
complete blood count (CBC) and plasma biochemical analyses at the same time points.  
Horses that were housed in paddocks or barn stalls were transported to the hospital 2 days 
beforehand for acclimatization to their environment. Testing procedures and treatment 
periods were staggered across a 2-week period with animals tested in pairs (one horse from 
each group).  The study protocol was approved by the University of Tennessee Institutional 
Animal Care and Use Committee. 
Physical examination measurements – Physical examination variables, including 
rectal temperature, heart rate, and respiratory rate were recorded along with morphometric 
measurements at 0, 8, and 16 weeks.  Morphometric measurements included body weight, 
body condition, girth circumference, and neck circumference.  Neck circumference was 
measured perpendicular to the neck crest at 0.25, 0.50 (mid neck), and 0.75 of the distance 
from the withers to the poll with a measuring tape, as previously described.6   
FSIGTT procedure − A 14-gauge polypropylene catheter was inserted into the 
jugular vein the day before each FSIGTT was performed.  Horses were fed grass hay and 
provided with water while testing was performed.  The insulin-modified FSIGTT procedure 
first described by Hoffman228 and modified by Tóth et al.381 was used.  Plasma and serum 
were harvested via low-speed (1,000 × g) centrifugation and then stored at –20 oC until 
further analysis. Pre-injection (time = 0) glucose and insulin concentrations are referred to as 
resting concentrations.  
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Blood glucose and insulin concentrations – Plasma glucose concentrations were 
measured by use of a colorimetric assayb on an automated discrete analyzer.c Serum insulin 
concentrations were determined by use of a radioimmunoassayd validated for use with equine 
sera in our laboratory.  Each sample was assayed in duplicate and intra-assay coefficients of 
variation < 5% or < 10% were required for acceptance of glucose and insulin assay results, 
respectively.  
Plasma lipid concentrations – Triglyceride and cholesterol were measured with 
enzymatic colorimetric reagentse,f on the same automated discrete analyzer. Nonesterified 
fatty acid (NEFA) concentrations were measured by use of an in vitro enzymatic colorimetric 
test kitg on a microtiter plate reader.h  Each sample was assayed in duplicate and intra-assay 
coefficients of variation < 5% were required for acceptance of results.   
Interpretation of FSIGTT data by use of the minimal model – Values for insulin 
sensitivity (SI), glucose effectiveness (Sg), acute insulin response to glucose (AIRg), and 
disposition index (DI) were calculated for each FSIGTT in accordance with the minimal 
model382 by use of commercially available softwarei,j and previously described methods.228,383  
Disposition index was calculated via multiplication of AIRg by SI.  
Statistical analysis – Insulin concentrations did not fit a normal distribution, so data 
were log-transformed prior to analysis. Groups were compared prior to treatment (time = 0 
months) using t-tests and then treatment, time, and treatment × time effects were evaluated by 
repeated-measures ANOVA, using statistical software.k When a main effect was significant, 
the protected least significant difference mean separation method was used to compare 
different groups and time points.  Significance was defined at a value of P < 0.05. 
 
 
                                                 
b
  Glucose, Roche Diagnostic Systems Inc, Somerville, NJ  
c
  Cobas Mira, Roche Diagnostic Systems Inc, Somerville, NJ  
d
  Coat-A-Count Insulin, Siemens Medical Solutions Diagnostics, Los Angeles, CA  
e
  Triglyceride, Wako Chemicals USA, Richmond, Va  
f
  Cholesterol, Wako Chemicals USA, Richmond, Va  
g
  NEFA C, Wako Chemicals USA, Richmond, Va  
h
  UV-160, Shimadzu, Kyoto, Japan  
i
  MinMod Millennium, version 6.10, Raymond Boston, University of Pennsylvania, Kennet Square, PA  
j
  Stata 9.2, Stata Corporation, College Station, TX   
k
  PROC MIXED, SAS, version 9.2, SAS Institute Inc., Cary, NC  
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2.3  Results 
Physical examination variables remained within normal limits for all horses, with the 
exception of one mare with clinical laminitis that suffered from persistent lameness and 
tachycardia.  Morphometric measurements did not change significantly throughout the study 
period in control or treated animals (Table 2.1).  Complete blood counts and plasma 
biochemical analysis results remained unaffected by treatment or time.  Gamma-glutamyl 
transferase and aspartate aminotransferase activities exceeded laboratory reference ranges on 
at least one occasion in 9/14 (64.3%) and 6/14 (42.9%) horses, respectively (Table 2.2).  
However, GGT activity was found to be significantly lower in treated animals versus control 
animals overall.   
Pre-treatment insulin concentrations ranged from 11.4 to 621.9 µU/mL (median; 57.1 
µU/mL) and hyperinsulinemia (> 30 μU/mL) was detected in 12 of 14 horses at the start of 
the study.  Pre-treatment SI values (n = 14) ranged from 0.05 to 2.11 (median: 0.48) × 10-4 
L.min-1.mU-1, and 8 horses had values ≤ 0.50 × 10-4 L.min-1.mU-1.  Glucose and insulin data 
from the mare with persistent lameness were excluded from statistical analyses because this 
animal remained painful and received phenylbutazone treatment.  Marked hyperinsulinemia 
was detected in this mare at all time points, with serum insulin concentrations ranging from 
417 to 1,098 µU/mL.  This mare had a pre-treatment SI value of 0.20 × 10-4 L.min-1.mU-1.   
Pre-treatment resting glucose and insulin concentrations did not differ between 
treatment (n = 7) and control (n = 6) groups, and hyperglycemia was not detected at any time 
during the study.   There were no effects of time or treatment on resting plasma glucose 
concentrations, but insulin concentrations significantly increased (P = 0.018) over time 
(Figure 2.1).   Plasma total cholesterol and non-esterified fatty acid concentrations were not 
affected by treatment or time, but mean triglyceride concentrations were higher (P = 0.024) in 
the control group.  Treatment × time effects were not significant for any of the lipid variables 
examined. Minimal model variables were not affected by time or treatment in this study 
(Table 2.3).   
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Table 2.1: Mean ± s.d. physical measurements for 14 laminitic obese horses that received a 
dietary supplement in their feed once daily or remained untreated for 16 weeks.   
Variable 
Group  Time (wk)  T × time 
 0 8 16 P 
BodyWeight 
(kg) 
Control (n = 6) 
Supplement (n = 8) 
492.5 ±57.5 
460.6 ± 63.8 
497.6 ± 56.5 
468.0 ± 57.0 
494.8 ± 51.7 
469.7 ± 46.0 
0.814 
BCS 
 
Control (n = 6) 
Supplement (n = 8) 
7.5 ± 0.5 
7.7 ± 0.8 
7.6 ± 0.7 
7.7 ± 0.7 
7.7 ± 0.8 
8.1 ± 0.7 
0.626 
0.25x neck (cm) 
Control (n = 6) 
Supplement (n = 8) 
84.8 ± 3.3 
83.5 ± 4.1 
84.1 ± 5.7 
82.9 ± 3.3 
81.3 ± 3.8 
81.9 ± 2.9 
0.667 
0.50x neck (cm) Control (n = 6) 
Supplement (n = 8) 
100.3 ± 6.6 
99.8 ± 5.2 
99.8 ± 9.2 
100.3 ± 6.1 
96.6 ± 8.9 
97.8 ± 5.0 
0.921 
0.75x neck (cm) Control (n = 6) 
Supplement (n = 8) 
111.5 ± 7.6 
113.4 ± 5.7 
111.5 ± 8.7 
114.1 ± 5.4 
110.3 ± 7.8 
113.7 ± 4.1 
0.530 
Mean neck 
circumference 
(cm) 
 
Control (n = 6) 
Supplement (n = 8) 
98.9 ± 12.6 
98.9± 13.4 
98.4 ± 13.8 
99.1 ± 13.9 
96.1 ± 13.9 
97.8 ± 13.8 
0.686 
BCS = Body condition score; x = Distance from the poll to the withers; T = Treatment 
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Table 2.2: Mean ± s.d. resting blood measures for 14 laminitic obese horses that received a 
dietary supplement in their feed once daily or remained untreated for 16 weeks.  Glucose and 
insulin data from one clinically laminitic horse that suffered from persistent lameness were 
excluded. 
Variable 
Group  Time (wk)  T × time 
 0 8 16 P 
Glucose 
(mmol/L) 
Control (n = 6) 
Supplement (n = 7) 
5.28 ± 0.30 
5.14 ± 0.30 
5.47 ± 0.67 
5.39 ± 0.48 
 
5.26 ± 0.37 
5.28 ± 0.51 
 
0.911 
 
Insulin 
(µU/mL) 
 
Control (n = 6) 
Supplement (n = 7) 
73.7 ± 38.7 
60.3 ± 55.7 
123.9 ± 104.2 
88.7 ± 81.2 
 
144.9 ± 136.1 
93.6 ± 106.7 
 
0.597 
 
GGT 
(IU/L) 
 
Control (n = 6) 
Supplement (n = 8) 
35.0 ± 17.3a 
23.6 ± 12.4b 
70.7 ± 84.8a 
26.1 ± 13.0b 
 
44.7 ± 21.5a 
26.9 ± 10.0b 
 
0.546 
AST 
(IU/L) 
Control (n = 6) 
Supplement (n = 8) 
317.5 ± 53.6 
284.1 ± 70.8 
364.5 ± 111.7 
304.1 ± 62.1 
335.7 ± 62.3 
330.3 ± 65.1 
0.565 
TG 
(mmol/L) 
Control (n = 6) 
Supplement (n = 8) 
0.53 ± 0.18a 
0.31 ± 0.07b 
0.55 ± 0.25a 
0.32 ± 0.07b 
0.50 ± 0.17a 
0.35 ± 0.08b 
0.259 
Cholesterol 
(mmol/L) 
Control (n = 6) 
Supplement (n = 8) 
1.92 ± 0.30 
1.91 ± 0.27 
1.95 ± 0.26 
1.91 ± 0.16 
1.98 ± 0.28 
1.95 ± 0.18 
0.935 
NEFA 
(µmol/L) 
Control (n = 6) 
Supplement (n = 8) 
101.8 ± 61.3 
150.1 ±  63.8 
117.6 ± 129.2 
109.4 ± 74.2 
 
59.0 ± 18.3 
69.8 ± 50.0 
 
0.949 
GGT = Gamma glutamyl transferase; AST = Aspartate aminotransferase; TG = Triglyceride; 
TC = Total cholesterol; NEFA = Non-esterified fatty acids; T = Treatment 
Means with different superscripts within the same row differ significantly when P < 0.05 
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Table 2.3: Mean ± s.d. minimal model analysis values obtained from frequently-sampled 
intravenous glucose tolerance test data for 13 laminitic obese horses that received a 
supplement containing chromium and magnesium (n = 7) or remained untreated (control 
group; n = 6) for 16 weeks. Data from one clinically laminitic horse that suffered from 
persistent lameness were excluded.   
Variable 
Group  Time (wk)  T × time 
 0 8 16 P 
 
SI × 10-4              
(L.min-1.mU-1) 
 
Control (n = 6) 
Supplement (n = 7) 
0.66 ± 0.71 
0.87 ± 0.73 
0.77 ± 0.94 
0.92 ± 0.74 
1.30 ± 2.20 
1.00 ± 1.05 
0.678 
 
  Sg × 10-2               
(min-1) 
 
Control (n = 6) 
Supplement (n = 7) 
2.19 ± 1.88 
1.67 ± 0.78 
1.67 ± 1.16 
1.40 ± 1.15 
2.50 ± 1.53 
2.49 ± 1.58 
0.822 
 
AIRg              
(mU.min. L-1) 
 
Control (n = 6) 
Supplement (n = 7) 
1,474 ± 593 
995 ± 511 
1,457 ± 826 
896 ± 838 
1,367 ± 777 
922 ± 752 
0.949 
DI × 10-2 
Control (n = 6) 
Supplement (n = 7) 
653 ± 591 
634 ± 427 
658 ± 777 
631 ± 531 
680 ± 854 
607 ± 514 
0.985 
SI = Sensitivity to insulin; Sg = Glucose effectiveness; AIRg = Acute insulin response to 
glucose; DI = Disposition index; T = Treatment 
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Figure 2.1: Mean ± s.d. resting serum insulin concentrations at 0 (light gray bars), 8 weeks 
(dark gray bars), and 16 weeks (white bars) in 13 laminitic obese horses that received a 
supplement containing chromium and magnesium (n = 7) or remained untreated (control 
group; n = 6) for 16 weeks. Data from one clinically laminitic horse that suffered from 
persistent lameness were excluded.  Insulin concentrations significantly increased (P = 0.018) 
over time. 
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2.4  Discussion 
Administration of a supplement containing chromium and magnesium once daily for 
16 weeks did not alter morphometric measurements, blood variables, or insulin sensitivity in 
this study of laminitic obese horses.  Serum insulin concentrations significantly increased 
over 16 weeks, which suggests an effect of season or diet on resting insulin concentrations.   
Chromium did not alter SI, Sg, AIRg, or DI in this study, and this finding is consistent 
with results of previous studies in which chromium has failed to alter glucose or insulin 
dynamics in horses.376,378,384  Vervuert et al.376 failed to detect any effects of yeast-chromium 
supplementation (4.15 or 8.3 mg/day) on glucose and insulin concentrations in horses, and 
Cartmill et al.315 reported that glucose dynamics and insulin sensitivity remained unaffected 
by chromium propionate administration (4 mg/day for 30 days) in high body condition score 
horses.   Frequently-sampled intravenous glucose tolerance tests and minimal model analyses 
were performed in the latter study and these variables remained unaffected by treatment.    In 
a recent study, Uyanik et al.  administered 0, 200, or 400 µg/day chromium picolinate orally 
to horses for 45 days and measured glucose and lipid concentrations.378  Glucose 
concentrations remained unaffected by treatment, but plasma triglyceride concentrations 
decreased with chromium treatment at the 400 µg/day dosage.  Administration of 200 µg or 
400 µg chromium picolinate once or twice daily for 3 months did not affect resting glucose or 
insulin concentrations, or responses to exogenous insulin in insulin-treated diabetic dogs.385  
Other studies have shown that chromium significantly alters glucose and insulin 
concentrations in horses.377,386,387   Ott and Kivipelto377 evaluated a basal diet alone and the 
same diet with 175, 350, or 700 µg chromium added per kilogram concentrate in 
Thoroughbred and Quarter Horse yearlings. Yearlings that received chromium at the highest 
dosage had faster glucose clearance rates than animals in the control group.  Pagan et al.387 
also reported a positive effect of chromium supplementation on glucose dynamics in adult 
horses.  Significantly lower plasma glucose concentrations were detected during exercise and 
3 hours following a meal containing 5g yeast-chromium.  Lower plasma glucose 
concentrations were also detected 1 hour post-feeding in the same horses.  In a study of aged 
(> 20 years) mares, Ralston et al.386 administered 0.01 mg/kg or 0.02 mg/kg chromium-L-
methionine for 4 weeks and detected lower peak insulin responses to a concentrate meal in 
the 0.02 mg/kg group.  
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Based upon the results reported here, the combination supplement evaluated in this 
study did not have its intended effects.  This may be explained by the subjects selected for 
study or the specific formulation tested.  Only horses with chronic health problems were 
evaluated in this study, so further studies are required to evaluate chromium and magnesium 
supplements in less severely affected animals.  Other formulations should also be evaluated 
in the future.  Several forms of chromium are available for use, including chromium 
picolinate, chloride, and complexes with nicotinic acid and amino acids, in addition to the 
yeast form evaluated here.294  Of the different formulations of chromium available for use in 
humans, chromium picolinate has the highest stability and bioavailability.294  Oral 
bioavailability of chromium chloride is 0.4% after administration of 1,000µg/d in humans 
whereas chromium picolinate has 2.8% bioavailability at the same dosage.  Further studies 
are required to determine the oral bioavailability of chromium in horses because results of 
this study may reflect inadequate absorption.  It is important to note that the dosage of 
chromium included in this supplement and the duration of administration may have had some 
influence on the lack of effect seen here.  As noted earlier, there are discrepancies in the 
literature in reference to dosages of chromium, duration of treatment studied, and effects of 
respective treatments.376-378,384-387  
To the authors’ knowledge, this is the first study to evaluate the effect of magnesium 
supplementation on insulin and glucose dynamics in horses.  According to National Research 
Council recommendations, adult horses should receive 15 mg magnesium/kg/d, which is 
equivalent to 7.5 g per day for a 500kg mature horse.388  The amount of magnesium provided 
in this study (8.8 g/day) therefore exceeded maintenance requirements.  Studies involving 
magnesium supplementation have yielded mixed results in humans.  Rodríguez-Morán and 
Guerro-Romero389 reported that magnesium supplementation increased insulin sensitivity in 
type 2 diabetic patients with low serum magnesium concentrations (≤ 0.74 mmol/L) prior to 
treatment.  In contrast, there was no improvement in insulin sensitivity detected when 
overweight nondiabetic adults received a magnesium oxide supplement for 12 weeks.390  
These differences suggest that supplements have a greater effect on insulin sensitivity when 
subjects suffer from magnesium deficiency.  Magnesium status was not determined in this 
study, so further research is required to examine this question in obese insulin-resistant 
horses.   
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Our results may also reflect inadequate magnesium absorption or improper dosing.  
Hintz and Schryve391 reported mean absorption of 49.5 ± 10.9%  when diets containing 25 to 
90 mg magnesium per kg body weight were fed to weanlings and ponies, and results of a 
second study by the same authors revealed 40.2 to 54.0 % absorption, depending upon the 
amount of magnesium provided in the diet.392  Absorption was not measured in the study 
reported here, so it is possible that the oral bioavailability of magnesium was lower when 
combined with other nutraceuticals.   
Body weight was monitored in this study, but administration of the supplement was 
not associated with weight loss. Effects of chromium supplementation on body weight have 
been inconsistent in human studies, with some subjects showing a decrease in body mass 
index and others remaining unaffected.303,308,311  It has therefore been concluded that 
chromium supplementation prevents weight gain, but does not induce weight loss  in 
humans.312  Anecdotal reports suggest that neck circumference decreases in horses with 
regional adiposity in response to magnesium supplementation.  Mean neck circumference 
positively correlates with area under the insulin curve values from combined glucose-insulin 
tests in obese insulin-resistant horses, indicating that this physical characteristic serves as a 
phenotypic marker for IR in horses.6  Neck circumference-to-height ratio also positively 
correlates with blood insulin, glucose, triglyceride, and leptin concentrations in ponies.13   
Both neck circumference and insulin sensitivity remained unaffected by chromium and 
magnesium supplementation in the study reported here.  
Blood lipid concentrations were not affected by treatment in this study.  This finding 
was unexpected considering results of previous studies.  Total cholesterol, low-density 
lipoprotein, and apolipoprotein B concentrations significantly decreased in humans after 
supplementation with 200 µg chromium picolinate per day for 6 weeks,303 and total 
cholesterol concentrations decreased significantly in subjects receiving 1,000 µg chromium 
picolinate per day for 4 months.308  Triglyceride concentrations were higher in the control 
group in the study reported here, but this was attributed to group allocation rather than 
treatment.      
Plasma biochemical analysis results provide new information because γ-glutamyl 
transferase and aspartate aminotransferase activities were elevated in laminitic obese horses.  
A definitive diagnosis could not be reached for this problem and only limited testing was 
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performed, but these findings suggest the presence of hepatic lipidosis, which occurs in 
humans and is described as non-alcoholic fatty liver disease.95 This condition is associated 
with obesity and IR in humans, and results from abnormal lipid droplet accumulation within 
hepatocytes.96 Triglyceride accumulates within hepatocytes because of increased caloric 
intake, increased fatty acid concentrations, and increased lipid synthesis.  Biopsy samples 
must be collected in the future to determine whether hepatic lipidosis is present in laminitic 
obese horses.   
A significant increase in serum insulin concentrations was detected across the 16-
week period between January and May.  Season affects plasma adrenocorticotropin hormone 
concentrations in horses, with higher values detected in September, compared with January or 
May, 356 but it has not been determined whether insulin concentrations are similarly affected.  
This change in insulin concentrations over time may also represent an effect of diet on this 
variable.  Horses were fed to provide digestible energy at 1.25 × the daily maintenance 
requirement with the goal of maintaining body weight. This strategy was successful because 
mean body weight did not vary significantly over time.  However, horses may have received 
more calories during the study or certain components of the diet may have affected insulin 
concentrations.  Resting insulin concentrations were measured in serum collected from horses 
with access to hay, rather than samples collected under short-term fasting conditions.  It is 
therefore conceivable that insulinemic responses to hay increased as the study progressed.  
Blood samples should be collected under both fasted (feed removed 6 hours beforehand) and 
fed conditions in future studies to further investigate seasonal alterations in insulin 
concentrations.   
In conclusion, the supplement containing chromium and magnesium evaluated in this 
study did not alter morphometric measurements, blood variables, resting insulin 
concentrations, or insulin sensitivity in previously laminitic obese horses, and did not support 
our hypothesis.  Additional research is required to determine the oral bioavailability and 
appropriate dosages for chromium and magnesium supplements in horses.   
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Chapter 3 
Effects of levothyroxine sodium on body condition, blood 
measures of metabolic status, and glucose dynamics in obese, 
previously laminitic horses 
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This chapter is a paper to be considered for submission to the American Journal of 
Veterinary Research. 
 My primary contribution to this paper included I) execution of the study discussed 
herein and II) primary author of this paper.  Co-authors include Dr. Nicholas Frank who I) 
served as mentor, II) co-designer, and III) editor of the study, Sarah B. Elliott who served as 
laboratory technical support, and Dr. Raymond Boston who served as data analyst (minimal 
model analysis).   
 
Abstract 
 Obesity, regional adiposity, insulin resistance (IR), and laminitis are components of 
Equine Metabolic Syndrome (EMS).  Previous work has shown that levothyroxine sodium 
induces weight loss and improves insulin sensitivity in healthy horses kept on a weight 
reduction diet.  The purpose of this study was to assess the efficacy of this treatment in horses 
with EMS kept on a maintenance diet.  It was hypothesized that levothyroxine sodium would 
significantly alter physical characteristics, glucose dynamics, and markers of metabolic status 
in horses with EMS.  Ten horses with obesity, IR, and a history of laminitis were evaluated 
over a 36-week period. Seven horses received levothyroxine sodium orally at a dosage of 48 
mg/day (24 weeks) and then 72 mg/day (12 weeks) once daily in 0.25 kg oats, while 3 other 
horses received oats alone.  Body weights, morphometric measurements, and frequently-
sampled intravenous glucose tolerance tests were performed at 0, 12, 24, and 36 weeks.   
Analysis of variance analysis revealed significant time × treatment effects for within-
horse change in body weight (P = 0.049) and mean neck circumference (P = 0.027), but no 
significant change in BCS (P = 0.350). Mean body weight decreased by 30.8 ± 14.0 kg over 
36 weeks in treated horses and by 6.5 ± 24.6 kg in the three control animals.  Treatment did 
not affect area under the glucose curve values (time × treatment; P = 0.511), but area under 
the insulin curve tended to decrease over time in treated animals (time × treatment; P = 
0.061; Fig. 4).  No significant treatment × time effects were detected for insulin sensitivity (P 
= 0.210) or other minimal model values.  Levothyroxine induces weight loss and reduces 
neck circumference in horses with EMS when animals are kept on a weight maintenance diet, 
but does not influence glucose dynamics or insulin sensitivity. 
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3.1  Introduction  
Obesity, regional adiposity, and insulin resistance (IR) are risk factors for laminitis in 
horses and this collection of conditions is referred to as Equine Metabolic Syndrome 
(EMS).372,373  Previous studies performed by our research group have shown that the 
administration of levothyroxine sodium (L-T4) at varying doses (24 to 96 mg L-T4/d) induces 
weight loss, and this is accompanied by increased insulin sensitivity in healthy adult 
horses.11,248,249,259  In one study, eight healthy adult mares received L-T4 at dosages of 24, 48, 
72, and 96 mg/d, with each dose administered for 2 weeks.249  Significant improvement in 
insulin sensitivity (SI) was detected as horses lost weight.  Improvements in circulating 
triglycerides (TG) and total cholesterol (TC) were also noted.249  In a more recent study, L-T4 
was administered at a dosage of 48 mg/d to 6 healthy adult mares for 48 weeks.11  A 
significant decrease in body weight occurred in response to treatment and SI significantly 
increased.  The effects of L-T4 administration on body weight have also been evaluated in 
obese Morgan horse mares.  Four horses received 48 mg L-T4/d for 24 weeks and four other 
horses remained untreated (unpublished data).  Body weight, BCS, and mean neck 
circumference significantly decreased and SI increased in both groups indicating that L-T4 
treatment and controlled calorie intake are both capable of eliciting significant improvements 
in body condition and insulin sensitivity.  
Results of our previous studies indicate that L-T4 treatment induces weight loss in 
healthy and obese horses and this is accompanied by an increase in SI.  However, diet was a 
confounding factor in our study of obese Morgan horse mares, so it must be determined 
whether L-T4 exerts independent effects on body weight in obese horses.  We hypothesized 
that the administration of L-T4 would significantly alter physical characteristics, glucose 
dynamics, and markers of metabolic status in horses with histories of laminitis and chronic 
obesity, when provided a maintenance diet.   
 
3.2  Materials and Methods 
Horses – Ten adult horses that were previously donated to the University of Tennessee were 
included in the study.  All horses had EMS and were obese with histories of laminitis.  
Laminitis status was determined from statements given by the owner or referring 
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veterinarian, as well as radiographic evidence of laminitis or divergent growth rings.  Obesity 
was defined by a body condition score (BCS) of ≥ 7/9 according to the 1 to 9 scoring system 
developed by Henneke et al.9  The study was performed between July 2008 and May 2009.  
Custom farrier care was provided as needed and animal housing assignments were 
determined by foot stability.  Horses were housed in pairs within three dirt paddocks 
measuring 15-m × 55-m (n = 6), or were housed alone in individual stalls (2.75-m × 3.5-m) 
with attached outdoor dry-lots in a barn (3.7-m × 10-m; n = 4).  Horses did not have access to 
pasture throughout the duration of the study.  Six geldings and four mares were included in 
the study and ranged in age from 6 to 20 years at the initiation of the study (median, 15 
years), with initial body weights ranging from 430 to 589 kg (median, 490 kg). 
Diet – All horses were fed to provide 1.25 × digestible energy for maintenance according to 
2007 National Research Council guidelines380 with 670 kcal/day supplied by 0.5 lb oats/d 
(fed in the morning) and the remainder with an Orchard/Timothy grass hay, as determined by 
the DE content of feeds, which was measured by a commercial forage testing laboratory.a  
Hay fed to study horses came from 3 different batches and provided 5.2 to 11.9 % water-
soluble carbohydrate, 3.9 to 6.0% ethanol-soluble carbohydrate, and 0.2 to 3.9% starch on a 
dry matter basis.  Water was available ad libitum and animals were fed between 0700 and 
0800 and again between 1430 and 1530. 
Experimental design – A completely randomized study design with repeated measures was 
used across a 36-week period.  Horses were allocated to treatment (n = 7) and control (n = 3) 
groups after pre-treatment (time = 0) testing.  Horses housed in pairs within paddocks were 
randomly assigned to the two groups and horses housed in the barn were allocated to 
treatment (n = 4) or control (n = 2) groups.  Physical measurements and insulin-modified 
frequently-sampled intravenous glucose tolerance test (FSIGTT) procedures were performed 
at 0, 12, 24, and 36 weeks. Blood was collected for a complete blood cell counts (CBC) at 
time 0 and for plasma biochemical analyses at times 0, 12, 24, and 36 weeks.  Horses were 
transported to the teaching hospital 2 days prior to testing procedures to allow acclimation to 
their environment.  Testing procedures and treatment periods were staggered across a 2-week 
period with animals tested in pairs.  Horses in the treatment group received levothyroxine 
sodium at a total daily dosage of 48 mg/d (0 - 24 weeks) and at a dosage of 72 mg/d for the 
remainder of the study (24 – 36 weeks).  Levothyroxine powder was top-dressed on oats in 
                                                 
a
  Dairy One Forage Testing Laboratory, Ithaca, NY  
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the morning for 36 weeks and horses were monitored to ensure that all feed and supplement 
was consumed.  Control animals received the same feed without addition of supplement.  At 
the completion of the study period treated animals received weaning dosages of L-T4 of 24 
mg L-T4/d for 1 week followed by 12 mg L-T4/d for 1 week. The study protocol was 
approved by the University of Tennessee Institutional Animal Care and Use Committee. 
CBC and plasma biochemical analysis – Complete blood cell counts were performed on 
whole blood using an automated analyzer.b  Plasma biochemical analyses were used to 
measure blood urea nitrogen, calcium, creatinine, glucose, phosphorus, total bilirubin, total 
protein, albumin and globulin, and activities of creatine kinase, aspartate transaminase, and γ-
glutamyl transferase in samples of heparinized plasma by use of an automated discrete 
analyzerc with reagents provided by the manufacturer. 
Morphometric measurements – Physical examination variables including rectal 
temperature, heart rate, and respiratory rate were recorded along with morphometric 
measurements at 0, 12, 24, and 36 weeks.  Morphometric measurements included body 
weight, body condition, girth circumference, and neck circumference.  Neck circumference 
was measured perpendicular to the neck crest at 0.25, 0.50 (mid neck), and 0.75 of the 
distance from the withers to the poll with a measuring tape, as previously described.6  Mean 
neck circumference values were calculated. 
FSGITT procedure – A 14-gauge polypropylene catheter was inserted into the jugular vein 
the day before each FSIGTT was performed.  Horses were allowed access to grass hay and 
water while testing was performed.  Patency of the IV catheter was maintained before the test 
by injection of 5 mL of saline solution containing heparin (4 U/mL) into the catheter every 
6h.  For the FSIGTT procedure, an injection cap and infusion setd (length, 30 cm; internal 
diameter, 0.014 cm) were attached to the catheter.  The FSIGTT procedure first described by 
Hoffman et al.228 and modified by Toth et al.381 was used; 100 mg glucose/kg bwt was 
infused as a bolus within 1 min as 50% (wt/vol) dextrose solutione followed by 20 mL 
heparinised saline.  Blood samples were collected via the catheter 10, 5 and 1 min before and 
1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, and 19 min after infusion of dextrose.  At 20 min, regular 
                                                 
b
  ADVIA 120 Haematology System, Bayer Healthcare LLC, Tarrytown, NY  
c
  Hitachi 911, Boehringer Manheim Corp., Indianapolis, IN    
d
  Butterfly, Abbott Laboratories, North Chicago, IL  
e
  Dextrose 50% injection, Abbott Laboratories, North Chicago, IL  
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insulinf was administered (20 mU/kg body weight) followed by 20 mL heparinised saline.  
Blood samples were subsequently collected at 22, 23, 24, 25, 27, 30, 35, 40, 50, 60, 70, 80, 
90, 100, 120, 150, and 180 min relative to dextrose infusion.  At each time point, 3 mL blood 
was withdrawn from the infusion line and discarded.  Blood was collected into tubes 
containing sodium heparin and tubes without anticoagulant and then 5 mL heparinised saline 
was infused.   Plasma and serum were harvested via low-speed (1,000 × g) centrifugation and 
then stored at –20o C until further analysis. Pre-injection (time = 0) glucose and insulin 
concentrations are referred to as resting concentrations. 
Blood and glucose concentrations – Plasma glucose concentrations were measured by use 
of a colorimetric assayg on an automated discrete analyzer.h  Serum insulin concentrations 
were determined by use of a radioimmunoassayi validated for use in horses.393  Each sample 
was assayed in duplicate and intra-assay coefficients of variation < 5% or < 10% were 
required for acceptance of glucose and insulin assay results, respectively.  Samples with 
insulin concentrations greater than the highest value of the standard curve were diluted with 
serum from a healthy horse.  
Plasma lipid concentrations – Triglyceride and total cholesterol concentrations were 
measured with enzymatic colorimetric reagentsj on an automated discrete analyzerh  Each 
sample was assayed in duplicate and intra-assay coefficients of variation < 5% were required 
for acceptance of results. 
Interpretation of FSIGTT data – Values for insulin sensitivity (SI), glucose effectiveness 
(Sg), acute insulin response to glucose (AIRg), and disposition index (DI) were calculated 
for each FSIGTT in accordance with the minimal model382 by use of commercially available 
softwarek,l and previously described methods.228,383  Disposition index was calculated via 
multiplication of AIRg by SI.  Area under the curve values for glucose (AUCg) and insulin 
(AUCi) concentrations were also calculated using statistical software.m  
                                                 
f
  Humulin R, Eli Lilly and Co., Indianapolis, IN  
g
  Glucose, Roche Diagnostic Systems Inc., Somerville, NJ 
h
  Cobas Mira, Roche Diagnostic Systems Inc., Somerville, NJ  
i
  Coat-A-Count insulin , Diagnostic Products Corp., Los Angeles, CA  
j
  Wako Chemicals USA, Richmond, VA  
k
  MinMod Millennium, version 6.10, Raymond Boston, University of Pennsylvania,  Kennet   Square, PA  
l
  Stata 9.2, Stata Corporation, College Station, TX  
m
 PROC MIXED, SAS, version 9.2, SAS Institute Inc., Cary, NC 
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Statistical analysis – Insulin and γ-glutamyl transferase concentrations did not fit a normal 
distribution, so data were log-transformed prior to analysis.  Repeated-measures analysis of 
variance (ANOVA) was performed using statistical software.m  Treatment, time, and 
treatment × time effects were evaluated.  When a main effect was significant, the protected 
least significant difference mean separation method was used to compare different groups and 
time points.  Significance was defined at a value of    P < 0.05.   
 
3.3  Results  
One horse from each group failed to complete the study.  A horse from the LT4 group was 
found dead with fibrinohemorrhagic colitis and a control group horse was euthanized due to 
persistent laminitis.  Horses in the treatment group received LT4 in amounts equivalent to 
dosages of 0.09 – 0.11 mg/kg bwt when receiving 48 mg LT4/d and 0.14 – 0.18 mg/kg bwt 
when receiving 72 mg LT4/d.  Physical examination variables remained within normal limits 
throughout the study in all horses.  Mean pre-treatment body weight did not differ between 
control and treatment groups (Table 3.1).  A significant time × treatment effect was detected 
for within-horse change in body weight with decreases of 31 ± 14 kg and 7 ± 25 kg occurring 
in  treatment and control groups, respectively (P = 0.049; Figure 3.1).  No difference in pre-
treatment BCS was detected between groups.  Treatment and time × treatment effects (P = 
0.125 and P = 0.350, respectively) were not statistically different.  Statistical analysis to 
assess the influence of housing did not reveal a significant effect (P = 0.195).  Mean ± s.d. 
neck circumference also showed a significant treatment × time effect (P = 0.027; Figure 3.2) 
with changes of -3.0 ± 2.0 cm and 1.6 ± 1.0 cm in treatment and control groups, respectively.  
A weak positive correlation was found between mean neck circumference and AUCi (r = 
0.24), whereas a weak negative correlation was found between treatment period and mean 
neck circumference (r = - 0.18).  Mean ± SEM neck circumference-to-height ratio also 
showed a significant treatment × time effect (P = 0.031; Figure 3.3).    
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Table 3.1: Mean ± s.d. physical measurements for 10 previously laminitic obese horses that 
received levothyroxine sodium at a dosage of 48 mg/d for 24 weeks and then 72 mg/d for 12 
weeks (n = 7) or remained untreated throughout the study period (n = 3). 
Variable Group 
Time (months) T × time 
 
P 0                            3                            6                          9 
Body Weight 
(kg) 
Control (n=3) 
Treated (n=7) 
524.8 ± 76.84 
489.1 ± 46.61 
521.1 ± 80.58 
473.2 ± 50.81 
511.1 ± 74.32 
471.9 ± 48.29 
518.3 ± 80.09 
458.3 ± 49.40 0.049 
  
     
BCS Control (n=3) Treated (n=7) 
8.7 ± 0.29 
7.9 ± 0.53 
8.3 ± 0.58 
7.9 ± 0.67 
8.2 ± 1.04 
7.8 ± 0.49 
8.3 ± 0.76 
7.4 ± 0.53 0.350 
  
     
0.25x neck 
(cm) 
Control (n=3) 
Treated (n=7) 
81.7 ± 3.21 
80.5 ± 3.62 
83.7 ± 2.08 
80.6 ± 3.78 
83.7 ± 2.25 
78.5 ± 3.89 
83.0 ± 2.00 
77.7 ± 2.80 0.334 
  
     
0.50x neck 
(cm) 
Control (n=3) 
Treated (n=7) 
99.0 ± 3.61 
95.1 ± 4.60 
98.7 ± 2.89 
96.1 ± 5.61 
98.5 ± 3.28 
93.1 ± 7.30 
101.8 ± 2.75 
92.7 ± 4.72 0.114 
  
     
0.75x neck 
(cm) 
Control (n=3) 
Treated (n=7) 
115.3 ± 3.51 
109.5 ± 5.19 
113.3 ± 0.58 
108.3 ± 5.25 
112.7 ± 4.51 
107.4 ± 6.22 
115.8 ± 3.33 
105.6 ± 6.49 0.046 
  
     
Mean neck 
circumference 
(cm) 
Control (n=3) 
Treated (n=7) 
98.7 ± 16.8 
95.0 ± 14.5 
98.6 ± 14.8 
95.0 ± 13.9 
98.3 ± 14.5 
93.0 ± 14.5 
100.2 ± 16.5 
92.0 ± 14.0 0.027 
  
     
Neck-to-height 
(ratio) 
Control (n=3) 
Treated (n=7) 
0.65 ± 0.04 
0.60 ± 0.02 
0.65 ± 0.05 
0.63 ± 0.02 
0.65 ± 0.03 
0.62 ± 0.02 
0.66 ± 0.03 
0.61 ± 0.02 0.031 
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Figure 3.1: Mean ± s.d. change in body weight (kg) at 12, 24, and 36 weeks  for 10 
previously laminitic obese horses that received levothyroxine sodium at a dosage of 48 mg/d 
for 24 weeks and then 72 mg/d for 12 weeks (n = 7) or remained untreated (n = 3).  
Treatment × time; P = 0.049.  Measurements were obtained at 12 (white), 24 (gray), and 36 
weeks (black).  Asterisk indicates a significant difference between groups at a specific time 
point. 
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Figure 3.2: Mean ± SEM mean neck circumference (cm) at 0, 12, 24, and 36 weeks for 10 
previously laminitic obese horses that received levothyroxine sodium at a dosage of 48 mg/d 
for 24 weeks and then 72 mg/d for 12 weeks (n = 7; white) or remained untreated throughout 
the study period (n = 3; black).  Treatment × time; P = 0.027.  Asterisk indicates a significant 
difference between groups at a specific time point. 
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Complete blood cell counts were normal for all horses prior to treatment, and plasma 
biochemical values did not change significantly over time.  However, γ-glutamyl transferase 
and aspartate aminotransferase activities exceeded laboratory reference ranges on at least one 
occasion in 5/10 (50 %) and 4/10 (40 %) horses, respectively (Table 3.2).  Plasma total 
cholesterol concentrations significantly increased over time in the control group, but not the 
L-T4 group (P < 0.001).  Plasma triglycerides did not differ between groups, but 
hypertriglyceridemia (> 85 mg/dL) was detected in 2/10 (20 %) animals on at least one 
occasion.       
Resting hyperinsulinemia (> 30 µU/mL) was detected in 6/10 (60%) of horses prior to 
treatment and concentrations ranged from 15.0 to 183.1 µU/mL (median; 51.53 µU/mL).  
Pre-treatment SI values (n = 10) ranged from 0.02 to 3.01 (control; 0.09 to 3.01, treated; 0.02 
to 2.35, median; 0.34) × 10-4 L·min-1·mU-1 (Table 3.3) and 5 horses had values ≤ 0.50 × 10-4 
L·min-1·mU-1.  There were no significant treatment × time effects detected for insulin 
sensitivity (P = 0.210), glucose effectiveness (P = 0.447), acute insulin response to glucose 
(P = 0.773), or disposition index (P = 0.639).   
 
3.4  Discussion 
 Results of this study indicate that the administration of L-T4 induces weight loss and 
reduces neck circumference in previously laminitic obese horses even when animals are  
consuming a weight maintenance diet.  Weight loss was significantly greater when treated 
horses received 72 mg L-T4/d, which suggests that this higher dose may be more appropriate 
for horses with chronic obesity and IR.  Our hypothesis that horses kept on a maintenance 
diet would lose weight with L-T4 treatment was supported, so a more pronounced decrease in 
body weight would be expected if L-T4 treatment were combined with a weight reduction 
diet.  Horses were fed to provide 1.25× DE because results of an earlier study demonstrated 
that horses maintained body weight on this diet (Chapter 2).  By providing a diet to maintain 
body weight, weight loss can be attributed to L-T4 treatment. 
Horses included in this study showed wide individual variation in weight loss and this 
may be explained by the chronicity of obesity.  Obese horses in this study showed only 4% 
loss in body weight compared to 4 – 10% loss in healthy horses from our previous  
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Figure 3.3: Mean ± SEM mean neck circumference-to-height ratio at 0, 12, 24, and 36 weeks 
for 10 previously laminitic obese horses that received levothyroxine sodium at a dosage of 48 
mg/d for 24 weeks and then 72 mg/d for 12 weeks (n = 7; white) or remained untreated 
throughout the study period (n = 3; black). Treatment × time; P = 0.031.  Asterisk indicates a 
significant difference between groups at a specific time point. 
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Table 3.2: Mean ± s.d. resting blood measures for 10 previously laminitic obese horses that 
received levothyroxine sodium at a dosage of 48 mg/d for 6 months and then 72 mg/d for 3 
months (n = 7) or remained untreated throughout the study period (n = 3). 
 
Variable Group 
Time (weeks) T × time 
 
0                             12                           24                        36 P 
Glucose 
(mg/dL) 
Control (n=3) 
Treated (n=7) 
92.85 ± 2.72 
90.07 ± 5.18 
91.44 ± 9.17 
89.13 ± 6.71 
91.43 ± 5.52 
96.12 ± 8.20 
101.68 ± 12.69 
96.50 ± 5.45 0.321 
Insulin 
(µIU/mL) 
Control (n=3) 
Treated (n=7) 
72.92 ± 95.48b 
83.72 ± 60.55ab 
47.92 ± 69.05b 
82.31 ± 57.00ab 
68.11 ± 69.80b 
82.36 ± 78.13ab 
141.26 ± 147.23a 
55.14 ± 42.16ab 0.009 
GGT 
(IU/L) 
Control (n=3) 
Treated (n=7) 
38 ± 33 
26 ± 8 
79 ± 110 
31 ± 17 
22 ± 10 
37 ± 27 
21 ± 10 
37 ± 22 0.295 
AST 
(IU/L) 
Control (n=3) 
Treated (n=7) 
313 ± 103 
296 ± 45 
262 ± 119 
295 ± 76 
242 ± 7 
291 ± 91 
286 ± 61 
316 ± 76 0.846 
TG 
(mg/dL) 
Control (n=3) 
Treated (n=7) 
44.76 ± 9.06 
48.77 ± 28.73 
59.26 ± 7.36 
43.71 ± 17.49 
32.12 ± 4.71 
48.01 ± 23.62 
31.51 ± 6.96 
40.88 ± 31.50 0.128 
TC 
(mg/dL) 
Control (n=3) 
Treated (n=7) 
63.23 ± 7.77cde 
68.94 ± 9.47bcde 
63.35 ± 3.06cde 
69.15 ± 10.32abc 
73.38 ± 9.13a 
67.76 ± 6.88abc 
75.16 ± 4.80a 
66.98 ± 6.03abc < 0.001 
GGT = Gamma glutamyl transferase; AST = Aspartate aminotransferase; TG = Triglyceride;   
TC = Total cholesterol; T = Treatment 
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Table 3.3: Mean ± s.d. minimal model analysis values obtained from insulin-modified 
frequently-sampled intravenous glucose tolerance test data for 10 previously laminitic obese 
horses that received levothyroxine sodium at a dosage of 48 mg/d for 6 months and then 72 
mg/d for 3 months (n = 7) or remained untreated throughout the study period (n = 3). 
 
Variable Group 
Time (weeks) Time × T 
0 12 24 36 P 
SI × 10-4 (L.min-1.mU-1) 
 
Control (n=3) 
Treated (n=7) 
1.38 ± 1.49 
0.55 ± 0.85 
0.52 ± 0.42 
0.74 ± 0.70 
0.94 ± 0.65 
0.85 ± 0.70 
0.83 ± 0.70 
0.88 ± 0.74 0.210 
Sg × 10-2 (min-1) 
 
Control (n=3) 
Treated (n=7) 
0.02 ± 0.01 
0.54 ± 1.38 
0.01 ± 0.00 
0.03 ± 0.01 
0.01 ± 0.01 
0.02 ± 0.01 
0.01 ± 0.01 
0.02 ± 0.01 0.447 
AIRg (mU.min. L-1) 
 
Control (n=3) 
Treated (n=7) 
679 ± 264 
1341 ± 500 
797± 344 
1403± 735 
953 ± 389 
1292 ± 603 
1003 ± 944 
1111± 457 0.773 
DI × 10-2 Control (n=3) Treated (n=7) 
1164 ± 348 
594 ± 766 
503 ± 475 
885 ± 1009 
666 ± 440 
958 ± 891 
608± 425 
786 ± 561 0.639 
SI = Sensitivity to insulin; Sg = Glucose effectiveness; AIRg = Acute insulin response to 
glucose; DI = Disposition index; T = Treatment 
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studies.11,248  Variation might also have arisen from differences in dose because the dosage of 
L-T4 ranged from 0.09 to 0.11 mg/kg for the first 24 weeks and then increased to 0.14 to 0.18 
mg/kg bwt.  Housing assignments could also have affected results because weight loss was 
greater in some of the treated animals housed outdoors in dirt paddocks. 
Levothyroxine sodium is a synthetic form of thyroxine that reduces body weight 
through an increase in metabolic rate via increased mitochondrial respiration rate and 
increased fatty acid cycling.394  Both lipolysis and lipogenesis increase creating a “futile 
cycle” that results in the dissipation of energy, with the ultimate favoring of lipolysis.394  
Thyroid hormone agonists have a favorable effect on cholesterol concentrations due to up-
regulation of hepatic enzymes responsible for degradation of cholesterol as well as reductions 
in circulating triglyceride concentrations.273  Administration of 500 µg/kg/d of L-T4 to rats to 
induce hyperthyroidism resulted in a 44% increase in insulin-stimulated glucose transport as 
well as an increase in the number of GLUT4 glucose transporters, indicating an improvement 
in insulin sensitivity.395   
In humans with hyperthyroidism, enhanced lipolysis can be attributed to increased 
production of cyclic adenosine monophosphate (cAMP) and enhanced hormone sensitive 
lipase (HSL) activity.267  This enhances hydrolysis of stored triglycerides and increases 
production of free fatty acids (FFA), which are used for energy by the body.82  Thyroid 
supplementation has also been associated with an increase in adenosine monophosphate 
kinase (AMPK) activity resulting in increased fatty acid oxidation and decreased fatty acid 
accumulation within peripheral insulin-sensitive tissues such as skeletal muscle and adipose 
tissue.269  This decrease in fat accumulation in insulin-sensitive tissues has been associated 
with increased insulin sensitivity.  Increased AMPK activity may impact insulin sensitivity 
by enhancing insulin receptor substrate-1 (IRS-1), which is an important rate-limiting 
component of the intracellular insulin signaling pathway.269,271   
In dogs, the administration of levothyroxine at a dosage of 22 µg/kg bwt to 
hypothyroid dogs resulted in an increase in energy expenditure which was significant when 
compared to pre-treatment values.396  Mean energy expenditure increased from 32.2 ± 9.4 
kcal/kg/d to 42.9 ± 10.6 kcal/kg/d.  Pre-treatment values were lower than normal dogs, but 
post-treatment values did not differ significantly.  A synergistic relationship between 
triiodothyronine and insulin has been proposed and this relationship may explain the 
89 
 
improvement in insulin sensitivity associated with L-T4 administration.397  Both insulin and 
T3 are involved in the regulation of glucose transport proteins, including GLUT4, and are 
also known to stimulate expression of hexokinase and glycogen synthase which have 
important roles in glucose uptake and disposal.397  Triiodothyronine and insulin reciprocally 
regulate glycolysis and glucose storage by influencing cyclic AMP activity.397  Conversion of 
L-T4 into T3 would therefore be expected to elicit this response.   
 A significant reduction in mean neck circumference was identified in the horses 
studied here and this is important because mean neck circumference has been positively 
correlated with AUCi in a previous study of obese insulin-resistant horses.6  Positive 
correlations have also been detected for mean neck circumference-to-height ratio and insulin, 
glucose, triglyceride, and leptin concentrations in ponies.13  Hyperinsulinemia was also 
detected in 40% of horses in a population of moderate, overweight, or obese horses when a 
cresty neck score of ≥ 3/5 was detected.13  A significant decrease in mean neck circumference 
was associated with a trend towards lower AUCi in the study reported here, but SI values did 
change significantly. 
 Blood concentrations of triglycerides and total cholesterol remained unaffected by 
treatment in this study.  This was an unexpected finding because studies in humans and 
horses have shown that plasma total cholesterol, triglyceride, and LDL concentrations 
decrease following administration of L-T4.249,394  Horses studied here did not suffer from 
hypercholesterolemia, but hypertriglyceridemia was detected in 2 of the 10 horses during the 
study period.    Triglyceride concentrations have been used to differentiate between never-
laminitic and pre-laminitic ponies in a previous study and may be an indicator of laminitis 
risk in equids.373  Since hypertriglyceridemia was only detected on one occasion in each of 
the affected horses in this study, this finding may reflect alterations in diet or L-T4 
administration.   
 Area under the insulin curve tended to decrease with treatment, suggesting an increase 
in insulin sensitivity or decrease in pancreatic insulin secretion.  However, SI did not increase 
significantly over time and AIRg, which is a measure of pancreatic insulin output, remained 
unaffected.  Individual horse variability within the control group may be attributed to 
differences in responses to diet or season.  Season affects SI in humans.  In a study of healthy 
elderly humans, SI decreased in the summer and increased during the winter months.398    A 
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larger number of horses should be included in future studies to strengthen the study design.  
Obese insulin-resistant horses may also show greater variability in SI and AIRg than healthy 
animals.  Individual horses also varied markedly over time with respect with minimal model 
values, particularly within the control group.  Resting hyperinsulinemia was detected in 6 of 
10 horses in this study and improvements in AUCi and AIRg suggest that insulin secretion by 
the pancreas was decreasing over time in treated animals.  This may be  important because  it 
has been shown that experimentally-induced hyperinsulinemia can induce laminitis in healthy  
ponies.363 Unfortunately, only three animals in the control group completed the study and this 
represents a weakness of the study design. 
Plasma biochemical analysis results showed elevations in γ-glutamyl transferase and 
aspartate aminotransferase activities in 50% and 40% of horses, respectively.  This provides 
new information regarding the effects of obesity and IR on general health.  Although only 
limited testing was performed, these findings suggest the presence of hepatic lipidosis.  
Hepatic lipidosis can occur in humans and is described as non-alcoholic fatty liver disease.  
This condition results from abnormal lipid droplet accumulation within hepatocytes, as a 
consequence of obesity and IR.95,96  Lipid droplets are triglycerides that accumulate within 
hepatocytes due to increased caloric intake, elevated FFA concentrations, and increased 
intrahepatic lipid synthesis.96  Additional research is required to determine whether hepatic 
lipidosis occurs in obese insulin-resistant horses. 
 In comparison with results of previous studies, L-T4 treatment did not significantly 
increase SI, but only a significant decrease in body weight and mean neck circumference was 
detected in the study reported here.  Explanations for this finding include the small number of 
horses evaluated, differences among individual horses, and additional variability introduced 
when minimal model analyses were performed.  Our results suggest that administration of L-
T4 at the 72 mg/d dosage would be expected to elicit greater changes in insulin and glucose 
dynamics, so this should be considered for future studies.  No obvious adverse health effects 
were associated with L-T4 treatment. However, it should be noted that one mare died 
unexpectedly following 2 weeks of L-T4 treatment at the 48 mg/d dosage.  It was concluded 
by necropsy and histopathology that this mare died from acute fibrinohemorrhagic colitis, 
which was unlikely to be a result of L-T4 administration.   
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It is also necessary to evaluate the pharmacokinetics and pharmacodynamics of L-T4 
in horses.  When the pharmacokinetics of levothyroxine were examined in dogs, an oral 
solution showed bioavailability of only 22% at a dosage of 40 µg/kg bwt and administration 
for 14 days did not result in drug accumulation.399  Food intake delayed both the rate and 
extent of absorption by 45% in dogs.  In humans, oral bioavailability of levothyroxine ranges 
from 70 to 80% when administered in a fasted state.400  Pharmacokinetic studies are therefore 
needed to determine whether oral bioavailability differs between normal and chronically 
obese insulin-resistant horses or if feeding affects absorption.     
We conclude that levothyroxine sodium induces weight loss and reduces mean neck 
circumference in previously laminitic obese horses and these changes occurred when horses 
were provided with a weight maintenance diet, supporting our hypothesis.  Although no 
significant improvement in insulin sensitivity was detected in this study, AUCi results 
suggest that L-T4 alters insulin dynamics.  
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Chapter 4 
Effects of metformin hydrochloride on glucose and insulin 
dynamics during transition to grass paddocks in obese insulin-
resistant horses 
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This chapter is a paper to be considered for submission to the American Journal of 
Veterinary Research. 
 My primary contribution to this paper included I) execution of the study discussed 
herein and II) primary author of this paper.  Co-authors include Dr. Nicholas Frank who I) 
served as mentor, II) co-designer, and III) editor of the study, Sarah B. Elliott who served as 
laboratory technical support, and Dr. Raymond Boston who served as data analyst (minimal 
model analysis).   
 
Abstract 
Metformin hydrochloride is used as a treatment for insulin resistance (IR) in equids.  
This drug may also be useful for controlling IR when insulin-resistant horses are reintroduced 
to pasture.  We tested the hypothesis that metformin alters glucose dynamics in insulin-
resistant horses undergoing reintroduction to grazing.  Six adult horses with chronic IR were 
transferred to grass paddocks after spending > 15 months confined in stalls with attached 
gravel turnout areas.  Glucose and insulin dynamics were assessed using the combined 
glucose-insulin test (CGIT) before and 1, 2, 4, 6, 8, and 10 wk after horses were transferred to 
grass paddocks.  After horses were housed in grass paddocks for 2 wk, they were treated with 
metformin (15 mg/kg q12h) for 2 wk, taken off treatment for 2 wk, and then treated with 
metformin at a high dosage (30 mg/kg q12h) for 2 wk. Horses were also reevaluated 2 wk 
later.   
Time effects were significant (P < 0.001) for resting plasma glucose concentrations 
and area under the glucose curve (AUCg) values. Mean glucose concentrations increased 
from 81.2 ± 3.4 to 99.4 ± 6.7 mg/dL over 1 wk and then decreased to 81.9 ± 4.0 mg/dL by 10 
wk.  No differences were detected between pre- and post-metformin mean values for resting 
glucose concentrations or AUCg at either dosage level.  However, mean AUCg significantly 
decreased (18.6%) across the 10-week study period.  Metformin did not affect glucose 
dynamics in this study, but AUCg decreased over time when insulin-resistant horses were 
transferred to grass paddocks.  Time effects were significant (P < 0.001) for fed and fasted 
serum insulin concentrations.  Area under the insulin curve (AUCi) values significantly (P = 
0.003) decreased by 42% throughout the study period.  All horses had insulin concentrations 
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> 100 mU/L at 45 min of the CGIT at the beginning of the study and 3 of 6 horses at week = 
10.   
Horses did not develop laminitis when turned-out on pasture, and insulin sensitivity 
appeared to improve over time according the AUC values.  This suggests that metformin may 
be able to prevent exacerbation of insulin resistance when at risk animals are turned-out on 
pasture.   
 
4.1  Introduction 
Insulin resistance (IR) is a major health concern in horses because of its association 
with pasture-associated laminitis.372,373  Metformin hydrochloride is an N,N-
dimethylbiguanide agent that has been available since the 1950s and is used for the treatment 
of type 2 diabetes in humans.401-403  Metformin lowers blood glucose concentrations without 
inducing hyperinsulinemia, hypoglycemia, or weight gain.287  Several mechanisms of action 
have been proposed for metformin including inhibition of hepatic gluconeogenesis 
glycogenolysis,401,403 increased glucose uptake by skeletal muscle and therefore increased 
glycogenesis,279 enhanced fatty acid oxidation in muscle and liver, and inhibition of 
lipogenesis and cholesterol and triglyceride synthesis.402  Metformin also enhances 
intracellular activity of the insulin receptor by inhibiting tyrosine phosphatase and stimulating 
tyrosine kinase,287 which increases insulin sensitivity.       
   Metformin is a potential treatment for IR in horses because generic forms are 
relatively inexpensive.  However, studies to date in horses have shown varying results. 
Johnson et al. 404 were the first to report metformin use in a horse with type 2 diabetes.  This 
animal showed positive response to metformin when the drug was administered a single time 
at a dosage of 500 mg, in combination with 5 mg glyburide.  Interstitial glucose 
concentrations returned to reference range 4.5 hours after metformin administration.  Vick et 
al. subsequently assessed the effects of metformin on insulin sensitivity and reproductive 
cyclicity in obese mares.281  This study showed inconsistent results, with an improvement in 
insulin sensitivity detected with twice daily administration of 1.5 grams metformin, but not 
with 3 or 4.5 grams.  Finally, a clinical study performed by Durham et al. showed that proxy 
measures of insulin sensitivity improved when horses with IR and recurrent laminitis 
received metformin at a dosage of 15 mg/kg bwt q12h.276  
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It has been assumed since Treiber et al.372 published their findings that insulin 
sensitivity decreases when horses and ponies are grazing on pasture.  In the aforementioned 
study, insulin-resistant ponies exhibited further decreases in insulin sensitivity between 
March and May when the starch content of pasture grass increased.  Ponies also developed 
laminitis during this period, which provided evidence of an association between IR and this 
condition in equids.  On the basis of these results, insulin sensitivity would be expected to 
decrease when insulin-resistant horses are transferred from stalls to grass paddocks.  
Metformin treatment can therefore be considered in this situation to address diet-induced IR.  
We therefore hypothesized that insulin sensitivity would decrease when obese insulin-
resistant horses were permitted to graze on grass and then increase again in response to 
metformin treatment.  Treatment with metformin was delayed for 2 weeks to assess glucose 
and insulin concentrations during the transition, and two dosages were evaluated.  
 
4.2  Materials and Methods 
Horses – Six adult horses with EMS that had previously been donated to the University of 
Tennessee were included in the study.  All horses were obese, as defined by a body condition 
score (BCS) ≥7/9 according to the 1 to 9 scoring system developed by Henneke et al.9  Mean 
BCS was 8 ± 1.  Each horse had a history of IR and at least one episode of laminitis 
according to the owner and/or referring veterinarian.  The study was performed over 10 
weeks beginning in August 2009 and ending in November 2009.  Custom farrier care was 
provided as needed.  All horses had been housed individually in stalls (2.75-m × 3.5-m) with 
attached outdoor drylots (3.7-m × 10-m) for ≥ 15 months.  Following baseline measurements, 
horses were transferred to individual orchard grass paddocks (15-m × 55-m) for the 
remainder of the study.  Three mares and 3 geldings were included in the study and horses 
ranged in age from 7 to 21 years (median, 15 years), with initial body weights ranging from 
432 to 558 kg (median, 465 kg). 
Diet – All horses were fed a standard ration consisting of 0.25 kg of oats twice daily which 
provided 1,340 kcal/day, and orchard/timothy grass mixture hay which provided 820 kcal/lb 
fed.  Horses received 8.5 to 10 lb hay twice daily to meet their digestible energy requirement 
for maintenance in the each day, and also consumed pasture grass after they were transferred 
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to paddocks.  Water was available ad libitum via automatic waterers.  Horses were fed 
between 0700 and 0800 and again between 1900 and 2000. 
Experimental design – A randomized block design, blocked on horse, was used across the 
10-week study period, with all horses receiving the same treatments.  Physical measurements 
and combined glucose-insulin test (CGIT) procedures were performed at 0 (stall), 1, 2, 4, 6, 
8, and 10 weeks.  Initial testing was performed when horses were housed in stalls (Week 0), 
and then repeated after the transition to grass paddocks.  Horses were treated twice daily for 
14 days during two treatment periods (Weeks 2-4 and 6-8) separated by a 2-week washout 
period.    Resting glucose and insulin concentrations were measured under fed conditions 24h 
before each CGIT and then again under fasting conditions at the beginning of each test.  The 
study protocol was approved by the University of Tennessee Institutional Animal Care and 
Use Committee.    
Treatments – Metformin tabletsa (1,000 mg) were ground to a powder and then top-dressed 
on oats.  Horses received metformin at the 15 mg/kg q12h dosage for the first treatment 
period and 30 mg/kg q12h for the second period.   
Morphometric measurements – Physical examination variables, including rectal 
temperature, heart rate, and respiratory rate were recorded along with morphometric 
measurements at 0, 2, 4, 6, 8, and 10 weeks.  Morphometric measurements included body 
weight, body condition, girth circumference, and neck circumference.  Neck circumference 
was measured perpendicular to the neck crest at 0.25, 0.50 (mid neck), and 0.75 of the 
distance from the withers to the poll with a measuring tape, as previously described.6  Mean 
neck circumference values were calculated. 
CGIT procedure – A 14-gauge polypropylene catheter was inserted into the jugular vein the 
night before each CGIT was performed.  Horses received a single flake of hay at 8 PM the 
night before, but no other feed until the test was completed the next morning.  Water was 
available ad libitum.  Patency of the IV catheter was maintained overnight by injecting 100 
mg of heparin into a heparin lock injection cap.b  For the CGIT procedure, an injection cap 
and infusion setc (length, 30 cm; internal diameter, 0.014 cm) were attached to the catheter.  
The CGIT procedure first described by Eiler238 was used.  Briefly, 150 mg glucose/kg bwt 
                                                 
a
    Metformin hydrochloride, Apotex Corp., Toronto, Ontario, Canada    
b
   Heparin Lock Injection Site, Medical Specialties Dist., LLC, Sloughton, MA 
c
   Butterfly, Abbott Laboratories, North Chicago, IL 
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was infused as a bolus within 1 minute using 50% (wt/vol) dextrose solutiond immediately 
followed by 0.1 IU regular insuline/kg bwt as a bolus followed by 20 mL heparinized saline.  
Blood samples were collected via the catheter 10, 5 and 1 min before, and 1, 5, 10, 15, 25, 35, 
45, 60, 75, 90, 105, and 120 min after infusion of dextrose and insulin.  At each time point, 3 
mL blood was withdrawn from the infusion line and discarded.  Blood was collected into 
tubes containing potassium oxalate/sodium fluoride and tubes without anticoagulant and then 
5 mL heparinized saline was infused.  Plasma and serum were harvested after centrifugation 
(3,500 × g) and then stored at -20o C until further analysis.  Pre-injection glucose and insulin 
concentrations were averaged and are referred to as fasted concentrations.  
Blood glucose and insulin concentrations – Plasma glucose concentrations were measured 
by use of a colorimetric assayf on an automated discrete analyzer.g  Serum insulin 
concentrations were determined by use of a radioimmunoassayh previously validated for use 
in horses.393  Each sample was assayed in duplicate and intra-assay coefficients of variation < 
5% or < 10% were required for acceptance of glucose and insulin assay results, respectively. 
Statistical analysis – Insulin concentrations did not fit a normal distribution, so data were log 
transformed prior to analysis.  Time and treatment effects were evaluated for all variables by 
repeated measures analysis of variance (ANOVA) using statistical software.i  When time or 
treatment effects were significant, the protected least square difference mean separation 
method was used to compare different treatment periods.  Significance was defined as a value 
P < 0.05. 
 
4.3  Results 
Physical examination parameters remained within normal limits for all horses 
throughout the study period.  Mean body condition score, mean girth circumference, and 
overall mean neck circumference did not change over time (Table 4.1), but mean body  
 
                                                 
d
   Dextrose 50% injection, Abbott Laboratories, North Chicago, IL 
e
   Humulin R, Eli Lilly and Co., Indianapolis, IN 
f
   Glucose, Roche Diagnostic Systems Inc., Somerville, NJ 
g
   Cobas Mira, Roche Diagnostic Systems Inc., Somerville, NJ 
h
   Coat-A-Count insulin , Diagnostic Products Corp., Los Angeles, CA 
i
   PROC MIXED, SAS, version 9.2, SAS Institute Inc., Cary, NC 
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Table 4.1: Mean ± s.d. physical measurements for 6 insulin-resistant, obese, previously 
laminitic horses that were returned to pasture for 10 weeks and received metformin for 2 
weeks at dosages of 15 mg/kg bwt q 12h and 30 mg/kg bwt q 12h 
 
BCS = body condition score; G only = horses were on pasture with no metformin 
a,bFor each variable, means with different superscripts differ significantly; P , 0.05 
 
 
  
Time (wk) 
Measure 
0  2  4  6  8  10  Time 
       
Stall G only 15 
mg/kg G only 
30 
mg/kg G only P 
Body weight (kg) 
 
483 ± 56a 477 ± 65ab 482 ± 60a 477 ± 59ab 482 ± 62a 471 ± 60b 0.015 
BCS 
 
7.8 ± 1.0 7.8 ± 1.0 7.5 ± 1.0 7.6 ± 0.9 7.3 ± 0.8 7.6 ± 0.7 0.080 
Mean neck 
circumference 
(cm) 
 
92.7 ± 
12.4 
91.9 ± 
12.4 
93.2 ± 
12.4 
93.0 ± 
12.5 
93.1 ± 
11.9 
93.0 ± 
13.0 0.320 
Girth (cm) 183.4 ± 7.5 
184.0 ± 
7.6 
183.6 ± 
7.7 
184.5 ± 
7.8 
185.0 ± 
7.0 
183.8 ± 
7.7 0.521 
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weight significantly decreased over time (2.5 %) when compared to the baseline value (P = 
0.015).  
Fed glucose concentrations significantly increased when horses were transferred to 
grass paddocks, but then decreased (P < 0.001) over time (Table 4.2).  Fasted glucose 
concentrations significantly decreased over time (P = 0.021) with the lowest concentration 
detected after metformin administration at the 30 mg/kg metformin dosage (Figure 4.1).  
Mean AUCg decreased (P < 0.001) by 19% across 10 weeks, with the lowest AUCg value 
detected at 8 weeks after 30 mg/kg metformin treatment (Figure 4.2).  Time for glucose 
concentrations to return to baseline during the CGIT ranged from 35 to 120 minutes at Week 
0 and 25 to 120 minutes at Week 10.  Five of 6 horses failed to return to baseline glucose 
concentrations by 45 minutes at week 0 and 3 of 6 horses at week 10.     
 Fed and fasted insulin concentrations significantly decreased over time (P < 0.001; 
Figure 4.1).  Mean fasted insulin concentration was significantly lower at the end of the 30 
mg/kg treatment period (Week 8) when compared with the pre-treatment (Week 6) value.  
Mean AUCi significantly decreased by 42% (P = 0.003) across the 10-week study period.  
The lowest AUCi value was detected following metformin treatment at the 30 mg/kg dosage 
(Figure 4.2).  Insulin concentrations at 45 minutes collected during the CGIT ranged from 
146.2 to 393.9 mU/mL at the beginning of the study and from 44.1 to 233.1 mU/mL at time = 
10 weeks.  Six of 6 horses had insulin concentrations > 100 mU/L at the beginning of the 
study and 3 of 6 horses at week = 10.      
 
4.4  Discussion 
Results of this study indicate that hyperinsulinemia and insulin resistance improved 
when obese, insulin-resistant horses were turned out into grass paddocks.  Horses lost weight 
in response to turn-out and this was attributed to increased exercise as exercise had been 
restricted in these horses for ≥ 15 months.  Metformin lowered resting insulin concentrations 
when administered at the 30 mg/kg dosage, but results remain inconclusive.  Horses in this 
study lost weight over time, with mean body weight decreasing by 2.5%.  Metformin induces 
weight loss and this has been attributed to reduced gastrointestinal absorption of 
carbohydrates, anorectic effects, and lower leptin concentrations, as well as the promotion of  
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Figure 4.1:  Mean ± s.d. plasma glucose (A) and serum insulin (B) concentrations during 
OGTs performed in 6 obese, insulin-resistant horses receiving metformin at 15 mg/kg q 12h 
for 14 days or 30mg/kg q 12h for 14 days while having access to pasture.  Samples were 
collected in the fed state (light bars; fine text) and the fasted state (dark bars; bold text).       
G-only = pasture only, no metformin; G-15 = pasture and 15 mg/kg bwt metformin q 12h;  
G-30 = pasture and  30 mg/kg bwt metformin q 12h.  
A 
B 
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Figure 4.2:  Mean ± s.d. area under the glucose curve (AUCg; top panel) and area under the 
insulin curve (AUCi; bottom panel) during OGTs in 6 obese, insulin-resistant horses horses 
receiving metformin at 15 mg/kg q 12h for 14 days or 30mg/kg q 12h for 14 days while 
having access to pasture.   
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Table 4.2: Mean ± s.d. resting, fasting, and area under the curve measures for 6 insulin-resistant, obese, previously laminitic horses that were 
returned to pasture for 10 weeks and received metformin for 2 weeks at dosages of 15 mg/kg bwt q 12h and 30 mg/kg bwt q 12h 
Time (wk) 0a 1 2 4b 6 8c 10 Time P 
Resting Glucose (mg/dL)   
Fed 81.18 ± 3.4e 99.35 ± 6.7a 97.12 ± 8.1ab 91.27 ± 4.3bc 88.21 ± 6.3cd 83.68 ± 7.3de 81.88 ± 4.0e < 0.001 
 
        
Fasted 94.74 ± 8.0ab 98.84 ± 7.1a 93.98 ± 4.7abc 90.83 ± 7.7bc 88.74 ± 4.1bc 88.09 ± 9.1c 88.55 ± 5.3c 0.021 
 
        
Resting Insulin (mU/mL)   
Fed 56.7 ± 38.8bc 130.2 ± 60.9a 108.4 ± 52.5a 60.1 ± 35.3bc 86.9 ± 45.4ab 50.0 ± 39.7bc 16.7 ± 12.8c < 0.001 
 
        
Fasted 106.4 ± 88.3a 38.8 ± 27.4bc 26.6 ± 13.8bcd 18.6 ± 10.8d 40.1 ± 34.0b 22.1 ± 13.6cd 16.7 ± 7.1d < 0.001 
 
AUCg ([mg/dl] · min) × 103 
 
15.3 ± 2.5ab 17.3 ± 2.1a 15.9 ± 2.2ab 14.8 ± 2.5bc 12.7 ± 2.1cd 12.0 ± 1.2d 12.5 ± 3.7d < 0.001 
AUCi (mU/ml] · min) × 103 
 
34.7 ± 9.6a 26.5 ± 9.9b 25.5 ± 7.1b 22.8 ± 6.7bc 24.3 ± 8.7bc 18.0 ± 6.8c 20.1 ± 7.0bc 0.003 
 
a, b, c
 For time, a = Horses housed in stalls; b = Day 14 of metformin treatment (15 mg/kg); c = Day 14 of metformin treatment (30 mg/kg)  
AUCg = area under the curve for glucose; AUCi = area under the curve for insulin  
 a,b,c,d,e For each variable, means with different superscripts differ significantly; P < 0.05. 
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lipolysis and fatty acid oxidation.405  However, it is also likely that horses lost weight as a 
result of increased exercise.   
Bioavailability of metformin depends upon the species.  In  humans, metformin 
pharmacokinetics result in a moderate oral bioavailability of 50 to 60% with maximal 
concentrations reached 1 to 3 hours post-dosing with 500 to 1000 mg.279  Metformin has a  
calculated half-life of 6 hours and terminal elimination of 9 to 17 hours in humans.279,283  In  
rats, metformin at a dose of 50 mg/kg bwt results in a maximal concentration of 3.9 µg/mL at 
1.3 hours post oral dosing and half-life of 3.2 hours.406  
Recently, pharmacokinetics of metformin have been assessed in horses.283  Metformin 
was administered at a dose of 6g three times orally (in fed or unfed states) or intravenously.  
Plasma concentrations were no longer detectable 4 hours post-IV administration, suggesting a 
clearance rate 10 times greater than humans.  Oral bioavailability was poor and varied with 
feeding.  Fed animals showed oral bioavailability of 3.9 ± 1.0 % compared with fasted 
animals (7.1 ± 1.5 %),283 suggesting administration after a short fast may be beneficial.  
These results suggest that the dosages selected, which were equivalent to 7.5 and 15 g for 
500-kg horse, were still too low to elicit full effects.  The half-life of orally administered 
metformin has not been determined in the horse, but more frequent dosing may also be 
necessary.  
Insulin resistance and resting hyperinsulinemia are predictors of pasture-associated 
laminitis in ponies.372,407  Metformin has been used to treat insulin resistance in horses and 
ponies in order to lower laminitis risk.  In this clinical study, metformin was orally 
administered at a dosage of 15 mg/kg bwt q 12h and insulin sensitivity was evaluated by 
proxy measures following short (6-14 days) and long-term therapy (23-220 days).276  Short-
term administration resulted in significant improvement in insulin sensitivity, but this was not 
detected with long-term treatment.  Results may have been confounded because animals 
included in the study were fed low-glycemic feeds, allowed zero to minimal grazing, and 
exercise.  In the study reported here, horses had unlimited access to grass within their 
paddocks and unstructured exercise.  Horses were observed running in paddocks and their 
activity level appeared to increase after turnout.     
Exercise has been associated with improvements in insulin sensitivity and glucose uptake into 
peripheral tissues as well as weight loss in humans.405  However, results of a study assessing 
the effect of exercise training on glucose and insulin dynamics in Arabian geldings did not 
support the assumption that exercise increases insulin sensitivity, although body weight and 
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fat mass decreased over time.408  Hypoglycemia is a potential complication of metformin use 
in horses.  This problem was suspected in a horse with type 2 diabetes mellitus when 
metformin was administered at a dosage of 15 mg/kg bwt q12h.409  Hypoglycemia was not 
detected in the study reported here. 
Weaknesses of our study design included the use of the CGIT to assess insulin 
sensitivity and unmeasured exercise.  Assessment of insulin sensitivity using the CGIT is 
complicated by the administration of exogenous insulin immediately following glucose.  
Interpretation of the CGIT for the diagnosis of insulin resistance is based upon the glucose 
and insulin concentrations at 45 minutes.  Insulin resistance is diagnosed when glucose 
concentration fails to return to baseline by 45 minutes and/or the insulin concentration 
exceeds 100 mU/mL at 45 minutes.379  The glucose measurement at 45 minutes represents the 
insulin sensitivity and the insulin measurement represents the pancreatic output.  Horses in 
this study met the criteria for IR based on these results. 
We conclude that insulin-resistant horses benefit from turnout into grass paddocks.  
Lower AUCi values indicated improved insulin sensitivity in these animals, suggesting that 
our hypothesis was supported.  Improvement in insulin sensitivity over time might also be 
attributed to metformin treatment, but effects of time and treatment cannot be separated in 
this study.  
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Chapter 5a 
Validation of an enzyme-linked immunosorbent assay (ELISA) 
for the measurement of active GLP-1 in equine plasma 
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This paper is formatted from a version to be submitted for consideration for 
publication to the American Journal of Veterinary Research 
My primary contribution to this paper included I) execution of the study discussed 
herein and II) primary author of this paper.  Co-authors include Dr. Nicholas Frank who I) 
served as mentor, II) co-designer, and III) editor of the study, and Amy Schuver who I) was 
involved in sample collection and II) animal management.   
 
Abstract 
Glucagon-Like Peptide 1 (GLP-1) is an incretin hormone secreted the small intestine that 
plays a role in satiety and stimulates insulin release from pancreatic β-cells.  The objective of 
this study was to validate a commercially available (Millipore Corporation) human active 
GLP-1 enzyme-linked immunosorbent assay (ELISA) for use with equine plasma.  Resting 
blood samples were collected from one insulin-resistant horse and one healthy horse.  Plasma 
was collected with EDTA and treated with dipeptidyl-peptidase IV inhibitor.  Dilution, 
linearity, and lowest limit of detection were assessed using sample buffer included in the kit 
and plasma from the insulin-resistant horse.  For spike and recovery, the high standard was 
diluted in equine plasma from one healthy horse.  Intra-assay variability was calculated from 
quadruplicate measures of GLP-1 in blood collected at 3 time points during oral sugar tests in 
3 healthy horses.  Inter-assay variability was assessed from concentrations of quality control 
solutions provided in the kit on 3 plates.  Dilution of equine plasma resulted in a linear plot of 
GLP-1 concentrations (r2 = 0.995).  The lowest limit of detection for the assay was 1.7 
pmol/L because this was the value obtained for the sample buffer.  Overall recovery was 
98.3%, for active GLP-1 in equine plasma.  Inter-assay coefficient of variation (CV%) value 
of 2.3% and 2.6% were obtained for the two quality control solutions.  Mean ± SD intra-
assay CV% was 9.5 ± 5.1%.  Results indicate that GLP-1 can be measured in equine plasma 
using the ELISA evaluated in this study. 
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5a.1 Introduction 
Glucagon-like peptide 1 (GLP-1) is an incretin hormone secreted by the L cells of the 
distal small intestine in a dose-dependent manner in response to dietary glucose.212,219  
Incretins act upon β-cells of the pancreas to enhance insulin secretion before blood glucose 
levels rise after a meal.215  Following ingestion, glucose and GLP-1 enter the portal 
circulation and circulate through the liver.  Glycogen synthesis is stimulated by increased 
activity of glycogen synthase and decreased activity of glycogen phosphorylase.225,410  Some 
studies in humans have shown alterations in the secretion and sensitivity of GLP-1 in states 
of obesity and insulin resistance, due to impaired potentiation of the beta cell response to 
glucose.217,411,412  In women with polycystic ovary syndrome, which is an established risk 
factor for type 2 diabetes, GLP-1 secretion follows a different time pattern after an oral 
glucose challenge, with lower concentrations detected in the latter part of the challenge in 
PCOS sufferers when compared with controls.217   A significant increase in GLP-1 has also 
been detected in men with insulin-resistant myotonic dystrophy.216   
Insulin resistance (IR) increases the risk of laminitis in horses and is a component of 
Equine Metabolic Syndrome (EMS).379  It is therefore important for IR to be detected in 
horses before laminitis develops.  Since IR affects GLP-1 responses to an oral glucose 
challenge in humans, it is our overall hypothesis that plasma incretin concentrations differ 
significantly between healthy and insulin-resistant horses.  The objective of the study 
reported here was to validate an ELISA to measure active GLP-1 in equine plasma, so that 
insulin-resistant and healthy horses can be compared in the future. 
 
5a.2 Materials and methods 
Horses – Five horses (one with IR and 4 with normal insulin sensitivity) from the University 
of Tennessee College of Veterinary Medicine teaching and research herd provided plasma 
samples for the validation.  Insulin resistance was defined by a resting insulin concentration > 
20 mU/L and previous history of sensitivity to insulin (SI) values < 1.0 from frequently-
sampled intravenous glucose tolerance testing and minimal model analysis.  Plasma was 
collected from the insulin-resistant horse following an overnight fast and at 30, 45, and 60 
minutes during an oral sugar test (OST).  These three plasma samples from the OST were 
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pooled together to provide a high GLP-1 concentration sample.  A resting blood sample was 
collected from one normal horse after an overnight fast, and samples were collected at 0, 15, 
and 30 minutes during an OST from 3 other normal horses (fasting conditions).   
Sample preparation – Blood was collected into EDTA-treated collection tubes and 
centrifuged (3,500 × g) immediately.  Ten µL dipeptidyl peptidase-4 inhibitor (DPP-IV)a was 
added to 1.5 mL microcentrifuge tubes and 1 mL of EDTA plasma was added immediately to 
the inhibitor and inverted to mix thoroughly.  Tubes were then flash frozen on dry ice and 
stored at - 20° C until analyzed.   
Validation – All samples were thawed on ice and assayb components were prepared 
according to kit directions.  Dilution, linearity, and spike and recovery were performed on a 
single 96-well plate with samples analyzed in duplicate.  The standard curve for the assay 
was performed in accordance with the assay protocol and consisted of the following 
concentrations: blank (assay buffer alone), 2, 5, 10, 20, 50, and 100 pmol/L, followed by 2 
quality controls representing low and high GLP-1 concentrations (QC1 = 5.1 – 10.5 pmol/L, 
QC2 = 27.8 – 57.7 pmol/l). 
Dilution and linearity:  Dilution and linearity were assessed by diluting the high GLP-1 
sample (pooled OST samples) from the insulin-resistant horse with assay buffer provided in 
the kit or fasted resting plasma sample from the insulin resistant horse.  Plasma and the 
respective diluent were plated in duplicate as 1:5, 2:5, 3:5, and 4:5 diluted plasma and plasma 
and diluent alone. 
Lowest limit of detection:  Lowest limit of detection was performed by analyzing serially 
diluted sample in duplicate.  Each of the 4 serial dilutions was performed by mixing 2 parts 
sample with 3 parts assay buffer and was plated to included assay buffer alone, 4 serial 
dilutions, and pooled GLP-1 sample from the insulin-resistant horse. 
Spike and recovery:  Spike and recovery was performed using the resting plasma from a 
fasted normal horse and the high standard solution (100 pmol/L) from the kit.  Samples were 
plated in duplicate as follows: high standard alone, 1:1 plasma and high standard, 1:3 plasma 
and previously diluted sample across 3 serial dilutions, and plasma alone.  
                                                 
a
  DPP-4 Inhibitor, Millipore Corp., Billerica, MA 
b
  Human Active GLP-1 ELISA, Millipore Corp., Billerica, MA  
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Inter- and intra-assay variability:  Inter-assay variability was calculated by plating the same 
QC1 and QC2 from the assay on 3 different plates.  Intra-assay variability was calculated 
from quadruplicate measures of active GLP-1 in 3 samples collected from 3 normal horses at 
0, 15, and 30 min during an OST. 
 
5a.3 Results  
A quadratic curve with r2 = 0.9997 was obtained with standards provided in the kit 
(Figure 5a.1).  Dilution and linearity tests of pooled equine plasma from an insulin-resistant 
horse diluted with assay buffer resulted in a linear plot of GLP-1 concentrations with an 
observed slope of 5.0 and r2 = 0.99, compared with an expected slope of 4.9 and r2 = 1.00 
(Figure 5a.2).  Dilution and linearity tests of pooled equine plasma from an insulin-resistant 
horse diluted with plasma from the same horse under fasted conditions resulted in a linear 
plot of GLP-1 concentrations, with an observed slope and r2 of 3.8 and 0.99, respectively 
versus expected values of 3.6 and 1.00, respectively (Figure 5a.3).  Lowest limit of detection 
for the assay was 1.7 pmol/L because this was the value calculated when assay buffer was 
plated alone (Figure 5a.4).  The manufacturer states a concentration of 2 pmol/L as the 
lowest detectable by the assay, with no background subtraction performed when calculating 
concentrations (personal communication).  Spike and recovery produced calculated slope and 
r2 values of 85.1 and 0.98, respectively, compared with the expected values of 97.6 and 0.99, 
respectively (Figure 5a.5).  Overall validation procedures for the ELISA revealed a mean ± 
s.d. observed-to-expected ratio for dilution and linearity of 97.0 ± 4.4% when using assay 
buffer as diluent and 100.0 ± 3.8% when samples were diluted with plasma from a fasted 
insulin-resistant horse.  Mean ± s.d. observed-to-expected ratio for spike and recovery was 
97.6 ± 10.5% and the overall recovery for this assay was 98.3% for active GLP-1 in equine 
plasma.  Mean ± s.d. intra-assay CV% was 9.5 ± 5.1% and inter-assay CV% for the 2 quality 
controls was 2.3% and 2.6%, respectively. 
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               Figure 5a.1: Standard curve for active GLP-1 in equine plasma. 
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Figure 5a.2: Dilution and linearity plot using assay buffer provided with the kit as the diluent 
and plasma from an insulin-resistant horse following an oral sugar test (pooled 30, 45, and 60 
minutes post-sugar) as the sample. 
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Figure 5a.3: Dilution and linearity plot using fasted plasma from an insulin-resistant horse as 
the diluent and plasma from the same horse during an oral sugar test pooled from 30, 45, and 
60 minutes post-sugar bolus. 
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Figure 5a.4: Lowest limit of detection plot using assay buffer provided with the kit and 
fasted plasma from an insulin-resistant horse. 
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Figure5a.5: Spike and recovery plot using the 100 pmol/L standard provided with the assay 
as the spike solution and fasted plasma from a clinically normal horse as the sample that was 
spiked. 
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5a.4 Discussion  
Results of this study indicate that active GLP-1 can be measured in equine plasma 
using an ELISA kit designed for humans.  This commercially available kit can be used to 
measure GLP-1 concentrations in horses and assess influences of different metabolic states 
and diets. 
 Glucagon-like peptide 1 may serve as a potential marker for identification of horses at 
risk for developing laminitis.  In humans, alterations in GLP-1 concentrations have been 
identified in conditions associated with insulin resistance and obesity.212,217  Relationships 
among obesity, fat oxidation, and its influence on GLP-1 are reflected in the “glucose-fatty-
acid-cycle proposed by Randle.219-221,413  According to the Randle Theory, competition exists 
between fat oxidation and glucose uptake, such that the body  preferentially utilizes fatty 
acids for energy and this impairs insulin action.413  Increased concentrations of fasting GLP-1 
have been detected in association with obesity and increased resting metabolic rates and fat 
oxidation in humans.219  Pima Indians have the highest reported prevalence of non-insulin 
dependent diabetes.221  In this population, there is an increased affinity for intestinal binding 
of long-chain fatty acids resulting in increased fat oxidation and a decreased insulin 
activity.221  Kunz et al.220 confirmed that a higher fat mass results in an increased resting 
metabolic rate and fat oxidation with a decrease in carbohydrate oxidation, most likely as a 
result of impaired insulin activity.  Obesity therefore impairs insulin action by enhancing fat 
oxidation, and this is associated with higher fasting GLP-1 concentrations.  Higher fasting 
concentrations of GLP-1 are detected in obese humans, but concentrations are lower during 
oral glucose tolerance tests.211,218  However, the opposite is noted in situations where IR is the 
predominant process.  In men with myotonic dystrophy, a condition characterized by IR and 
hyperinsulinemia, resting GLP-1 concentrations are lower compared to healthy individuals, 
but higher during oral glucose tolerance tests.216  
 Diet influences GLP-1 concentrations in rats, dogs, and humans.414-417  In rats, high-
fat feeding attenuated GLP-1 secretion following oral glucose loads, whereas no change was 
detected when rats were fed a standard chow diet.415  In contrast, high fat and high-calorie 
feeding increased GLP-1 concentrations in dogs and humans, respectively.415,416  Diets of 
different fiber types have also been associated with alterations in GLP-1 concentrations.417-419  
Results have varied however, with significant increases in GLP-1 concentrations observed 
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when dogs ingested high-fermentable fiber over long periods.418  Humans also required 12 
months on a high-wheat fiber before GLP-1 concentrations increased after oral glucose 
challenge.417  However, there was no significant effect of feeding a highly fermentable fiber 
diet on GLP-1 concentrations in another study performed in dogs.419 
Horses that are at higher risk of IR and laminitis are generally obese and have 
elevated blood lipid concentrations.6  Since higher GLP-1 concentrations have been 
associated with obesity and impaired insulin action in humans, it is likely that GLP-1 will 
reflect the metabolic status of the horse.  However, GLP-1 responses appear to vary 
according to the predominant mechanism (obesity versus IR), which explains the variation in 
reported results from other species.216,217   
Human metabolic syndrome (MetS) is similar to Equine Metabolic Syndrome in that 
both syndromes include hyperinsulinemia, IR, dyslipidemia, and obesity122,420.  These 
conditions are risk factors for cardiovascular disease and type 2 diabetes in humans and 
laminitis in horses.  In humans, GLP-1 concentrations were higher in subjects with a cluster 
of MetS risk factors that did not include adiposity.122  Basal active GLP-1 concentrations 
range from 28.4 to 42.9 pg/mL, with overweight individuals having lower concentrations 
compared to lean controls.421  Concentrations also vary according to sampling location, with 
portal vein concentrations ranging from 50 to 60 pmol/L in humans and 30 to 60 pmol/L in 
dogs due to clearance from the circulation.422,423  In dogs, basal concentrations range from 4.4 
to approximately 15 pmol/Lin different studies.414   
 Normal ranges have not been established in horses as this is, to the authors’ 
knowledge, the first study to measure active GLP-1 in equine plasma.  The strong correlation 
with MetS risk factors and GLP-1 concentrations in humans suggests that this incretin 
hormone may be a useful marker for EMS and laminitis risk in horses.  However, it is 
apparent from studies performed in other species that concentrations must be measured under 
different metabolic and dietary conditions in order to fully understand the normal physiology 
of GLP-1 in horses.  We conclude that a commercial assay is available to measure GLP-1 in 
equine plasma.  
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Chapter 5b 
Plasma glucagon-like peptide 1 (GLP-1) concentrations in 
response to an oral sugar test in healthy and insulin-resistant 
horses 
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 This paper is a version to be submitted for consideration for publications in the 
American Journal of Veterinary Research. 
My primary contribution to this paper included I) execution of the study discussed 
herein and II) primary author of this paper.  Co-authors include Dr. Nicholas Frank who I) 
served as mentor, II) co-designer, and III) editor of the study, and Amy Schuver who I) was 
involved in sample collection and II) animal management.   
 
Abstract 
Glucagon-like peptide 1 (GLP-1) is an incretin hormone secreted by the small 
intestine in response to feeding.  Studies in other species indicate that obesity and insulin 
resistance are associated with alterations in GLP-1 concentrations after feeding.  An enzyme-
linked immunosorbent assay for human active GLP-1 has recently been validated for use with 
equine plasma in our laboratory.  We tested the hypothesis that healthy and insulin-resistant 
horses differ in their GLP-1 response to an oral sugar test (OST).  Eleven healthy horses and 
six insulin-resistant horses underwent an OST after overnight fasting.  After baseline blood 
samples were collected, 50 mg sugar per kg body weight was administered as Karo® 
Original Light Corn Syrup (10g sugar/30 mL syrup) via dose syringe.  Blood samples were 
then collected at 15, 30, 45, 60, 75, 90, 105, and 120 min.  Active GLP-1 was measured in 
EDTA plasma treated with dipeptidyl-peptidase IV inhibitor.  
   Mean GLP-1 concentrations significantly increased (P < 0.001) during the OST, but 
individual responses varied widely.  Median (range) maximum percent increase in GLP-1 
concentration after sugar administration was 67% (–15% to 188%) in healthy horses and 
148% (35% to 286%) in insulin-resistant horses.  Metabolic status did not affect GLP-1 
concentrations (P = 0.623), percent change (P = 0.167), fold change (P = 0.161), or area 
under the curve in response to sugar administration (P = 0.281). Healthy and insulin-resistant 
horses did not differ with respect to GLP-1 responses to Karo® syrup in this study, but 
specific nutrients should be tested in the future.     
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5b.1 Introduction 
Incretin hormones are peptide hormones that are secreted by the intestine in response 
to glucose intake and enhance secretion of insulin following glucose intake.217  Glucagon-like 
peptide 1 (GLP-1) is an incretin hormone secreted from L-cells of the small intestine that 
exerts its effect on the β-cells of the pancreas resulting in elevations in insulin in a glucose 
dependent manner.214,215,222  Other effects of GLP-1 secretion include slowing gut motility 
and gastric emptying, which delays blood sugar increases following a meal,215 inhibition of 
glucagon release and promotion of satiety,410 reduction in insulin clearance, which raises 
blood concentrations,20 and effects on cardiac function.210  Receptors for GLP-1 have been 
identified in the pancreatic islets, gastrointestinal tract, kidney, heart, lung, central nervous 
system, and adipose tissue.214 
 Aberrations in GLP-1 secretion and function have been detected in diabetes and other 
medical conditions associated with impaired glucose regulation, insulin resistance, and 
obesity.210,217,219  In humans, type 2 diabetes, polycystic ovary syndrome (PCOS), and 
myotonic dystrophy are associated with insulin resistance (IR) and abnormal GLP-1 
responses following oral glucose challenges.216,217,416  Results have differed among studies 
with some showing greater increases in GLP-1 concentrations following oral glucose in 
males with myotonic dystrophy216, and others revealing that concentrations are lower in the 
later stages of oral glucose tolerance tests in women with PCOS.217  In states of obesity, basal 
fat oxidation is increased, and this is associated with higher fasting GLP-1 concentrations.219-
221
 
   We hypothesized that there would be a difference in GLP-1 concentrations in 
response to an oral sugar test (OST) between insulin-resistant and normal horses. 
 
5b.2 Materials and Methods 
Horses – A total of 17 horses were included in the study.  Six horses with EMS which 
included histories of IR and obesity were compared with 11 healthy mares.  Geldings and 
mares were included in the IR group.  All horses were owned by the University of Tennessee.  
Insulin-resistant horses were housed alone in individual stalls (2.75-m × 3.5-m) with attached 
outdoor dry-lots (3.7-m × 10-m) in a barn.  Healthy horses were part of the teaching and 
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research herd and were housed outdoors on pasture with access to run-in sheds.  Insulin-
resistant horses did not have access to pasture for ≥ 15 months prior to and throughout the 
study.  Body condition scores (BCS) of insulin-resistant horses were obese (≥ 7/9), whereas 
healthy horses ranged from 4 to 6/9.  Body weights ranged from 429 to 559 kg (mean, 475 ± 
59 kg) for insulin-resistant horses, and from 445 to 507 kg (mean, 469 ± 25 kg). 
Diet – Insulin-resistant horses were fed orchard/timothy grass hay ad libitum and healthy 
horses were allowed to graze unrestricted.  Water was available ad libitum via automatic 
waterers or water troughs. 
Experimental design – A randomized block design, blocked on metabolic status with 
repeated measures was used.  Each horse underwent an OST on a single occasion with blood 
samples collected q15 min for 120 minutes following baseline samples and sugar 
administration.   
Oral sugar test procedure – A 14-gauge polypropylene jugular catheter was placed the 
evening prior to OST testing. All horses were enclosed in stalls overnight and received a 
single flake of hay at 2000 and then no feed until after testing the following morning.  Water 
was available ad libitum throughout the procedure. Patency of the IV catheter was maintained 
overnight by injecting 100 mg heparin into a heparin lock infusion cap.a  For the OST 
procedure, an injection cap and infusion setb (length, 30 cm; internal diameter, 0.014 cm) 
were attached to the catheter.  An OST procedure designed by our research group was used.  
Baseline blood samples were collected at 0800 via the catheter and then corn syrup was 
administered via dose syringe at a dosage of 0.15 mL/kg bwt to provide 150 mg dextrose 
derived digestible sugars per kg bwt.  Samples were then collected via the catheter at 15, 30, 
45, 60, 75, 90, 105, and 120 minutes relative to sugar administration.  At each time point, 3 
mL of blood was withdrawn from the infusion line and discarded.  Blood was collected into 
tubes containing EDTA and then 5 mL of heparinised saline was infused.  Plasma for active 
GLP-1 measurements was centrifuged immediately (3500 × g) for 3 minutes.  After plasma 
was harvested, a 1 mL aliquot was added to 10 µL dipeptidyl peptidase-IV inhibitorc in a 1.5 
mL microcentrifuge tube on ice.  Samples were immediately inverted to mix thoroughly and 
were then flash frozen on dry ice.  Samples were stored at      -20° C until further analysis. 
                                                 
a
  Heparin Lock Injection Site, Medical Specialties Dist., LLC, Sloughton, MA  
b
  Butterfly, Abbott Laboratories, North Chicago, IL  
c
  DPP-4 inhibitor, Millipore Corp., Billerica, MA  
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Plasma GLP-1 concentrations – Plasma active GLP-1 concentrations were measured by use 
of a commercially available human active GLP-1 ELISAd previously validated by our 
laboratory for use in the horse.  Each sample was assayed in duplicate and intra-assay 
coefficients of variation (CV%) < 10% were required for acceptance of assay results. 
Statistical analysis - Active GLP-1 concentrations did not fit a normal distribution, so data 
were log transformed prior to analysis.  Metabolic status and time effects for all variables 
were evaluated by repeated measures analysis of variance (ANOVA) using statistical 
software.e  When main effects were significant, the protected least square difference mean 
separation method was used to compare different effects.  Significance was defined as a value 
P < 0.05. 
 
5b.3 Results  
Overall active GLP-1 concentrations significantly increased (P < 0.001; Figure 5b.1) 
over time during the OST compared to baseline, with peak concentrations measured at 60 to 
75 minutes.  However, individual animals varied markedly.  No group × time (P = 0.623) or 
group (P = 0.320) effects were detected for active GLP-1 concentrations.  Baseline 
concentrations of GLP-1 in the study reported here ranged from 1.5 to 6.5 pmol/L (median, 
3.3 pmol/L) for healthy horses and 2.2 to 6.3 pmol/L (median, 3.4 pmol/L) for insulin-
resistant horses, and did not differ between groups.  Peak concentrations ranged from 2.8 to 
12.7 pmol/L (median, 4.6 pmol/L) in healthy horses and 3.7 to 18.3 pmol/L in insulin-
resistant horses (median, 9.2 pmol/L). Area under the curve values for active GLP-1 did not 
differ (P = 0.281; Figure 5b.2) between groups.  Median (range) maximum percent increase 
in active GLP-1 concentrations after sugar administration was 67% (˗15% to 188%) in 
healthy horses and 148% (35% to 286%) in insulin-resistant horses, but groups did not differ 
significantly  (P = 0.170).  Metabolic status did not affect percent change in GLP-1 (P = 
0.167) or fold change in GLP-1 (P = 0.161) during the OST.  
 
                                                 
d
  Human active GLP-1 ELISA, Millipore Corp., Billerica, MA  
e
  PROC MIXED, SAS, version 9.2, SAS Institute Inc., Cary, NC  
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Figure 5b.1: Mean ± s.d. active GLP-1 concentrations in healthy (n = 11; circles) and 
insulin-resistant (n = 6; squares) horses during an oral sugar test (OST) with Karo® corn 
syrup.  Within a group, a significant difference from the baseline (time = 0) mean values is 
denoted by an asterisk (time effect; P < 0.001). 
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Figure 5b.2: (A) Scatterplots of mean GLP-1 AUC for normal (n = 11) and EMS (n = 6) 
horses (left) and peak active GLP-1 concentrations of normal (n = 11) and EMS (n = 6) 
horses; (B)Mean ± s.d. area under the GLP-1 curve in healthy (n = 11) and insulin-resistant (n 
= 6) horses during an oral sugar test (OST) with Karo® corn syrup (treatment × time effect; P 
= 0.281).  
A 
B 
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5b.4 Discussion  
Results of this study indicate that the OST can be used to assess active GLP-1 
secretion in horses.  However, no significant differences were detected between healthy and 
insulin-resistant horses when corn syrup was used for this test, so further studies are required 
to examine the GLP-1 response to different oral sugars in horses. 
Results of this study contrast with findings from studies performed in humans.216,217  
Conditions associated with IR and/ or type 2 diabetes, such as PCOS in women and myotonic 
dystrophy in men, have been studied in regards to active GLP-1 concentrations.216,217  
Women suffering from PCOS have the same GLP-1 responses during the majority of the 
OGTT when compared to controls, except at 180 min when concentrations are significantly 
lower.217  However, results of another study were consistent with our findings in that GLP-1 
responses were the same in healthy women and those with PCOS during an OGTT.424  It is 
important to note that horses were only sampled until 120 minutes in this study, so the OST 
should be extended to 180 minutes in the future. 
 When GLP-1 was measured in men with myotonic dystrophy, significantly higher 
concentrations were detected during OGTTs in insulin-resistant subjects compared to those 
with normal insulin sensitivity.216  Although plotted GLP-1 concentrations here appeared 
higher in insulin-resistant horses, values were not significantly different.  The question of 
whether IR impairs GLP-1 secretion has not been answered yet in human medicine.  Short-
term glucosteroid administration, which induces glucose intolerance and IR, impairs the 
incretin effect in humans.416  It has also been shown that impairment of the incretin response 
can be reversed after normalization of glucose tolerance, as reported with gestational 
diabetes, suggesting that this impairment results from IR.213 
 Metabolic syndrome in humans is a collection of risk factors for cardiovascular 
disease and diabetes.122  In contrast, Equine Metabolic Syndrome (EMS) is a set of risk 
factors for the development of laminitis.379  There are similarities between the two disorders, 
including obesity, insulin resistance, hyperinsulinemia, and dyslipidemia.122,420  A condition 
in humans referred to as non-alcoholic fatty liver disease (NAFLD), or hepatic steatosis, 
results from  ectopic accumulation of triglycerides within the cytoplasm of hepatocytes, and 
is closely related to obesity and sometimes associated with IR.425  It has been established in 
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humans that NAFLD increases dipeptidyl peptidase-IV (DPP-4) activity, which is the enzyme 
responsible for rapid degradation of active GLP-1 in the circulation.212,426,427  This may 
explain the common finding that GLP-1 concentrations following a meal are often diminished 
in people with type 2 diabetes.  In horses suffering from EMS, a state of hepatic insulin 
resistance is believed to play a role in hyperinsulinemia that is commonly detected.  It is 
possible that this may result in elevated activity of DPP-4 and explain the lack of significant 
findings in the study reported here.379  Hepatic insulin resistance is a result of ectopic lipid 
accumulation and has been documented on post-mortem examination of some obese, insulin-
resistant horses studied by our research group (unpublished data).  Hepatic lipid accumulation 
may lead to elevated DPP-4 concentrations and lowered GLP-1 responses during the OST. 
 In has been shown in humans that a higher body mass index (BMI), which reflects a 
state of obesity, results in significantly greater basal energy expenditure as a result of 
increased fat oxidation.220  Higher rates of fat oxidation have been associated with increased 
fasting plasma GLP-1 concentrations in humans.219  The Randle Theory suggests that lipids 
and carbohydrates compete as the oxidative fuel source for skeletal muscle and by doing so, 
skeletal muscle glucose uptake is impeded and results in IR.221,413  This may explain why 
some studies have shown elevated fasting GLP-1 concentrations in obese individuals.211 
 In healthy humans, peripheral blood GLP-1 concentrations can rise to 30 pmol/L, but 
generally remain below 10 pmol/L following a meal.422  Rats show a postprandial 
concentration of approximately 20 pmol/L.422  Studies in dogs have detected basal 
concentrations of approximately 4.9 pmol/L after feeding once or twice daily.414  These 
baseline concentrations are similar to the concentrations detected in the study reported here 
(range, 1.5 to 6.5 pmol/L).  In a study of women with PCOS, peak GLP-1 concentrations 
were approximately 7 pmol/L following an oral glucose load,217 and 60 pmol/L and 27 
pmol/L following a carbohydrate or fat meal, respectively in healthy women.211  In contrast, 
obese women with PCOS showed peak responses of approximately 25 pmol/L and 27 pmol/L 
following a carbohydrate or fat meal, respectively.211  Peak responses did not differ 
statistically between normal and insulin-resistant horses in this study.  
    As previously discussed, GLP-1 is secreted in response to dietary glucose in a dose 
dependent manner so a commercially available sugar source was utilized in this study.  
However, studies in rats and dogs have shown variability in GLP-1 responses, depending 
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upon food type.  A study performed by Massimino et al.418 determined that the chronic 
ingestion of high fermentable dietary fiber in dogs resulted in significantly greater GLP-1 
concentrations when compared to dogs fed low fermentable fiber.  In conjunction with 
elevated GLP-1 secretion, an increase in intestinal glucose transport capacity and glucose 
homeostasis following an oral glucose challenge was also detected.  A more recent study 
found opposite results.419  Post-prandial concentrations of GLP-1 did not differ significantly 
between groups of dogs fed high and low fermentable fiber diets, and interestingly dogs 
consuming the high fermentable fiber showed lower voluntary feed intake.419  A study by 
Lubbs et al.414 assessed the effects of different dietary macronutrients on GLP-1 secretion in 
dogs.  An overall higher GLP-1 concentration was measured in dogs fed twice daily 
compared to dogs fed once daily.  When dogs were challenged acutely with water, 
carbohydrates, fat, or protein, those dosed with carbohydrates peaked at 60 minutes and then 
decreased, before spiking once more at 360 minutes, which was the final time point in the 
study.  A study in rats detected a decrease in GLP-1 concentrations when rats were fed a 
high-fat diet compared to a basic chow diet.415   
 This is, to the authors’ knowledge, the first study to evaluate active GLP-1 
concentrations in horses in response to an oral sugar test.  Insulin-resistant horses in the study 
reported here were restricted to a hay-only diet whereas normal horses had access to pasture.  
It is possible that variability in the amount and type of fiber consumed by these horses may 
have influenced results.  Although statistical significance was not attained in this study, and 
as a result did not support our hypothesis, horses within groups varied markedly with insulin-
resistant horses often having higher GLP-1 concentrations when compared to healthy 
controls.  Further studies are therefore required to determine whether certain horses with IR 
exhibit abnormal GLP-1 responses compared to controls and if this abnormality impacts the 
health of the animal.  Further study is required to assess GLP-1 responses in individual 
animals during transition from one metabolic state to another in an attempt to eliminate 
variability.  More animals must be evaluated to determine whether obesity and IR affect 
GLP-1 responses to feeding in horses. 
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Chapter 5c 
 
Effects of weight gain on plasma active glucagon-like peptide 1 
(GLP-1) concentrations and glucose tolerance test responses in 
horses 
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Abstract 
Insulin resistance (IR) is associated with obesity, type 2 diabetes, metabolic 
syndrome, polycystic ovary syndrome, and myotonic dystrophy.  Aberrations in glucagon-
like peptide 1 (GLP-1) have been identified in these conditions.  Insulin resistance and 
obesity also occur, in association with laminitis, and this syndrome is referred to as Equine 
Metabolic Syndrome (EMS).  We have previously observed that some horses with EMS have 
higher GLP-1 concentrations (Chapter 5).  However, it is unclear whether obesity and IR 
raise or lower GLP-1 concentrations in horses.  We therefore tested the hypothesis that 
induction of weight gain in horses with histories of IR and chronic obesity would result in 
alterations in GLP-1 concentrations.  Six horses with histories of IR and obesity underwent 
weight gain over 8 weeks by providing 2.0 × DEm per day.  Oral glucose tolerance tests 
(OGTT) were performed prior to initiation of weight gain and 8 weeks later.  Glucose, 
insulin, and GLP-1 from the OGTT were analyzed by area under the curve and repeated 
measures ANOVA.   
Mean body weight significantly increased (P = 0.003) over 8 weeks.  Glucagon-like 
peptide 1 concentrations increased over time during the OGTT (P = 0.023) but did not differ 
with weight gain.  Area under the GLP-1 curve did not change significantly with weight gain. 
Mean glucose concentrations did not differ with weight gain, whereas insulin concentrations 
increased over time (P = 0.027) as well as area under the insulin curve (AUCi; P = 0.003).  
An increase in body weight over 8 weeks did not result in changes in GLP-1 concentrations.  
Future studies should include more animals in order to determine whether GLP-1 
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concentrations can be used to identify insulin-resistant horses and assess reductions in insulin 
sensitivity due to diet.  
 
5c.1 Introduction 
Insulin resistance is a condition in which physiologic concentrations of insulin are 
unable to elicit the appropriate response by insulin sensitive tissues such as skeletal muscle, 
adipose tissue, or the liver.428  It is a condition that has been associated with states of obesity, 
type 2 diabetes, polycystic ovary syndrome (PCOS), metabolic syndrome, and myotonic 
dystrophy.122,216,217,221,429  In horses, it is a component of the Equine Metabolic Syndrome 
(EMS) and is believed to be a factor predisposing horses to laminitis.379 
 In diseases such as myotonic dystrophy, type 2 diabetes, and PCOS where obesity and 
insulin resistance occur, aberrations in glucagon-like peptide 1 (GLP-1) have been 
observed.216,217  Glucagon-like peptide 1 is an incretin hormone released by the L-cells of the 
distal small intestine in a dose dependent response to dietary glucose resulting in enhanced 
insulin secretion by the pancreas.210  Results of studies in humans and other species have 
varied with respect to fasting GLP-1 concentrations and GLP-1 responses to oral glucose 
challenges.217,219,430  
 States of higher resting energy expenditure and fat oxidation have been associated 
with higher fasting concentrations of GLP-1.219  States of obesity have been associated with 
elevated states of basal fat oxidation and a resulting decrease in insulin action, both of which 
could be associated with elevated GLP-1 concentrations.219-221  We hypothesized that 
inducing weight gain and obesity in horses with histories of chronic insulin resistance would 
increase basal concentrations and GLP-1 responses during oral glucose tolerance tests. 
 
5c.2 Materials and methods  
Horses – Six adult horses that had been donated to the University of Tennessee and 
maintained for > 24 months were included in the study.  Each horse had been donated due to 
histories of laminitis and chronic insulin resistance.  At the beginning of the study horses had 
a mean body condition score of 6/9 and ranged from 4 to 8.5/9; scores ≥ 7 are considered 
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overweight according to the 1 to 9 scoring system devised by Henneke et al.9  The study was 
performed from May 2010 to July 2010.  Custom farrier care was provided as needed.  All 
horses were housed individually in orchard grass paddocks (15-m × 55-m) with run-in sheds. 
Three mares and 3 geldings were included in the study and ranged in age from 8 to 22 years 
(median, 16 years), with initial body weights ranging from 381 to 533 kg (median, 423 kg). 
Diet – All horses were allowed free access to pasture, and were supplemented with a diet to 
provide 2 × DEm.  Forty percent of digestible energy was provided by timothy/orchard grass 
hay which provided 1100 kcal/lb, on a dry matter basis, and 60% with a sweet feed that 
provided 1330 kcal/lb on a dry matter basis.  Hay provided 13.7% water-soluble 
carbohydrates (WSC), 0.9% starch, and 10.8% simple sugars (ESC) on a dry matter basis and 
sweet feed provided 8.8% WSC, 17.4% starch, and 6.2% ESC on a dry matter basis, as 
determined by a commercial forage testing laboratory.a  Horses were transitioned to the diet 
over a span of 1-week by incrementally feeding 0.25 × target amount twice daily on day 1, 
0.5 × target amount on days 2, 3, and 4, 0.75 × target amount on days 5, 6, and 7, and the full 
amount by day 8.  Water was available ad libitum via automatic waterers and grain and hay 
were offered between 0700 and 0800 and again between 1500 and 1530. 
Experimental design – A longitudinal prospective study with 6 horses serving as their own 
controls was performed.  All horses underwent intravenous glucose tolerance test (IVGTT) 
and oral glucose tolerance test (OGTT) procedures prior to the initiation of weight gain (time 
= - 1 week) and again after 8 weeks on the weight gain diet (time = 9 weeks).  Tests were 
performed on consecutive days with the IVGTT being performed on the first day and the 
OGTT being performed the next day.  Horses were transported to the teaching hospital in 
pairs 2 days prior to the first test to allow acclimation to the surroundings.  At both time 
points, morphometric measurements were collected along with blood samples.  The study 
protocol was approved by the University of Tennessee Institutional Animal Care and Use 
Committee. 
Morphometric measurements – Morphometric measurements included neck circumference, 
body weight, body condition score (BCS), girth circumference, and rump fat thickness.  Neck 
circumference was measured perpendicular to the crest of the neck at 0.25, 0.50 (mid neck), 
and 0.75 of the distance from the withers to the poll with a measuring tape as previously 
                                                 
a
  Dairy One Forage Testing Laboratory, Ithaca, NY  
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described.6  Mean neck circumference values were calculated.  Rump fat thickness was 
measured via ultrasonography placed 5 cm lateral from the dorsal midline at the center of the 
pelvic bone as previously described by Carter et al.431   
Testing procedure – Two 14-gauge polypropylene catheters were inserted into the left and 
right jugular veins using aseptic technique the day before the first test was performed.  Horses 
underwent an overnight fast before testing was performed and tests were performed under 
fasting procedures with the exception of water which was available throughout the 
procedures.  Patency of IV catheters was maintained by infusion of 5 mL saline solution 
containing heparin (4 U/mL) into the catheter q 6h.  An injection cap and infusion setb 
(length, 30 cm; internal diameter, 0.014 cm) were attached to each catheter. 
IVGTT procedure – Dextrose as a 50% solution (wt/vol) dextrose solutionc was infused in 
one jugular catheter at a concentration of 150 mg/kg bwt followed by 20 mL heparinised 
saline.  Blood samples were collected from the other jugular catheter 15 minutes before 
dextrose infusion and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 15, 16, 19, 22, 23, 24, 25, 27, 30, 35, 45, 
50, 60, 75, 90, 105, 120, 150, and 180 minutes relative to dextrose infusion.  At each time 
point, 3 mL of blood was discarded and then blood was collected into tubes containing a 
glycolytic inhibitor (potassium oxalate/ sodium fluoride) and tubes without anti-coagulant.  
Following sample collection, 5 mL heparinised saline was infused.  Plasma and serum were 
harvested via centrifugation (3,500 × g) and then stores at -20° C until further analysis.  Pre-
injection insulin and glucose concentrations are referred to as baseline concentrations.  
Following completion of this test, the dextrose infusion catheter was removed. 
OGTT procedure -  During the OGTT procedure, dextrose powderd was weighed to provide 
150 mg/kg bwt dextrose.  Powder was mixed with water and gently heated to bring into 
solution.  The dextrose solution was administered to horses via dose syringe.  Blood samples 
were collected 15 minutes prior to dextrose administration and 15, 30, 45, 60, 75, 90, 105, 
120, 135, 150, 165, and 180 minutes relative to oral dextrose administration.  At each time 
point, 3 mL of blood was withdrawn and discarded and blood samples for glucose and insulin 
were collected into tubes containing a glycolytic inhibitor (potassium oxalate/ sodium 
fluoride) and tubes without anti-coagulant.  Samples for GLP-1 were collected into EDTA 
                                                 
b
  Butterfly, Abbott Laboratories, North Chicago, IL  
c
  Dextrose 50% Injection, Abbott Laboratories, North Chicago, IL  
d
  D - (+) – Dextrose Powder, Sigma Life Sciences, St. Louis, MO  
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treated tubes and centrifuged immediately (3,500 × g for 3 minutes).  Following 
centrifugation, 1 mL of plasma was added to 10 µL of dipeptidyl peptidase-IV inhibitor 
(DPP4)e in 1.5 mL microcentrifuge tubes on ice.  Samples were inverted to mix thoroughly 
and then flash frozen on dry ice and stored at -20° C until further analysis.  Samples for 
glucose and insulin were centrifuged following sample collection.   
Blood glucose, insulin, and GLP-1 concentrations – Plasma glucose concentrations were 
measured by use of a colorimetric assayf on an automated discrete analyzer.g  Serum insulin 
concentrations were determined by use of a radioimmunoassayh previously validated for use 
in horses.393  Each sample was assayed in duplicate and intra-assay coefficients of variation 
(CV%) < 5% or < 10% were required for acceptance of glucose and insulin assay results, 
respectively.  Glucagon-like peptide 1 was measured by use of an enzyme-linked 
immunosorbent assay (ELISA)i previously validated for use with horse plasma in our 
laboratory.  Each sample was assayed in duplicate and CV% of < 10% was required for 
acceptance of GLP-1 results. 
Statistical analysis – Area under the glucose curve (AUCg) data did not fit a normal 
distribution, so data were rank transformed prior to analysis.  Time, treatment, and test effects 
were evaluated for all variables by repeated measures analysis of variance (ANOVA) using 
statistical software.j  When time, test, or treatment effects were significant, the protected least 
square mean separation method was used to compare different treatment periods.  
Significance was defined as a value P < 0.05.   
 
5c.3 Results  
Testing was performed at baseline and 4 weeks later in one mare due to the development of 
laminitis.  Mean body weight significantly increased over the treatment period (P = 0.003; 
Table 5c.1; Figure 5c.1).  Mean body weight prior to diet intervention was 438 ± 61 kg 
(range, 381 to 533 kg) and increased to 464 ± 61 kg (range, 394 to 550 kg).  Percent body  
                                                 
e
  Dipeptidyl Peptidase – IV Inhibitor, Millipore Corporation, Billerica, MA  
f
  Glucose, Roche Diagnostic Systems Inc., Somerville, NJ  
g
  Cobas Mira, Roche Diagnostic Systems Inc., Somerville, NJ  
h
  Coat-A-Count insulin, Diagnostic Products Corp., Los Angeles, CA  
i
  GLP-1 (Active) ELISA, Millipore Corporation, Billerica, MA  
j
  PROC MIXED, SAS, version 9.2, SAS Institute Inc., Cary, NC  
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Table 5c.1: Mean ± s.d. physical measurements for 6 horses with chronic insulin resistance 
that received a diet providing 2 × DEm per day for 8 weeks.  
Variable Treatment Treatment 
Pre (0 wks)                    Post (8 wks) P 
Body Weight 
(kg) 438 ± 61 464 ± 61 0.003 
 
   
BCS 
(1 to 9 scale) 6.1 ± 1.6 8.0 ± 0.8 0.006 
 
   
0.25 × neck 
(cm) 74 ± 3 80 ± 5 0.003 
 
   
0.5 × neck 
(cm) 88 ± 7 97 ±5 < 0.001 
 
   
0.75 × neck 
(cm) 105 ± 7 112 ± 6 0.002 
 
   
Mean neck circumference 
(cm) 89 ± 6 96 ± 5 < 0.001 
 
   
Girth circumference 
(cm) 180 ± 7 184 ± 8 0.012 
 
   
Rump fat thickness 
(cm) 1.85 ± 0.69 2.50 ± 0.86 0.002 
 
   
Neck-to-height 
(ratio) 0.60 ± 0.04 0.64 ± 0.4 < 0.001 
BCS = Body condition score; x = Distance from the poll to the withers; P < 0.05 
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Figure 5c.1: Mean ± s.d. body weight at baseline and following administration of a diet 
providing 2 × DEm per day for 8 weeks to horses with chronic insulin resistance (n = 6).  
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weight gain ranged from 2 to 10%, with the lowest gain occurring in a horse that was on the 
diet for 8 weeks.  Body condition score significantly increased over the treatment period (P = 
0.006).  Mean BCS was 6 ± 2 (range, 4 to 8.5) prior to diet intervention and increased to 8 ±1 
(range, 7 to 9).  Mean neck circumference significantly increased during the study (P < 
0.001).  Girth circumference increased by the end of the diet intervention and was 
significantly (P = 0.011) different when compared to baseline measurements.  Rump fat 
thickness also increased significantly (P = 0.002) when horses were fed a weight gain diet, 
with mean values increasing from 1.85 ± 0.69 cm to 2.50 ± 0.86 cm.  Mean neck-to-height 
ratios significantly increased with weight gain (P < 0.001).  Weak correlations were detected 
between body weight and mean neck circumference (r = 0.22; P = 0.678) and rump fat 
thickness (r = 0.24; P = 0.643) following weight gain.  Mean neck circumference 
measurements showed a strong correlation with rump fat thickness (r = 0.85; P = 0.031), 
BCS (r = 0.91; P = 0.013), and a weak correlation with girth circumference (r = 0.16; P = 
0.770) following weight gain.  Rump fat thickness was correlated with BCS (r = 0.62; P = 
0.186) and girth circumference (r = -0.29; P = 0.573) after weight gain.   
Blood glucose concentrations were higher during the IVGTT (P < 0.001) compared to 
the OGTT, and were higher prior to weight gain (P = 0.001).  When AUCg data for the 
IVGTT were rank transformed (Figure 5c.2), significant treatment (P = 0.012), test (P < 
0.001), and treatment × test effects (P = 0.049) were detected when comparing the IVGTT 
with the OGTT.  This was a result of AUCg values being greater prior to weight gain, greater 
during the IVGTT, and the highest during the pre-weight gain IVGTT. 
Baseline OGTT serum insulin concentrations did not differ after weight gain (P = 
0.142; Figure 5c.3), but differed dependent on tests (P < 0.001; Table 5c.2), and a treatment 
× test effect was detected for the IVGTT (P = 0.038).  Insulin concentrations were higher 
after weight gain and highest in the post-weight gain IVGTT.  For the OGTT, baseline insulin 
concentrations did not differ significantly after weight gain, but AUCi differed between pre- 
and post-weight gain values (P = 0.003) and between the two tests (P = 0.024).  Area under 
the insulin curve during the IVGTT significantly increased following weight gain (P = 0.001; 
Figure 5c.4).  Insulin concentrations during the OGTT were significantly higher after weight-
gain.  Plasma GLP-1 concentrations did not show a treatment effect (P = 0.141), but did show 
a time effect within the OGTT (P = 0.023; Figure 5c.5 with the highest concentrations 
measured at 45 minutes compared to baseline.    
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Figure 5c.2:  Mean ± s.d. glucose concentrations during an IVGTT at baseline and following 
administration of a diet providing 2 × DEm per day for 8 weeks to horses with chronic insulin 
resistance (n =6; pre-weight gain (•), post-weight gain (■). Inset: Mean ± s.d. area under the 
glucose curve. 
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Figure 5c.3: Mean ± s.d. insulin concentrations during an OGTT at baseline and following 
administration of a diet providing 2 × DEm per day for 8 weeks to horses with chronic insulin 
resistance (n =6; pre-weight gain (•), post-weight gain (■). Inset: Mean ± s.d. area under the 
insulin curve. 
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Figure 5c.4:   Mean ± s.d. insulin concentrations during an IVGTT at baseline and following 
administration of a diet providing 2 × DEm per day for 8 weeks to horses with chronic insulin 
resistance (n =6; pre-weight gain (•), post-weight gain (■). Inset: Mean ± s.d. area under the 
insulin curve. 
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Figure 5c.5: Mean ± s.d. GLP-1 concentrations during an OGTT at baseline and following 
administration of a diet providing 2 × DEm per day for 8 weeks to horses with chronic insulin 
resistance (n =6; pre-weight gain (•), post-weight gain (■). Inset: Mean ± s.d. area under the 
GLP-1 curve. 
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Table 5c.2: Mean ± s.d. blood measures for 6 horses with chronic insulin resistance that 
received a diet providing 2 × DEm per day for 8 weeks. 
Variable Treatment Treatment P Pre (0 wks)                   Post (8 wks) 
Mean baseline 
OGTT glucose 
(mg/dL) 
86.77 ± 6.80 81.30 ± 8.09 0.261 
 
   
AUCg 
([mg/dL] · min) × 103 16.93 ± 7.35 18.71 ± 1.63 0.012 
 
   
Mean baseline 
OGTT insulin 
(mU/L) 
10.88 ± 3.78 24.18 ± 16.16 0.142 
 
   
AUCi 
([mU/L] · min) × 103 7.26 ± 4.30 11.37 ± 4.63 0.003 
 
   
GLP-1 
(pmol/L) 
0 min – 5.8 ± 2.2 0 min – 5.5 ± 2.2 0.836 45 min – 7.6 ± 3.7 45 min – 6.8 ± 4.0 
 
   
AUC GLP-1 
([pmol/L] · min) × 103 1.33 ± 0.48 1.24 ± 0.49 0.285 
AUCg = area under the glucose curve; AUCi = area under the insulin curve;  
GLP-1 = Glucagon-Like Peptide 1; OGTT = oral glucose tolerance test; P < 0.05 
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A weak correlation was detected between insulin and GLP-1 (r = 0.29; P = 0.583) and mean 
neck circumference (r = 0.34; P = 0.511) prior to weight gain, but there was a stronger 
correlation between insulin and girth circumference (r = 0.61; P = 0.200).  Area under the 
GLP-1 curve showed a negative correlation with body weight before weight gain (r = -0.019; 
P = 0.972; Figure 5c.6) and a positive correlation following weight gain (r = 0.379; P = 
0.459).  However, the relationship between insulin and GLP-1 became negative following 
weight gain (r = -0.23; P = 0.660; Figure 5c.7). 
 Minimal model data analysis for IVGTT data detected a non-significant decrease in 
insulin sensitivity (P = 0.721; Figure 5c.8) in response to weight gain, as well as a non-
significant increase in the disposition index (P = 0.665).  However, a significant increase in 
the AIRg was detected (P = 0.042) as a result of weight gain. 
 
5c.4 Discussion 
 Provision of a diet containing 2 × DEm for 8 weeks resulted in significant weight gain 
in 6 horses with chronic insulin resistance.  Increase in weight gain was associated with 
increased OGTT and IVGTT AUCi values but not GLP-1 concentrations.  However, weight 
gain was positively correlated with area under the GLP-1 curve and negatively correlated 
with AUCi during both the IVGTT and OGTT.  Data from the mare that was removed from 
the weight gain diet after 4 weeks was included in the analysis with all other animals.  This 
mare had gained an acceptable amount of weight in that time period (6% gain) for her data to 
be included with the other animals.  This mare was removed from the study because laminitis 
developed and this problem subsided once she was removed from the diet.  An earlier study 
performed to compare active GLP-1 concentrations between normal and insulin resistant 
horses did not detect a significant effect of metabolic status; however, the numbers were low 
(8 normal horses and 10 insulin-resistant horses) and horses underwent an OST versus the 
OGTT performed here.   
Studies in other species have revealed varying findings with respect to GLP-1 concentrations 
and obesity.210,219  Some studies have shown an association between higher rates of basal fat 
oxidation, which is related to the state of obesity, and fasting GLP-1 concentrations219-221 and  
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Figure 5c.6: Correlation plot of body weight against GLP-1 AUC for 6 horses pre- (•;    
r = -0.019; P = 0.972) and post-weight gain (■; r = 0.379; P = 0.459). 
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Figure 5c.7: Line plot showing the relationship between GLP-1 AUC and Insulin AUC for 6 
horses with EMS prior to (r = 0.286; P = 0.583) and after weight gain (r = -0.231; P = 0.660). 
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Figure 5c.8: Minimal model data analysis of IVGTT data pre- and post-weight gain for 6 horses with histories of EMS; A) Insulin sensitivity, B) 
acute insulin response to glucose, and C) disposition index.
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others have reported reduced secretion in states of obesity, with improved secretion measured 
following weight loss.210  This reported decrease in secretion associated with obesity has been 
suggested to be a result of L-cell responsiveness, presumably due to elevations in circulating 
free fatty acid concentrations.210  However, in a study of type 2 diabetic and non-diabetic 
humans, free fatty acids did not appear to have an effect, but body mass index was negatively 
associated with GLP-1 secretion.218   
In the study reported here, body weight increased after feeding of a diet designed to 
provide 2 × DEm for 8 weeks.  This amount of digestible energy induced weight gain over a 
period of 16 weeks in horses, which resulted in an overall gain of 20%,431 supporting its use.  
In horses, an association has been found between the presence and severity of a cresty neck 
and alterations in insulin sensitivity6 and that the mean neck circumference-to-wither height 
ratio can be used as an indicator of the severity of neck adiposity.13  It was determined that a 
neck-to-height ratio of ≥ 0.63 ± 0.1 is an indicator of a cresty neck score of ≥ 3, which 
indicates increased risk for pasture-associated laminitis.13  Horses in this study had mean 
neck-to-height ratio representative of a cresty neck score < 3 at the beginning of the study and 
a value representing a cresty neck score of ≥ 3 after weight gain. 
Glucose and insulin concentrations were higher during the IVGTT when compared 
with the OGTT. This was expected because glucose is administered directly into the 
circulation resulting in a more rapid response by the pancreas; however, GLP-1 
concentrations were not significantly different between pre- and post-weight gain in the study 
reported here during the OGTT.  A negative relationship was also detected between AUCi for 
both tests and area under the GLP-1 curve and this was not expected, but is supported by 
findings in humans with normal glucose tolerance or type 2 diabetes.218  Toft-Nielsen et al.218 
concluded that this occurs as a result of a negative feedback effect of insulin on GLP-1 
secretion.  
 The study diet was not analyzed for fat content or fermentability of fiber.  This may 
have influenced results of GLP-1 concentrations because it has been shown that an acute dose 
of fat resulted in a GLP-1 peak by 60 minutes and concentrations remained elevated 
throughout a 360 minute period.414  It was also shown that GLP-1 increases following a 
carbohydrate bolus, resulting in a peak at 60 minutes, which is similar to the findings in this 
study, and decreased until peaking again at 360 minutes.414  Unfortunately, the study here 
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was only extended to 180 minutes, so it is possible that we may have detected a greater 
difference between pre- and post-weight gain if samples been collected for longer.  In rats, 
administration of a high fat diet resulted in a significant decrease in GLP-1 concentrations 
when measured during an OGTT every ten days for 60 days.415   
Dietary fibers with different fermentability have also been shown to influence GLP-1 
secretion.  In a study of dogs consuming a high- or low-fermentable fiber diet for 14 days, it 
was determined that the consumption of high fermentable fiber induced a pronounced GLP-1 
response to the OGTT.418 An increase in maximal glucose uptake by the small intestine was 
also observed.418  It was determined that the enhanced glucose uptake was most likely 
responsible for the increase in GLP-1 secretion.418  A more recent study failed to show an 
effect of fiber type on post-prandial GLP-1 concentrations, but samples were collected after 
regular meals rather than a specific challenge.419   
 Insulin resistance and obesity are components of EMS as well as metabolic syndrome 
(MetS) in humans, and higher concentrations of GLP-1 have been observed in humans with 
naturally occurring and experimentally induced insulin resistance.122,216,416,420  We 
hypothesized the gain in body weight would lower insulin sensitivity, and GLP-1 
concentrations would increase as a result.  We did not detect a change in GLP-1 
concentrations following weight gain in horses with chronic IR.  However, we did detect an 
increase in AUCi values, suggesting a decrease in insulin sensitivity.  The negative 
relationship we detected between AUCi and area under the GLP-1 curve are consistent with 
results of another study.218  It is also possible that our results reflect the diet being fed to 
induce weight gain or variability among assays used to measure GLP-1.  The assay used in 
the study reported here measures active GLP-1 which is measured after treatment of plasma 
samples with DPP-IV inhibitor.  However, there are assays available that measure total GLP-
1 and this may explain differences among studies. 
 This study assessed the effects of weight gain on active GLP-1 secretion in horses 
with chronic insulin resistance.  A significant effect was not detected here, which did not 
support our hypothesis, but future work should focus upon the effects of diet type on GLP-1 
concentrations.  It would also be appropriate to evaluate horses after a longer duration of 
obesity.  More animals should be included in future studies and insulin resistant horses 
should be compared with healthy animals as obesity is induced.      
147 
 
Chapter 6 
Identification and assessment of high-molecular weight 
adiponectin in horses 
 
6.1 Introduction 
 Adiponectin is a 247 amino acid adipocytokine that was discovered by multiple 
laboratories in the 1990s.168-172    This protein forms multimers within adipocytes and four 
species are identified in human plasma.432  These include a trimer composed of three 30 kDa 
monomers that is approximately 90 kDa in size and referred to as low-molecular weight 
adiponectin (LMW), an albumin-binding trimer that is approximately 158 kDa, a hexamer 
that is 180 kDa referred to as mid-molecular weight (MMW) adiponectin, and a high-
molecular weight (HMW) form that is generally comprised of 12 to 18 monomers (360 to 
540 kDa).432,433  Adiponectin has been identified and measured in several other species, 
including horses.86,433,434 
 Of normal circulating plasma proteins, adiponectin accounts for approximately 0.01% 
in mammalian species and normal concentrations of total adiponectin appear to vary among 
species.433,434  Ranges include 5 to 30 µg/mL for humans, 9 to 17.4 µg/mL for mice, 3 to 12 
µg/mL in the arctic blue fox, 4 to 10 µg/mL in chickens, and 4.34 ± 0.12 µg/mL have been 
measured for weanlings and 2.69 ± 0.17 µg/mL for mature mares.433-435  In dogs, a lower 
range of 0.85 to 1.5 µg/mL has been detected, with a mean concentrations of 1.22 µg/mL.433  
It has been determined that the HMW adiponectin is the biologically active form and is 
capable of suppressing serum glucose concentrations in a dose-dependent manner, as well as 
improving insulin sensitivity.436  The ratio of HMW to LMW is used as a determinant of 
insulin sensitivity.436 
Despite the fact that adiponectin is primarily secreted by adipose tissues,  
concentrations of this adipokine are inversely proportional to the level of adiposity in both 
humans and horses, with a location association in humans indicating that larger visceral fat 
depots result in lower circulating concentrations.118,434  Obesity represents a chronic state of 
inflammation and hypoadiponectinemia is observed in patients with visceral obesity and 
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IR.98,108,174  This observation is especially important in circumstances of excess visceral 
adipose tissue, as inflammation reduces adiponectin secretion.192,437  Adiponectin possesses             
anti-inflammatory properties, so lower production leads to increased secretion of other 
inflammatory cytokines such as tumor necrosis factor-α (TNF- α).192,437 
Aberrations in adiponectin have been associated with states of obesity, type 2 
diabetes, and metabolic syndrome in humans.438  A genetic heritability of 55.1% has also 
been detected in a population of humans in which the prevalence of metabolic syndrome was 
29.3% in women and 37.1% in men.439  Since obesity, insulin resistance, and circulating 
adiponectin concentrations are associated in humans, we hypothesized that horses with 
Equine Metabolic Syndrome (EMS) would have lower circulating HMW adiponectin 
concentrations when compared to healthy horses. 
 
6.2 Materials and Methods 
Horses – Nine healthy horses with normal body condition scores and resting insulin 
concentrations and 16 horses diagnosed with EMS were included in the study.  Equine 
Metabolic Syndrome was defined by general and/or regional adiposity, hyperinsulinemia, and 
abnormal intravenous glucose tolerance test results (SI values < 1.0 L·min-1·mU-1).  Breeds of 
EMS horses included Tennessee Walking Horse (TWH) or TWH cross (n = 2), Morgan (n = 
2), Arabian or Arabian cross (n = 5), Paso Fino (n = 3), Missouri Fox Trotter (n = 1), Azteca 
(n = 1), and Saddlehorse Breeds (n = 2).  Healthy horses were Quarter Horse or TWH crosses 
(n = 9).   
Samples – Serum samples were collected from animals under fed conditions.  All horses 
were being maintained on a hay only (EMS), or hay and grass diet (healthy).  Samples were 
collected via jugular catheter into blood tubes containing no preservative or anti-coagulant.  
Samples were allowed to clot at room temperature for a minimum of 20 minutes and serum 
was collected via high-speed centrifugation (3,500 to 4,000 × g).  Serum was stored at -80° C 
until further analysis. 
Morphometric measurements – Morphometric measurements included body weight, body 
condition score, girth circumference, and neck circumference which was obtained by dividing 
the total neck length (x) from the poll to the cranial aspect of the withers into quarters and 
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obtaining circumference measurements at 0.25x, 0.5x, and 0.75x.  Body condition scores 
were assessed for healthy horses.   
Dialysis procedure – Dialysis buffer was made by adding 0.01 mol sodium phosphate dibasic 
(Na2HPO4), 0.16 mol sodium chloride (NaCl), and 0.01 mmol ethylenediaminetetraacetic 
acid (EDTA) into a total volume of 2L distilled water.  Samples were added to dialysis 
cassettesa in a volume of 50 µL and floated in dialysis solution at 4° C overnight 
(approximately 12 h) with a stir bar to maintain uniform temperature.  Samples were removed 
from dialysis cassettes by attaching a gel loading tip to a 1 mL syringe and withdrawing the 
dialysate.  Recovered volume was recorded and total sample volume was brought to 500 µL 
to produce a 1:10 dilution of the original sample.  Dialyzed samples were then further diluted 
to a total dilution of 1:500 prior to mixing with sample buffer and loading onto gels. 
Western blot procedure – Three procedures were used in which samples were mixed with 
three different sample buffers according to overall running conditions.  These included 
sodium dodecyl sulfate (SDS; Procedure 1), Laemmli (Procedure 2), and Tris-HCl 
(Procedure 3) for reducing, reducing and denaturing, and native gel conditions, respectively.    
Transfer buffer was the same for all procedures (Tris/glycine buffer plus 800 mL methanol 
into a total volume of 4L).  All samples were thawed on ice before use in the system.  
Positive and negative standards to assess specificity of antibodies included recombinant 
human adiponectinb, equine IgGc, equine albumind, and human apolipoprotein Be.  Gel 
electrophoresis and blotting were performed as described in Appendix I with a primary anti-
adiponectin antibody produced in rabbitsp and a peroxidase labeled secondary antibody 
against rabbit IgG produced in goatsq.  
 
6.3 Results 
Healthy horses had body condition scores ranging from 4 to 6/9 and all EMS horses had BCS 
of ≥ 7/9.  Mean resting insulin concentrations collected under fed conditions were 2.5 ± 1.3 
mU/L for healthy horses and 82.5 ± 66.0 mU/L for insulin resistant horses. 
                                                 
a
  Slide-A-Lyzer Dialysis Cassettes, 20,000 dalton, Rockford, IL 
b
  Recombinant Human Adiponectin, San Diego, CA  
c
  Equine IgG, Montgomery, TX    
d
  Equine Albumin, Rancho Dominguez, CA  
e
  Human Apolipoprotein B, Billerica, MA  
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Procedure 1 – Under reducing conditions, HMW adiponectin band density showed wide 
variability among horses classified in both groups.  However, horses with EMS subjectively 
appeared to have lower density HMW adiponectin bands when compared to healthy horses.  
Multiple bands were visible with this method and were located at 50 to 75 kDa, 100 kDa, 150 
kDa, and > 250 kDa (Figure 6.1 a and b).  Recombinant adiponectin was used as a positive 
control and showed similarity in banding pattern compared to samples.  Negative standards 
did not show any visible bands in response to the antibodies (Figure 6.2). 
Procedure 2 – When samples were reduced and denatured, band pattern changed to show 
recombinant adiponectin as a single band of ~37 kDa and horse samples produced three main 
bands at ~37 kDa, 37 to 50 kDa, and 50 to 75 kDa.  Differences in band density were not 
evident when healthy and EMS horses were compared (Figure 6.3). 
Procedure 3 – Bands differed in appearance with the native system when compared to the 
first two procedures in which SDS was included.  Band density differed between groups with 
EMS horses having lower density HMW adiponectin bands.  Three main bands were visible 
for recombinant adiponectin with this procedure and were between 140 and 232 kDa, 440 to 
669 kDa, and > 669 kDa.  Horse samples showed two bands located at 440 to 669 kDa and   
> 669 kDa (Figure 6.4).  These bands were presumed to be MMW and HMW adiponectin, 
respectively. 
 
6.4 Discussion 
 Of the three different procedures assessed, only the third procedure represented a true 
native protein protocol as no reducing agents or denaturing steps were included.  Sodium 
dodecyl sulfate is a detergent that functions by binding proteins in a sample, resulting in 
linearization of the folded protein by disrupting the secondary structure and altering 
charge.440,441  In the case of adiponectin, it results in disruption of the disulfide bonds that are 
involved in the tertiary structure of the protein and HMW form.440,441  The sulfate groups 
within SDS are negatively charged and by binding to lipophilic portions of a protein, it results 
in an overall negative charge.441  By altering the structure of proteins to a more linearized 
form and producing an ultimate negative charge, proteins that are loaded on a polyacrylamide 
gel will migrate in 
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Figure 6.1a: Procedure 1 – High-molecular weight adiponectin band density of 4 healthy 
horses and 8 EMS horses (1 to 8 out of 16). 
 
         
 
                               
 
Figure 6.1b: Procedure 1 – High-molecular weight adiponectin band density of 4 healthy 
horses (same in Figure 6.1a) and 8 EMS horses (9 to 16 out of 16). 
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Figure 6.2: Positive (human recombinant adiponectin) and negative (human apolipoprotein 
b, equine IgG, and equine albumin) standards used to assess specificity of antibodies. 
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Figure 6.3: Procedure 2 – High-molecular weight adiponectin band density of 4 healthy 
horses and 6 EMS horses under reducing and denaturing conditions.  
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Figure 6.4: Procedure 3 – High-molecular weight adiponectin band density of 4 healthy 
horses and 4 EMS horses under native conditions.   
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relation to their molecular size, rather than charge, therefore resulting in band patterns 
reflecting the different sizes of individual proteins or the different parts of a multimeric 
protein.   
 Use of a sample buffer that included 2-mercaptoethanol in Procedure 2 and boiling for 
10 minutes reduced and denatured proteins.  Heat denatures proteins by disrupting the weak 
interactions that hold proteins together, including hydrogen bonds and hydrophobic 
interactions, and this affects three dimensional structure.82  The secondary structure of the 
protein is no longer in place after denaturation, so only the primary structure is left, which is 
comprised of the amino acid sequence.82  When proteins in serum samples were exposed to 
SDS, 2-mercaptoethanol, and heat, the band pattern of the protein changed to bands with 
smaller molecular weights than native samples.  This was also a different band pattern when 
compared to the samples that were exposed to SDS alone (Procedure 1).  The recombinant 
adiponectin showed a single band at 37 kDa and the equine samples showed the same band 
and 2 slightly higher bands at approximately 50 and 50 to 75 kDa, which most likely 
represent dimer forms.  It is possible that the temperature of the water was not high enough to 
fully dissociate the oligomers of adiponectin.  Chicken adiponectin completely dissociates at 
100° C, whereas boiling at 70° C does not have the same effect, and this may explain the 
findings in the study here.435  It was concluded that adiponectin will undergo incomplete 
dissociation resulting in multiple bands under certain circumstances.  The fact that the HMW 
isoform appears to dissociate in the presence of reducing agents suggests that disulfide bonds 
are involved.  Dimer forms may be held together by non-covalent bonds since heat is capable 
of dissociating them. 
 In the native procedure, proteins migrated within the gel based on molecular weight 
and electrical charge.  The native conformation was important for the purposes of this work 
because the HMW form is the most biologically active.435  Circulating levels of HMW, rather 
than total adiponectin, are inversely related to the incidence of type 2 diabetes and insulin 
resistance, and selective down-regulation of the HMW isoform is associated with 
hyperinsulinemia in humans.435  Two bands were seen under native conditions.  These may 
represent two HMW forms because multimers can form from 12 monomers to >18.435  
Chicken HMW adiponectin is >669 kDa, but can also occur as oligomer forms with 242 kDa 
and 330 kDa bands.435  Alternatively, the second band reported here represented MMW 
adiponectin.    
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 There were similarities in band pattern identified in the work reported here when 
compared to other mammalian species, however some discrepancies were noted and these 
could be a species differences.  Currently no work had been performed to evaluate the native 
distribution of HMW adiponectin in the horse.  It has been established in humans that 
different environmental factors, such as glucose concentration affect post-translational 
modification of adiponectin.435  Differences among animal species are thought to be a result 
of variation in the amino-terminal variable region which contains the cysteine residues 
involved in the formation of the different multimer forms via the formation of disulfide 
bonds.440  It has been established that mice have one HMW species whereas multiple HMW 
species have been detected in humans.440  In Procedures 1 or 3, no bands representing the 
monomer form of adiponectin were evident.  This is similar to findings in human and mouse 
samples, because under non-reducing and heat-denaturing conditions, adiponectin monomers 
were not detected.442  It was concluded that trimer and monomer forms are less abundant in 
serum samples under non-reducing and heat-denaturing conditions and may not be abundant 
enough concentrations to be detected with some procedures.442   
 Band densities for HMW adiponectin bands appeared to differ between healthy horses 
and those with EMS, but there was considerable individual variability.  This may reflect 
differences in the ability of multimerization of adiponectin into the HMW isoform or 
differences in adipose distribution of individual animals.  In chickens, it has been determined 
that abdominal fat pad mass is inversely proportional to adiponectin concentrations in 
plasma.435  In horses, a clinical sign of EMS is the deposition of adipose tissue along the 
nuchal ligament of the crest as well as above the tail-head and along the ventral aspect of the 
abdomen.  The amount of adiposity within the crest of the neck has also been associated with 
the level of insulin resistance and risk of developing laminitis.13,373  Recent findings have 
determined that the nuchal adipose tissue is a more biologically active depot for the 
production of pro-inflammatory cytokines.443  Increased gene expression of interleukin-6 (IL-
6) and interleukin-1β (IL-1 β) have been detected in nuchal adipose tissue when compared to 
omental adipose, which differs from the situation in humans.443  Adiponectin has an anti-
inflammatory role so inflammation may become more pronounced when concentrations 
decrease, and this may be associated with insulin resistance.444 
 By showing that many horses with EMS have lower HMW adiponectin band 
densities, we may be able to identify animals with insulin resistance.  In humans, differences 
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in multimerization potential of adiponectin have been associated with the diabetic phenotype 
and hypoadiponectinemia.440  Eight mutations of human adiponectin have been reported, but 
four main mutations have been associated with the diabetic and hypoadiponectinemic 
phenotype.440  When these mutants are present, adiponectin is secreted only as a trimer, or as 
MMW multimers and trimers that are unable to form stable HMW multimers.440  Mutants are 
not only defective in the synthesis of adiponectin multimers, but also its secretion.445  
Multimers are formed exclusively within the adipocyte and are stable, preventing 
interconversion to other forms once in the circulation.445  More recently, a disulfide-bond A 
oxidoreductase-like protein was found to have a regulatory role in the formation of different 
adiponectin multimers and is diminished in fat tissues with obesity.445  To date, the genetic 
component of adiponectin formation has not been investigated in horses, so it is possible that 
similar mutations exist in this species.  These mutations might predispose animals to the 
development of insulin resistance and, as a consequence, decreased concentrations of HMW 
adiponectin.    
 This study provides preliminary evidence to support the hypothesis that HMW 
adiponectin band density is lower in horses with EMS, when compared to healthy 
counterparts.  Our findings add to the work of determining different metabolic aspects that 
play a role in the development of EMS and laminitis.  Differences in HMW adiponectin 
concentrations might explain why some horses are overweight but not insulin resistant.   
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Chapter 7 
Conclusions and Future Directions 
 
 Equine Metabolic Syndrome (EMS) resembles human metabolic syndrome, except 
that horses develop laminitis instead of atherosclerosis or cardiovascular disease.446  The 
human metabolic syndrome is still being investigated and scientific advances are needed to 
truly understand its connection with type 2 diabetes and cardiovascular disease.  However, 
some of the advances made in human medicine can be applied to horses as both syndromes 
include obesity, insulin resistance, and dyslipidemia.446  Results of studies presented in this 
dissertation have advanced our knowledge of EMS in some areas, while also revealing new 
areas for study.  
 When horses were treated with a combined chromium and magnesium supplement to 
assess the effects of body weight, adiposity, insulin sensitivity, and glucose dynamics, no 
improvements were noted following its administration for 16 weeks.  It is possible that 
bioavailability of the compounds was poor, as pharmacokinetics and pharmacodynamics of 
chromium and magnesium have not been assessed in horses.  The 2 oz. dose administered to 
horses was considered to be the loading dose by the manufacturer and is recommended as a 
therapeutic dose, whereas 1 oz. of the supplement is considered to be a maintenance dose.  
Horses in our studies were severe chronic cases of EMS and it is possible that a longer 
duration of treatment was needed or components included in the supplement were ineffective 
in severe cases.  Horses were not exercised or placed on a weight loss diet, so this too may 
have had an effect on the results observed.  Additional studies are required to determine the 
bioavailability of this supplement and assess management interventions because most owners 
would be inducing weight loss by feed restriction and exercise as the same time. 
 The administration of levothyroxine sodium to horses suffering from insulin 
resistance and obesity resulted in similar findings to earlier studies performed by our research 
group.11,249  Administration of 48 mg levothyroxine per day for 24 weeks resulted in mild 
decreases in body weight, but increasing the dosage to 72 mg/d an additional 12 weeks 
induced a significant decrease in body weight when compared to baseline values.  Over the 
duration of the study there was also a significant decrease in mean neck circumference, which 
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might reflect an improvement in insulin sensitivity because neck adiposity and circumference 
are inversely related to insulin sensitivity in horses.  These measures can serve as indicators 
of the risk of developing insulin resistance, and neck circumference-to-height ratio is a 
predictor for pasture-associated laminitis.6,13  The nuchal fat has also been shown to actively 
secrete inflammatory cytokines which have been associated with aberrations in insulin 
sensitivity.443  However, in the study reported here, we did not see a significant improvement 
in insulin sensitivity following administration of levothyroxine for 36 weeks. It is possible 
that a longer duration of treatment or using the higher dosage throughout the study period 
would have resulted in greater improvements.  The initial dosage of 48 mg/d was chosen on 
the basis of our previous results, but these studies were performed in healthy horses.  Our 
results indicate that a higher dosage of levothyroxine is appropriate for horses with severe 
chronic EMS.  
 Metformin hydrochloride has been used as a therapy for diabetes since the 1950s.401-
403
  Its primary function is to inhibit hepatic gluconeogenesis but the drug also plays a role in 
enhancing fatty acid oxidation in the muscle and liver and enhances the intracellular activity 
of the insulin receptor pathway.287,402  Studies of metformin in horses with insulin resistance 
have shown that the drug has positive effects, but they appear variable and short-lived.276  We 
administered metformin at two dosages (15 mg/kg q 12h and 30 mg/kg q 12h) to our obese, 
insulin-resistant horses and observed improvements in insulin and glucose concentrations 
across the study period.  Interestingly, we did not see expected rebounds in values when 
metformin was discontinued.  Overall glucose and insulin values decreased as an effect of 
time and it is difficult to determine if this resulted from change in season or unrestricted 
access to the outdoors and exercise after having been confined for over a year.  Further work 
is therefore required to determine whether effects were due to treatment or the other 
confounders mentioned.  Since our study was performed, it has been shown that metformin 
has poor oral bioavailability in horses.283  This drug warrants further examination because 
generic metformin is relatively inexpensive and administration with a small amount of oats 
was accepted by the horses in the study performed here. 
 Glucagon-like peptide 1 is an incretin hormone secreted by the small intestine in 
response to oral glucose in a dose dependent manner.222  Aberrations in secretion and 
sensitivity of GLP-1 following oral glucose challenge tests have been identified in medical 
conditions involving insulin resistance.217,411,412  We hypothesized that insulin-resistant horses 
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would differ in their GLP-1 response to an oral glucose tolerance test when compared to 
horses with normal insulin sensitivity.  We were unable to detect a significant difference 
between groups although insulin-resistant horses generally showed higher concentrations, as 
visualized with a scatterplot, but there was obvious variability between and within groups.  
The number of horses included in this study was small, so more horses should be included in 
the future to increase power.  We also evaluated the effects of weight gain another study to 
determine if it had an effect on GLP-1 concentrations; we expected that obesity would 
increase the severity of insulin resistance.  For the 6 horses used in this study, we were unable 
to detect a significant difference after weight gain, and this may be explained by the modest 
amount of weight gained, which was lower than that observed in a another weight-gain study 
with Arabian geldings.431  Further studies are required to examine more animals and the 
effects of greater weight gain.  A model for experimentally induced insulin resistance could 
also be used to determine differences between insulin-sensitive and insulin-resistant animals. 
 Adiponectin is an important circulating marker for insulin resistance.  This measure 
can identify individuals at risk for developing type 2 diabetes because low percentages of 
HMW adiponectin are detected in type 2 diabetics, when compared to total adiponectin.447  
The concentration of HMW adiponectin relative to total adiponectin is referred to as the SA 
index and is used as a marker for diabetes because it is tightly correlated with glucose 
intolerance and the phenotypes of metabolic syndrome.447  We attempted to show that horses 
with insulin resistance have low concentrations of circulating HMW adiponectin compared to 
normal controls, as represented by band density during western blotting procedures.  More 
work is needed in this area to obtain consistency in band appearance, but our preliminary 
results indicate that horses with insulin resistance have lower concentrations of HMW 
adiponectin.  Interestingly, there is obvious intra-group variability as some normal animals 
show band density similar to insulin-resistant horses and vice versa.  In the future, we must 
try to determine the cause of these differences within groups. 
 The work performed here with a genetically diverse population of horses suffering 
from EMS has introduced more questions than answers.  The physical characteristics of EMS 
were perhaps the only component that was consistent within the 16 horses included in our 
studies.  We observed that responses to pharmacologic interventions varied among horses and 
group responses differed from earlier studies, although this was attributed to the chronic 
disease state of horses included our studies. 
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The primary goal of this work was to examine strategies for diagnosing and managing 
EMS in horses.  After completing this work, it can still be concluded that diagnosis is most 
consistent when methods currently used in veterinary practice are applied, including the 
frequently-sampled intravenous glucose tolerance test (FSIGTT) and combined glucose-
insulin tolerance test (CGIT).  However, our research group was able to establish a simple 
diagnostic test that we refer to as the oral sugar test (OST).  Horses with insulin resistance 
showed a more pronounced response to an oral sugar challenge when compared to normal 
animals.  This test shows great promise because it is less invasive than the CGIT or FSIGT, 
and is easier to perform by the veterinarian or researcher; the corn syrup used in the test is 
readily available.  From a clinical standpoint, an owner can administer the syrup to their 
horse while it remains in its normal environment, which should reduce stress and minimize 
confounding of results.  The veterinarian can arrive at a pre-established time to collect a 
blood sample. 
The goal of identifying easily measured blood markers proved to be more challenging 
than anticipated.  Adiponectin is a difficult protein to work with because it forms multimers 
in circulation (HMW adiponectin) and this is the form of interest.  Results obtained by 
western blotting techniques were very difficult to obtain consistently.  It is possible that the 
protein would be better measured prior to freezing or it may degrade over time.  Currently, 
there is no easy method to measure equine adiponectin, although a human HMW adiponectin 
ELISA has recently been validated for use with equine serum.448 It must also be recognized 
that ELISAs are expensive and the cost of performing a western blot is considerably cheaper. 
Glucagon-like peptide 1 can now be measured in equine plasma using an ELISA 
validated by our research group, but significant differences have not been detected between 
normal and insulin-resistant animals.  This may be a result of the low number of animals 
studied to date, so more work is required in the future to truly conclude if differences are 
detectable between these groups of animals. 
Current management practices for horses with EMS include weight loss by dietary 
restriction in conjunction with exercise, along with restricted grazing or complete prohibition 
of grazing.  Induction of weight loss has been shown to result in improvements in insulin 
sensitivity.11  In more severe cases, pharmacologic intervention is undertaken and this has 
included levothyroxine sodium, metformin, and herbal supplements in the past.  To date, 
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levothyroxine and metformin are the only compounds with supportive scientific evidence of 
efficacy.  However, as we saw with our population of EMS horses, results were variable.  
This further supports the notion that EMS is not a “black and white” disorder, so one method 
does not work for all.  The best results we obtained were with the administration of 
levothyroxine, but it was still the case that some horses responded better than others.  This 
suggests that there are different levels of severity of this disorder and it must be managed on 
an individual basis. 
Interestingly, we discovered that an acute re-introduction to pasture did not adversely 
affect the health of insulin-resistant horses.  Insulin concentrations decreased over time, and 
animals lost weight, presumably due to increased exercise.  No lameness related to grazing 
was identified, and some horses used in these studies had histories of laminitis related to 
grazing.  In contrast, we observed that 2 of 6 horses developed laminitis (with a third showing 
equivocal signs) while undergoing weight gain via overfeeding.  It was not clear whether this 
was a result of the amount of grain fed, presence of grain in the diet, or the combination of 
grain and pasture grass.  This point again reinforces how responses are very variable among 
horses, so these points must be taken into account when attempting therapy and management. 
As the results of the studies discussed here indicate, EMS is not an easy disorder to 
understand.  The work performed here has introduced more questions than answers, so more 
studies are required to elucidate the causes and treatments for this syndrome in horses.  
Ongoing genetic studies may reveal mechanisms and targets for therapies so that we may one 
day identify animals at risk for developing laminitis prior to its occurrence. 
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Buffer components 
 
1) Sodium dodecyl sulfate (SDS) 5x sample buffera - 0.3 M Tris-HCl, 5% 
SDS, 50% Glycerol and proprietary pink dye 
2) SDS running bufferb 0.025 M Tris, 0.192 M Glycine, and 0.1% SDS per 
4L 
3) 2x Laemmli sample bufferc 4% SDS, 20% Glycerol, 10% 2-
mercaptoethanol, 0.004% Bromophenol Blue, and 0.125 M Tris-HCl pH 
6.8 
4) Tris/Glycine running bufferd - 0.025 M Tris and 0.192 M Glycine per 4L  
5) Native sample buffere - 62.5 M Tris-HCl pH 6.8, 40% Glycerol, and 
0.01% Bromophenol Blue 
Procedure 1 
1. Gently remove the comb from a pre-cast Tris/HCl 4 to 15% gradient gelf and 
carefully cut along the solid black line along the bottom with a scalpel and 
carefully remove the tape strip, rinse both sides of the gel cassette with de-ionized 
water.  Place gels within gel electrophoresis unitg according to instruction manual. 
2. Fill the gel assembly (upper chamber) with SDS running buffer to the top of the 
wells.  Place the gel assembly into the tank (lower chamber) and fill with running 
buffer to approximately 2/3 height. 
3. Dilute samples 1:200 with distilled water and mix with non-reducing sample 
buffer.   
4. Load samples into wells in a final volume of 15 µL.  A kaleidoscope standard 
ladderh which consisted of 10 pre-stained recombinant proteins of 10, 15, 20, 25, 
37, 50, 75, 100, 150, and 250 kDa was loaded into lane 1. 
5. Run samples at 80 V for 20 minutes and then increase voltage to 120 V until the 
dye front reaches the bottom of the gel. 
                                                 
a
  Lane Marker Non-Reducing Sample Buffer, Rockford, IL 
b
  Tris/Glycine/SDS Buffer, Solon, OH  
c
  Laemmli 2x concentrate, St. Louis, MO 
d
  Tris/Glycine Buffer, Solon, OH  
e
   Native Sample Buffer, Hercules, CA 
f
  4-15% Tris-HCl Gradient Gels, Hercules, CA  
g
  Mini-PROTEAN Tetra Cell, Hercules, CA  
h
  Precision Plus Protein Kaleidoscope Standards, Hercules, CA  
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6. Chill transfer buffer at 4° C.  Soak paper membranes, fiber pads, and 
nitrocellulose membrane in chilled transfer buffer. 
7. Remove gel from its frame by cutting along the solid black lines on either side of 
the gel and place gel plastic side down in chilled transfer buffer and store at 4° C 
for 15 minutes to allow for shrinkage. 
8. Assemble gel holder cassettes for transfer as follows:  
a. Fiber pad 
b. Paper membrane 
c. Gel- placed glass side up 
d. Nitrocellulose membrane 
e. Paper membrane 
f. Fiber pad 
9. Place assembled gel holder cassette into the electrode module with the black side 
of the cassette facing the black side of the electrode module. 
10. Place an ice pack in the buffer tank and place the electrode module into the buffer 
tank with the black side of the electrode module facing the ice pack.  Place a small 
stir bar below the cassette.  Add chilled transfer buffer to the base of the lip of the 
buffer tank. 
11. Place the unit on a stir plate to allow adequate circulation of the transfer buffer. 
12. Run the transfer at 80 V for 1 ½ h. 
13. Following transfer, remove the membrane and cover with ponceau staini for 
approximately 5-minutes to visualize quality of the transfer. 
14. Rinse membrane 3 times in a 0.5% Phosphate Buffered Saline (PBS)-Tween (500 
µL Tween-20j per 100 mL of PBS) solution for 5-minutes per rinse until all 
visible ponceau stain is removed. 
15. Place membrane in 5% milk solution (5g powdered non-fat milk per 100mL of 
PBS-Tween) and block for 1h at room temperature on a rocker. 
16. Rinse membrane 3x in PBS-Tween for 5-minutes per rinse. 
17. Incubate membrane with 1° antibody (Anti-adiponectin antibody produced in 
rabbitk) for 1h at room temperature at a concentration of 1:250 with 5% milk 
solution. 
                                                 
i
  Ponceau-S, St. Louis, MO  
j
  Tween-20, Fairlawn, NJ  
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18. Rinse membrane 1x in PBS-Tween for 5 minutes. 
19. Incubate membrane with 2° antibody (Peroxidase-labeled affinity purified 
antibody to rabbit IgGl) for 1h at room temperature at a concentration of 1:8,000 
with 5% milk solution. 
20. Rinse membrane 3x in PBS-Tween for 5 minutes per rinse. 
21. Rinse membrane 3x in PBS for 5 minutes per rinse. 
22. Blot membrane of excess PBS using lint-free paper and cover with prepared 
chemiluminescent substratem and incubate for 5 minutes at room temperature. 
23. Blot membrane of excess substrate with lint-free paper and place in a clear sheet 
protector or plastic wrap and expose to x-ray filmn.  Develop film in x-ray 
processor. 
 
Procedure 2 – steps differing from Procedure 1 
 Protocol procedure is the same as Procedure 1 with the exception of the following 
steps: 
 3.  Mix diluted samples with 2x Laemmli buffer (in 1:1 ratio).  Boil samples for 10  
                 minutes.  Perform a quick spin with a microcentrifuge to release steam from the 
                 samples. 
 
Procedure 3 – steps differing from Procedure 1  
 2.  Fill the buffer tank with Tris/Glycine running buffer. 
 3.  Dilute samples 1:500 following the dialysis procedure and then mix 
                with 2x native sample buffer (in 1:1 ratio).   
 4.  Load samples to provide a total volume of 20 µL per well.  Load native high-        
                 molecular weight standard consisting of lyophilized proteins of   
                  thyroglobulin (669 kDa), ferritin (440 kDa), catalase (232 kDa), lactate  
                dehydrogenase (140 kDa), and bovine serum albumin (67 kDa) in lane 1. 
 5.  Run gel at 80 V until dye front runs down 2/3rd distance (approximately 3.3 cm) 
                 from the base of the wells. 
 7.  Do not chill gel in transfer buffer prior to assembling gel holder cassette. 
                                                                                                                                                        
k
  Anti-adiponectin antibody produced in rabbit, St. Louis, MO  
l
  Peroxidase-labeled Affinity Purified Antibody to Rabbit IgG (H+L), Gatlinburg, MD  
m
  SuperSignal West Pico Chemiluminescent Substrate, Rockford, IL  
n
  Blue X-ray Film, Candler, NC  
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          17.  Incubate membrane with 1° antibody for 1h at room temperature at a  
                 1:2,000 dilution. 
          19.  Incubate membrane with 2° for 1h at room temperature at a 1:12,000 dilution. 
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